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Drug resistance, and the role of p53, in lung cancer cell lines 
Abstract
This thesis sets out to increase our knowledge of mechanisms by which lung cancer 
cells develop resistance to chemotherapeutic agents. The involvement of the tumour 
suppressor p53 in the development of drug resistance in lung cancer cell lines was 
investigated. p53 is a tumour suppressor gene, which is mutated in more than half of 
all tumours. Most chemotherapeutic drugs cause DNA damage that is sensed by p53, 
which either arrests the cell cycle to allow DNA repair or induces apoptosis. Wild- 
type p53 was transfected into several cell lines; A549, which expresses wild-type p53, 
DLKP-SQ, which expresses mutant p53 and H I299 which is p53 null. Clones were 
isolated from these cell lines and tested for changes in sensitivity to the 
chemotherapeutic agents adriamycin, taxol and carboplatin. A549 transfected clones 
showed an increase in p53 protein after transfection, however, these cells did not 
display substantial changes in sensitivity to the chemotherapeutic agents tested. The 
cell line H1299, which is p53 null, expressed p53 protein after stable transfection, and 
was chosen for further analysis. This p53-expressing cell line displayed only small 
changes in sensitivity to chemotherapeutic agents compared to control-transfected 
cells. No correlation was observed between the p53 status of the cell lines and the ease 
of developing resistant variants. To further investigate the molecular basis of drug 
resistance in lung cancer, a panel of four cell lines were chosen for pulse-selection with 
chemotherapeutic agents. The cell lines include two adenocarcinoma (AC) and two 
large cell carcinoma (LCC) cell lines. They were pulse-selected with taxol and 
carboplatin, both of which are clinically relevant drugs for treatment of this type of 
cancer. The eight novel cell lines obtained were tested for sensitivity to a cross-section 
of chemotherapeutic agents and for expression of the multidrug resistance (MDR) 
efflux pump proteins, Pgp and MRP-1. The taxol-selected variants were chosen for 
further analysis because the resistance profile was stable and the concentration of drug 
used for selection was at a clinically achievable level. Microarray analysis was used to 
identify genes associated with the development of taxol resistance. Ten differentially 
expressed genes with a possible role in taxol resistance were chosen from this analysis. 
These genes were further investigated by siRNA transfection, in order to determine the 
functional relevance of these genes in drug resistance. The taxol-selected variants 
analysed by microarray analysis provide a unique opportunity to study less well 
characterised mechanisms of taxol resistance, since these variants do not display 
classical MDR.
Section 1.0: Introduction
1.1 Lung Cancer
Cancer has become the most feared disease of the last century in the western world.
In fact, the term “cancer” includes over a hundred different forms of the disease. 
Cancer can develop from nearly every tissue in the body. It develops when a mutation 
occurs in a gene in a normal cell resulting in its transformation. The cell might then 
undergo uncontrolled proliferation and gain the ability to migrate away from its tissue 
of origin (Weinberg, 1996). Among all types of cancer, lung cancer is the most 
common form. The national cancer registry (All-Ireland cancer statistics 1994-1996) 
reported that there is an average of 2300 lung cancer deaths per year in Ireland. It is 
approximated that 87% of lung cancer cases are caused by cigarette smoking (Hecht, 
2002), but this figure may be as high as 95%. Smoking has also been associated with 
many cancers other than lung cancer such as oral and oesophageal cancers. The most 
powerful carcinogens in tobacco are polycyclic aromatic hydrocarbons (PAHs), N- 
nitrosamines and aromatic amines. Since only approximately 20% of smokers develop 
lung cancer (Hecht, 2002), it is believed that some people are more susceptible to the 
carcinogens in tobacco than others. Other causes of lung cancer include exposure to 
chemicals such as asbestos and arsenic, as well as the naturally occurring radioactive 
gas radon. Passive smoking of environmental tobacco smoke (ETS) has been linked 
with the development of lung cancer in non-smokers. Lung cancer, therefore is one of 
the easiest cancers to prevent, but remains one of the most difficult to cure.
1.1.1 Lung cancer classification
Symptoms associated with lung cancer are cough, dyspnoea, haemoptysis and post 
obstructive pneumonia, (Hoffman et al., 2000), although lung cancer can present 
initially with no symptoms. Diagnosis is achieved by either invasive or non-invasive 
methods. Non-invasive methods for diagnosing lung cancer include sputum cytology 
and chest radiography. From here, invasive techniques such as bronchoscopy and lung 
biopsy are usually necessary. While the location and size of the lung tumour can be 
estimated from a chest x-ray or CT scan, accurate diagnosis and staging requires a 
biopsy, to histologically type the cells and determine if local nodes are involved.
1
Lung cancer is divided into 2 main groups, small cell lung cancer (SCLC) and non­
small cell lung cancer (NSCLC). The cellular classification of lung cancer types can 
be seen in Table 1.1.
Table 1.1 Lung cancer -  cellular classification
NSCLC Squamous cell carcinoma
(a) Spindle cell variant
Adenocarcinoma
(a) Acinar
(b) Papillary
(c) Bronchioalveolar
(d) Solid carcinoma with mucin formation
Large cell carcinoma
(a) Giant cell carcinoma
(b) Clear cell carcinoma
SCLC Small cell carcinoma
(a) Oat cell carcinoma
(b) Intermediate cell type
(c) Combined oat cell carcinoma
This histologic classification was compiled by the World Health Organisation (WHO). 
SCLC and the subtypes of NSCLC -  adenocarcinoma, squamous cell carcinoma and 
large cell carcinoma, account for 95% of lung cancers. SCLC accounts for 
approximately 20% of all lung cancers. These tumours are very aggressive and 
generally present with distant métastasés at diagnosis. SCLC usually originates from a 
central location in the lung. These tumours have a rapid growth rate, and have the 
poorest prognosis of all lung cancer subtypes.
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NSCLC is further divided into three categories, squamous cell carcinoma (30% of all 
lung cancers), adenocarcinoma (40%) and large cell carcinoma (10%). Squamous cell 
carcinoma usually develops from within a central bronchus in the lung and commonly 
displays central cavitation from necrosis. They are characterised by keratin formation. 
Squamous cell carcinomas are slow growing and develop metastases at a late stage. 
Adenocarcinomas usually develop centrally from surface epithelial cells in larger 
bronchi. They are characterised by gland formation or the presence of mucus 
production. These tumours tend to metastasise early and have a rapid growth rate. A 
common subtype of adenocarcinoma is bronchioloalveolar carcinoma (BAC). This is 
one of the rarer classes of lung cancer that is not associated with tobacco. Large cell 
carcinoma is characterised by large cells with large nuclei and prominent nucleoli. 
These tumours are usually poorly differentiated and tend towards large peripheral 
masses.
Staging of lung cancer is very important, since it will determine the type of treatment 
received. The international staging system for lung cancer can be seen in Table 1.2. 
This staging system classifies the cancer based on the Tumour, Node, Metastasis 
(TNM) designation.
The designation Tl-4 refers to the size and location of the primary tumour: T1 refers 
to a tumour that is less than 3 cm in size; T2 refer to a tumour that is greater than 3 cm 
dimension, involves the main bronchus and invades visceral bronchus; T3 refers to a 
tumour of any size involving chest wall, diaphragm, mediastinal pleura or parietal 
pericardium and T4 refers to a tumour of any size that invades major structures e.g. 
heart, oesophagus, mediastinum, or has a malignant pleural effusion.
The involvement of regional lymph nodes is assessed next in the staging process: NO -  
no metastasis to nodes; N1 -  metastasis to ipsilateral peribronchial and intrapulmonary 
nodes; N2 -  metastasis to isilateral mediastinal or subcarinal lymph nodes and N3 -  
metastasis to contralateral mediastinal, hilar scalene or supraclavicular lymph nodes.
In cases where distant metastases are present (Ml), the tumour is diagnosed as stage 
IV lung cancer. Early stage lung cancers are the most treatable, with later stage 
cancers such as stage IIIB and IV being virtually incurable.
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Table 1.2 International staging system for lung cancer
Stage Tumour (T) Nodes (N) Metastasis (M)
Occult TX NO MO
0 Tis NO MO
IA T1 NO MO
IB T2 NO MO
IIA T1 N1 MO
HB T2 N1 MO
T3 NO MO
111A T1 N2 MO
T2 N2 MO
T3 N1 MO
T3 N2 MO
111B Any T N3 MO
T4 N2 MO
IV Any T Any N Ml
(TX -  primary tumour cannot be assessed; Tis -  carcinoma in situ)
1.1.2 Treatment of lung cancer
The choice of treatment for patients with lung cancer depends strongly on the stage. 
Other details taken into account include clinical stage, pulmonary function and cell 
type. Surgery is the major therapeutic option for lung cancer patients, however; 
approximately 75% of lung cancers are inoperable at time of diagnosis. The type of 
surgery available for treatment of lung cancer are segmental resection, lobectomy, 
sleeve resection and pnemonectomy. Surgery is only curative in patients with early 
stage lung cancer. Radiation therapy can also be curative for a small percentage of 
patients. Currently, chemotherapy can offer improvement in median survival, but 
overall survival from lung cancer is poor. Chemotherapy is the use of pharmaceutical 
agents for the treatment of a disease and overall has been very successful in the
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treatment of certain types of cancer. The main aim of chemotherapy is to kill the 
tumour cells with the least possible effect on normal cells. Chemotherapy is mainly 
based on empirical data and clinical experience (Debatin, 2000). Chemotherapy is 
often used in combination with surgery or other therapies such as radiotherapy, known 
as adjuvant chemotherapy. It is especially important for increased survival in cancer 
patients were these other treatments have failed.
For patients with early stage (I or II) NSCLC, surgery is the treatment of choice. After 
resection of these tumours, adjuvant chemotherapy is generally given to the patients. 
Locally advanced NSCLC is treated with a combination of radiotherapy and 
chemotherapy. In advanced NSCLC, surgery is not usually attempted. Chemotherapy 
is the treatment of choice for these tumours. This generally consists of a platinum 
agent in combination with another anticancer agent. In these situations, chemotherapy 
is used to increase survival time, rather than to cure the patient. Chemotherapeutic 
drugs used to treat NSCLC patients are traditionally cisplatin, carboplatin, VP-16, 
vinblastine, vindesine and more recently taxol, taxotere, irinotecan, vinorelbine and 
gemcitabine. Regimens using a combination of two or more chemotherapy drugs have 
shown higher response rates and increased survival for lung cancer patients. In 
particular, the combination of gemcitabine and cisplatin has been shown to be a very 
effective combination against NSCLC (Manegold, 2002).
SCLC is such an aggressive cancer that at diagnosis, median survival time is 3 months 
without treatment (Chrystal et al., 2004). In the treatment of SCLC primarily cisplatin, 
carboplatin VP-16, cyclophosphamide, adriamycin, vincristine, lomustine and 
ifosfamide are used. Although combination therapy has shown good response rates, 
median survival time of SCLC patients remains low. The most commonly used 
combination in the treatment of SCLC is etoposide and cisplatin.
Chemotherapy has a role in increasing median survival time in advanced lung cancer, 
and preventing recurrence in resected early stage lung cancer. However, the promise 
of better treatments for lung cancer lies in a better understanding of the disease. New 
agents such as tyrosine kinase inhibitors and angiogenesis inhibitors show potential 
both on their own and particularly in combination with the standard treatments (Hirsch 
et al., 2002).
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1.2 Chemotherapeutic agents
The most commonly used chemotherapy drugs are classified in different chemical 
groups, e.g. taxanes, vinca alkaloids, platinum compounds, antracyclines, 
epipodophyllotoxins and antimetabolites, to name only a few. The agents used in this 
study are discussed below.
1.2.1 Taxol and Taxotere
Taxol (paclitaxel) and taxotere (docetaxel) are members of the taxane family. The 
taxanes are complex esters. Taxol was originally isolated from the pacific yew tree 
(Taxus brevifolia) in 1971. Taxotere is a semisynthetic derivative from the european 
yew tree (Taxus baccata). Both drugs share a tricyclic taxane skeleton (Figures 1.1 
and 1.2). Taxanes interfere with microtubules by reversible high affinity binding of 
the drugs to polymerised microtubules (Francis et al., 1995). The drugs promote 
assembly of microtubules by shifting the equilibrium between soluble tubulin and 
microtubules towards assembly. This results in a stabilisation of microtubules even 
under conditions that usually promote disassembly. This stabilisation damages the 
cells by disturbing microtubule-dependent cytoplasmic structures that are required for 
mitosis and maintenance of cellular morphology. Inhibition of depolymerisation of 
microtubles leads to cell cycle arrest between the prophase and anaphase stages and to 
eventual apoptosis (Miller & Ojima, 2001). Resistance to taxol is usually associated 
either with altered expression of a- and p* tubulins or with overexpression of P-gp.
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Figure 1.1 Structure of taxol
Figure 1.2 Structure of taxotere
7
1.2.2 Vincristine
Vincristine is a naturally occurring vinca alkaloid derived from the periwinkle plant 
Catharanthus roseus. The structure of vincristine is shown in Figure 1.3. Vincristine 
is used in the treatment of many cancers including leukaemia, breast cancer and lung 
cancer. This agent may have a variety of mechanisms of action, but it is mainly 
believed to exert its antitumour effect by interfering with the function of microtubules. 
Vincristine inhibits polymerisation of mitotic spindle microtubules by binding to 
tubulin, resulting in the inhibition of mitosis (Gidding et al, 1999). Resistance to 
vincristine is usually associated with an overexpression of P-gp and MRPs. Other 
possible mechanisms of resistance to vincristine include changes in tubulin and 
apoptosis.
Figure 1.3 Structure of vincristine
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1.2.3 Carboplatin and Cisplatin
Two platinum agents were used in this work, cisplatin (cis-diamminedichloro-platinum 
(II)) and carboplatin (cis-diammine-l,l-cyclobutandicarboxylateplatinum (II)). Their 
structures can be seen in Figure 1.4. Platinum-containing chemotherapeutic agents 
most likely exert their cytotoxic effect by reacting with DNA and interfering with 
DNA replication and cell division, however the mechanism of action is not very well 
understood. Resistance to cisplatin and carboplatin is associated with decreased 
uptake of the drug into the cells; inactivation of the drug by cellular thiol compounds 
and enhanced repair of platinum-related DNA damage and absence of mismatch repair. 
The formation of conjugates between the thiol glutathione (GSH) and platinum drugs 
results in a complex, which is a substrate for ABC transporter proteins. This is 
considered a key step in the mechanism of resistance for these drugs (Longley & 
Johnston, 2005).
O
(a)
O
Figure 1.4 Structure of (a) cisplatin and (b) carboplatin
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1.2.4 Adriamycin
Adriamycin, also known as doxorubicin, is a member of the anthracyclines. The 
structure of adriamycin can be seen in Figure 1.5. Antracyclines are widely used in the 
treatment of cancer. Adriamycin has a number of known mechanisms of action. It can 
bind tightly to DNA by intercalation, interfering with RNA and DNA synthesis. 
Adriamycin also induces protein-linked double stranded DNA breaks and interferes 
with the repair mechanism of topoisomerase II. The drug somehow interferes with the 
DNA strand breakage reunion of topoisomerase II. Resistance to adriamycin is usually 
caused by decreased drug accumulation due to actions of members of the ATP-binding 
cassette family. Resistance may also be caused by downregulation or mutation of 
Topoisomerase II.
Figure 1.5 Structure of adriamycin
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1.2.5 VP-16
VP-16 (etoposide) is a semi-synthetic derivative of podophyllotoxin, a microtubule 
inhibitor found in extracts of the mandrake plant (Figure 1.6). The enzyme 
topoisomerase II is the major target of this drug in eukaryotic cells. VP-16 poisons 
Topoisomerase II converting the enzymes into physiological toxins and generally 
leading to cell death by apoptosis (Hande, 1998). Resistance to VP-16 may involve 
altered expression of Topoisomerase II or overexpression of P-gp and MRP-1 leading 
to decreased intracellular accumulation of the drug.
0P03H,
0
Figure 1.6 Structure of VP-16
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1.2.6 5-Fluorouracil
The most commonly used member of the antimetabolite group of agents is 5- 
Fluorouracil (5-FU). Its structure is shown in Figure 1.7. 5-FU has several major 
mechanisms of action. It can be metabolised to 5-Fluorodeoxyuridine monophosphate 
(5dUMP), which inhibits thymidylate synthetase and consequently DNA synthesis. 
Secondly, it can be converted to 5-fluorouridine triphosphate (FUTP) which is 
incorporated into RNA leading to impairment in the function and processing of RNA. 
5-FU residues can also be incorporated into DNA. These residues are excised leading 
to DNA damage. Resistance to 5-FU may be due to increased expression of 
thymidylate synthetase and alterations in the metabolism of the drug.
Figure 1.7 Structure of 5-Fluorouracil
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1.3 Chemotherapy resistance
A major obstacle in the use of chemotherapy for cancer treatment is the development 
of resistance. Consequently, a better understanding of the mechanisms of drug 
resistance would help to overcome this obstacle. Intrinsic and acquired drug resistance 
are believed to cause treatment failure in over 90% of patients with metastatic cancer 
(Longley & Johnston, 2005). Some tumours are initially sensitive to an anticancer 
agent and, over time, develop a resistance to it and this is referred to as acquired 
resistance. Whereas, other tumours are resistant before treatment and this is known as 
intrinsic resistance. One of the major factors leading to drug resistance is decreased 
drug accumulation. This is caused by decreased drug influx or enhanced drug efflux, 
both of which result in the chemotherapeutic agent not exerting its effect on the 
tumour. Drug resistance can also be caused by modified drug activation, drug 
inactivation, alterations in DNA repair mechanisms and altered response to apoptosis. 
Treatment with one agent can often lead to associated resistance to a number of 
unrelated agents. The development of resistance to a variety of unrelated 
chemotherapeutic drugs is called multiple drug resistance (MDR). MDR is caused by 
a variety of changes in the cancer cells and is almost always multifactorial.
1.3.1 P-gp
Classical multidrug resistance is mediated by P-glycoprotein (P-gp) and is the best- 
characterised mechanism of resistance. P-gp is a member of the ATP-binding cassette 
(ABC) family of transporter molecules. It is a 170kDa membrane-bound glycoprotein, 
encoded by the MDR1 gene present on chromosome 7q21. P-gp is made up of two 
homologous halves which contain six transmembrane domains and an ATP-binding 
domain, separated by a linker protein. P-gp is an energy dependent pump, capable of 
transporting hydrophobic compounds out of the cell (Ambudkar et al., 1999). P-gp is 
frequently overexpressed in post-chemotherapy tumours where it hinders the cytotoxic 
response to drugs, thus somewhat desensitising the cells. Overexpression of P-gp is 
associated with decreased cellular uptake of a drug, which allows cells to survive in the 
presence of higher drug concentrations. This drug transport can happen against a 
concentration gradient. Drug enters the cells via a non-energy dependent mechanism 
and leaves via this active ATP pump (Germann, 1993). P-gp can transport a wide
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range of compounds, which share little significant structural similarity. These 
compounds can vary in size from 250Da to 1.9kDa and are usually organic (Schinkel, 
1997). Chemotherapeutic agents known to be pumped by P-gp include vincristine, 
taxol and adriamycin (Figure 1.8).
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Figure 1.8 P-glycoprotein (P-gp) as a transmembrane drug efflux pump. 
(Sorrentino, 2002).
1.3.2 MRP family
Multidrug resistance-associated proteins (MRPs) are ATP-binding cassette 
transmembrane transporter proteins. MRP1 is the most characterised member of the 
group. The MRP1 gene encodes a 190kDa transmembrane protein whose structure is 
somewhat homologous to P-gp/MDRl. It is located in the plasma membrane and 
endoplasmic reticulum of drug-resistant cells. MRP1 is thought to transport both 
hydrophobic compounds and anionic drug conjugates (Klein et al., 1999). In general, 
MRP1 relies on intracellur levels of glutathione (GSH) for drug transport. 
Chemotherapeutic agents known to be pumped by MRP1 include etoposide and 
adriamycin. Increased expression of MRP 1 is associated with drug resistance, which 
can be reversed by a decrease in its expression. MRPs are often overexpressed in 
NSCLC.
Both P-gp and MRP are members of the ABC-protein family. These proteins function 
as transport ATPases hydrolysing ATP in conjunction with transporting their substrate 
molecules through cellular or intracellular membranes. Although P-gp and MRP-1 
have only 15% sequence homology, both function in an energy-dependent drug efflux 
system which reduces intracellular accumulation of drug. Other members of the ABC 
family of transporters include MRP2, MRP3, MRP4, MRP5 and BCRP. These family 
members are also involved in drug efflux, however, they are not as extensively studied 
as P-gp and MRP1.
1.3.3 LRP
Lung resistance-related protein (LRP) is a llOkDa vesicular protein which is 
overexpressed in a variety of tumour cells that display intrinsic or acquired 
chemoresistance. LRP is identical to the human major vault protein. Vaults are the 
largest known ribonucleoprotein complexes and are highly conserved among 
eukaryotes. The function of vaults is not fully understood; they might play a role in 
the transport of drugs into cytoplasmic vesicles or directly out of a cell (Borst et a l, 
1997). Upregulation of LRP has been shown to be associated with an increase in drug 
resistance, however, a study by Siva et al. (2001), showed that upregulation of this 
protein alone is not sufficient to confer drug resistance to a cell line in vitro.
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1.3.4 Reversal of MDR
A large number of studies have focussed on blocking the function of multidrug 
resistance pumps, thus attempting to reverse MDR. Some non-toxic compounds can 
inhibit drug transport by acting as competitive or non-competitive inhibitors or 
inhibiting ATP binding. Non-steroidal anti-inflammatory drugs (NSAIDS) such as 
sulindac and indomethacin have been shown to increase the cytotoxic effects of 
commonly used chemotherapy drugs in cells which have become resistant. Early 
studies in this area observed that P-gp inhibitors such as verapamil were efficient in 
vitro but were poor inhibitors in vivo. This led to the development of second- and 
third-generation P-gp inhibitors such as GF120918, also known as elacridar. This 
inhibitor is highly effective and was developed specifically for P-gp (Schinkel and 
Jonker, 2003). It has proven more difficult to obtain a specific MRP1 inhibitor. 
Studies in our laboratories show that sulindac is a potent inhibitor of MRP 1, enhancing 
the effect of doxorubicin in human tumour xenografts (O’Connor et al., 2004).
1.3.5 MDR and invasion and metastasis
The ability of tumour cells to move from the primary tumour, travel through the 
circulatory system and establish a secondary tumour at a distant site is known as 
metastasis and is a leading cause of death among cancer patients. Many processes are 
necessary to allow a tumour cell to metastasise. These include angiogenesis, changes 
in cellular attachment, degradation of the extracellular matrix and the ability of the 
tumour cells to grow in the secondary site (Woodhouse et al, 1997).
Invasion is a critical step in the process of metastasis. Invasion is the active 
translocation of neoplastic cells across tissue boundaries and through host cellular and 
extracellular barriers (Liang et al., 2002). In order for a cancer cell to invade, three 
steps must occur: proteolysis of the extracellular matrix (ECM); pseudopodial 
extension and cell migration (Woodhouse et al., 1997). Proteolysis of the ECM can be 
caused by matrix metalloproteinases, a family of zinc-binding enzymes.
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The correlation between drug resistance and invasion in cancer cells remains unclear. 
There is reason to suspect a link considering that tumour cells selected for resistance to 
chemotherapeutic drugs often become more invasive relative to sensitive parental cells 
(Liang et al., 2004) and that it has been observed that secondary metastatic tumours are 
in some cases more resistant to chemotherapy than primary tumours (Furukawa et al., 
2000). Studies in our laboratories on the human nasal carcinoma cell line, RPMI- 
2650, indicate that pulse-selection with taxol while leading to an increase in drug 
resistance, did not promote in vitro invasiveness in the human nasal carcinoma cell 
line. However, selection with the anticancer agent melphalan increased in vitro 
invasiveness (Liang et al., 2001). Furthermore, mitoxantrone, 5-FU, methotrexate, 
BCNU, cisplatin and chlorambucil induced an invasive phenotype in the human lung 
carcinoma cell line, DLKP, whereas VP-16, vincristine, taxotere and CCNU did not 
(Liang et al., 2004.).
1.4 Taxol resistance
As mentioned earlier, taxol is a drug from the taxane family used in the treatment of 
many cancers. Resistance to taxol is a significant problem associated with the use of 
this drug. Studies have shown that development of resistance to taxol is associated 
with cellular transport of the drug and the binding of taxol to microtubules. It has also 
been shown recently that certain oncogenes may be involved in taxol resistance.
Taxol-resistant cell lines have been shown to overexpress the efflux pump P-gp, but 
not MRP1 (Van Ark-Otte et al., 1998; Dumontet et al., 1996). Huang et al. (1997) 
demonstrated that in a taxol resistant subline of HL60, P-gp overexpression led to 
decreased taxol accumulation in the cells and impaired taxol-induced apoptosis. This 
group also demonstrated that MRP1 overexpression did not confer resistance against 
taxol in HL60 cells. In an earlier study by this group various taxol-resistant sublines of 
HL60 were found to overexpress P-gp and the resistance to taxol observed in these 
sublines was partially circumvented by treatment with cyclosporine or verapamil. This 
study demonstrated that the taxol resistance observed was not solely due to P-gp 
overexpression, since treatment with P-gp inhibitors only partially reversed taxol 
resistance (Bhalla et al., 1994).
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Other groups have demonstrated that resistance to taxol can be due to a P-gp-unrelated 
mechanism. The main target of taxol in cells is the microtubules. Microtubules are 
involved in a wide range of cellular functions, for example, mitosis and maintenance of 
cell shape. Microtubules are hollow cylindrical tubes consisting of highly dynamic 
polymers made up of a  and P tubulin heterodimers (Jordan, 2002). These heterodimers 
are associated to form protofilaments and these arrange laterally to form the hollow 
microtubules (Orr et al., 2003). Microtubules exhibit dynamic instability. This non­
equilibrium behaviour occurs due to the association and dissociation of tubulin dimers 
from the microtubule ends, which leads to rapid growth and shrinkage of the 
microtubules. Microtubule-associated proteins (MAPs) and proteins such as stathmin 
can stabilise microtubules through interaction with tubulin dimers and play a role in 
regulation of microtubule stability.
Alterations in assembly and disassembly dynamics of microtubules play a key role in 
the antimitotic effects of stabilising agents such as taxol. In vitro, taxol can bind to 
the microtubule polymer, enhancing the polymerisation of taxol. Taxol binds to the P- 
tubulin subunit in microtubules in a specific and reversible manner (Orr et al., 2003). 
The effect of taxol is to alter the kinetics of microtubules assembly. Taxol treatment 
leads to a decrease in the critical concentration of microtubule protein needed for 
microtubule assembly but also increases polymer mass and induces microtubule 
bundle formation. Since the microtubules of a cell are the target for the action of taxol, 
changes associated with microtubules have been implicated in resistance to the agent.
A study by Goncalves et al. (2001) on taxol resistant variants of the lung cancer cell 
line A549, which are also dependent on taxol for normal growth, determined that 
dynamic instability of microtubules was significantly increased in these 
resistant/dependent cells. They hypothesise that this instability might explain the 
dependence of these resistant cell lines on taxol for growth.
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Parekh et al. (1997) established a series of taxol-resistant human ovarian carcinoma 
clones with increasing degrees of resistance. These were used to study the 
mechanisms by which cancer cells develop resistance to taxol. The cell lines displayed 
resistance to taxol in the range of 250 to >1500-fold. They found that taxol resistance 
could develop via P-gp-mediated and non-P-gp-mediated mechanisms. Non-P-gp- 
mediated resistance to taxol may be due to alterations in the taxol-binding affinity of 
the microtubules and alterations in tubulins.
There are six P-tubulin isotypes termed class I, II, III, IVa, IVb and VI (Kavallaris et 
al., 1997). Numerous studies have demonstrated that mutations in P-tubulin, and 
differential expression of these P-tubulin isotypes have a role in determining sensitivity 
to taxol. Kavallaris et al. (1997) demonstrated the involvement of altered expression 
of P-tubulin in taxol resistance in vivo. This group studied tubulin expression in 
untreated primary and taxol-resistant ovarian tumours. They found that the taxol- 
resistant samples displayed increased expression of P-tubulin isotypes class I, III and 
IVa and proposed that it was these alterations that led to the taxol-resistant phenotype. 
In agreement with this study, Derry et al. (1997) found that microtubules composed of 
aPm- and aPiv-tubulin were less sensitive to the suppressive effects of taxol than other 
forms of tubulin.
A study by Monzo et al. (1999) identified a correlation between taxol resistance and 
mutations in P-tubulin. Missense mutations of P-tubulin were discovered in NSCLC 
patients, without prior chemotherapy treatment. The group postulate that these 
mutations might provide a survival advantage to the cells when treated with a 
microtubules-stabilising agent such as taxol. Similarly, Giannakakou et al. (1997) 
identified specific point mutations in P-tubulin which lead to decreased taxol activity 
in vitro and confer resistance to taxol. This group suggests that the mutated P-tubulin 
may alter the taxol binding site on P-tubulin, so that taxol binding is inhibited by the 
mutations.
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More recently alterations in a-tubulin have been implicated in taxol resistance. This 
was the focus of a study by Han et al. (2000). The group developed a taxol-resistant 
NCI-H460 cell line (H460/T800), which is 1000 fold more resistant to taxol than the 
parent cells and showed cross-resistance to colchicine, vinblastine and doxorubicin. 
Besides an increased expression of P-gp, the resistant cells had an overexpression of a- 
and P-tubulin. They found that down-regulation of the a-tubulin expression by 
antisense resulted in an increased drug sensitivity of the cell line, suggesting a role for 
a-tubulin in determining sensitivity to taxol. Martello et al. (2003) demonstrated that 
two taxol-resistant variants of the lung cancer cell line A549, although they display 
normal binding of taxol to the microtubules, have a mutation in the major a-tubulin 
isotype K al. The location of this mutation suggests that it may lead to altered binding 
of the regulatory proteins stathmin or MAP4 to a-tubulin.
Other studies on the development of taxol resistance have focussed on individual 
proteins involved in cell processes such as apoptosis. Survivin is a member of the 
family of inhibitors of apoptosis proteins (IAPs). IAPs are evolutionarily conserved 
proteins that interfere with the process of cell death by inhibiting caspases. Survivin 
has been linked to taxol resistance in several studies. Zafforoni et al. (2002) reported a 
correlation in vitro and in vivo between expression of survivin and resistance to taxol 
and taxotere in ovarian cancer. Similarly, Ling et al (2004) demonstrated that 
survivin expression is induced by taxol treatment and that survivin is involved in the 
evasion of taxol-induced apoptosis in resistant cells. Other proteins involved in 
apoptosis such as the Bel family of proteins have also been implicated in taxol 
resistance (Huang et al., 1997; Tang et al., 1994; Liu etal., 1998).
The tumour suppressor gene p53 has also been associated with taxol resistance. 
Rakovitch et al. (1999) demonstrated that colorectal carcinoma cells lacking functional 
p53 were more sensitive to taxol than cells expressing functional wild-type p53. There 
is conflicting literature on the importance of p53 status in determining sensitivity to 
chemotherapeutic agents. A recent study by Reinecke et al. (2005) showed p53 status 
of renal cell carcinomas did not correlate with sensitivity of these cells to taxol. The 
role of p53 in drug resistance is further discussed in section 1.6.
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Recent studies have identified novel genes and proteins believed to be involved in 
taxol resistance in cancer. Duan et al. (1999) discovered a novel gene that was 
overexpressed in a taxol resistant cell line called taxol resistance associated gene-3 
(TRAG-3). This gene was also found to be overexpressed in other cell lines 
displaying resistance to taxol. TRAG-3 is not expressed in normal tissue but is 
expressed in 43% of cancer cell lines. More recently, the same group have identified a 
novel intracellular mitochondrial protein MM-TRAG believed to be involved in both 
taxol resistance in vitro (Duan et al., 2004). Early studies on this novel gene indicate 
that it may have an association with Mdrl expression.
A study by Parekh et al. (2002) detected overexpression of a calcium-binding protein, 
sorcin, in a taxol-resistant ovarian carcinoma cell line. Introduction of sorcin into a 
number of cell lines led to a low-level taxol resistance developing. The group 
concluded that sorcin has a role in determining taxol sensitivity; however since no 
changes in calcium were detected, the mechanism was unclear. Interestingly, another 
study by Padar et al. (2004) indicated that altered intracellular calcium homeostasis 
might be involved in the development of taxol resistance in NSCLC.
Wang et al. (2004) identified a role for the helix-loop-helix protein TWIST in taxol 
acquired resistance. Upregulation of TWIST was observed in a number of different 
cancer types in association with treatment of microtubule-disrupting agents. Recent 
studies have implicated the expression of other proteins in taxol resistance such as E- 
cadherin (Ferreira et al., 2005), the mitotic kinesin Eg5 (Marcus et al., 2005) and 
caveolin-1 (Yang etal., 1998; Roussel etal., 2004).
The various studies that have focussed on mechanisms of taxol resistance reveal the 
complexity of this problem in the treatment of cancer patients with taxol.
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1.5 Drug resistance in lung cancer
Most lung cancers exhibit an intrinsic resistance to chemotherapy already at the time of 
diagnosis. Most SCLCs are chemotherapy sensitive at diagnosis, but any recurrence of 
the disease usually displays acquired drug resistance. NSCLC, on the other hand, are 
predominantly intrinsically resistant to chemotherapy. It is likely that both acquired 
and intrinsic resistance share common factors, such as expression of drug transporters.
Many groups have studied the expression of the genes involved in this type of 
resistance. Canitrot and his co-workers examined MRP-1 and MDR-1 gene expression 
in a panel of seventeen SCLC xenografts established from tumours of chemotherapy- 
treated and -untreated patients (Canitrot et al., 1998). The previously treated SCLC 
expressed MRP-1 but not MDR-1, whereas within the untreated tumour samples, six 
expressed only MRP-1, three expressed only MDR-1, five expressed both and two 
expressed none. The expression of the drug resistance markers MRP-1, LRP and 
topoisomerase II (a and (3) was studied in advanced NSCLC (Dingemans et al., 2001). 
This study found that expression of these markers did not correlate with the response 
of patients with NSCLC to standard chemotherapy. The chemotherapy regimens used 
in the study were in three combinations: cisplatin and paclitaxel; cisplatin and 
VP16/VM26; cisplatin and VP16 and ifosfamide.
Many groups have compared in vitro and in vivo lung cancer samples in order to 
determine similarities in the development of resistance. For example, Young et al. 
(1999) examined a panel of 23 unselected cell lines (SCLC and NSCLC) as well as 15 
patient samples to determine possible correlations between the expression of MRPs 
and the resistance to four chemotherapeutic agents. They showed that the cell lines 
exhibited a wide range of sensitivities. They found a higher level of resistance to all 
tested drugs in the NSCLC compared to the SCLC, a strong correlation between MRP3 
mRNA levels and the resistance to doxorubicin and a moderate correlation with 
resistance to vincristine, VP-16 and cisplatin.
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Another study linked chemoresistance of the lung cell line A549 to the expression of 
LRP (Meschini et al., 2002). The group studied two cell lines established from 
untreated tumours, A549 and the breast cell line MCF-7. A549 was much more 
resistant to doxorubicin, whereas MCF-7 cells treated with doxorubicin had 
significantly higher intracellular levels of the drug. Both cell lines express P-gp and 
MRP-1 at similar levels, but the study revealed much higher levels of lung resistance 
protein LRP in A549 cells, which could account for the difference.
1.6 The tumour suppressor p53
Termed “Guardian of the genome” p53 is a tumour suppressor gene, whose 53kDa 
phosphoprotein product is involved primarily in cell cycle arrest and apoptosis. Li 
Fraumeni syndrome (LFS) is a genetic disease where there is a germline mutation in 
p53, (Cadwell & Zambetti, 2001). People who have this disease usually develop 
malignant tumours early in life. A mutation in the p53 gene occurs in over half of all 
tumours. Mice that lack p53 can develop normally but usually die from a malignancy 
within six months, (Cadwell & Zambetti, 2001).
1.6.1 Structure and function of p53
Discovered in 1979, the p53 gene is located on human chromosome 17 and is 
approximately 20kb in length. The p53 gene is mutated in more than half of all 
tumours, giving rise to a mutated protein with a single amino acid substitution in most 
cases. Initially p53 was believed to be an oncogene because of its involvement in so 
many cancers. It was later discovered that it is the mutant form of p53 that is capable 
of immortalising and transforming cells (Cadwell & Zambetti, 2001). The gene 
contains five domains that are highly conserved through evolution, (Figure 1.9A).
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The structure of p53 can be seen in Figure 1.9B. The N-terminal sequence from amino 
acids 1-42 contains an acidic domain that is involved in activation of transcription of 
target genes. From amino acids 64-92 there is a proline rich domain consisting of five 
PXXP repeats (where P is proline and X is any amino acid). This domain is required 
for apoptosis and may be involved in the negative regulation of p53, (Figure 1.9B). 
The central core domain from amino acids 102-292 is involved in sequence specific 
DNA binding. From amino acids 324-355 the oligomerisation domain of p53 is 
responsible for the formation of p53 tetramers which is important for DNA-binding in 
a sequence specific manner. The C-terminus of p53 holds a nuclear localisation region 
capable of non-specific DNA and RNA binding, (Cadwell & Zambetti, 2001).
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Figure 1.9 Structural and functional domains of p53 protein, (Cadwell & 
Zambetti, 2001). A - The five evolutionary conserved domains of p53. B -  The 
functional domains of p53
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p53 is a sequence specific transcription factor and usually executes its function by 
activation or repression of target genes, predominantly involved in cell cycle arrest and 
apoptosis, (Colman et a l, 2000). It has a hydrophobic interface in the N-terminal for 
interaction with transcriptional machinery of the cell, and with its negative regulators, 
(Levine, 1997). p53 carries out its functions by interacting with specific protein
partners (Gallagher & Brown, 1999).
1.6.2 Activation and stabilisation of p53
In normal cells, p53 is inactive and is found at low levels, due to its relatively short 
half-life. When a genotoxic stress causes DNA damage, p53 becomes phosphorylated 
and p53 protein levels rapidly accumulate in the cell. DNA strand breaks induce rapid 
and specific activation of p53 (Pluquet & Hainaut, 2001). P53 accumulates due to 
enhanced translation of mRNA and is stabilised by post-translational modifications, 
(Cadwell & Zambetti, 2001). These post-translational modifications have been shown 
to improve the sequence specific DNA binding and transcriptional activities of p53, 
(Ryan et al., 2001). P53 translocates to the nucleus where p53 tetramers target p53- 
responsive genes to activate transcription of proteins necessary to carry out the p53 
function required, for example apoptosis or cell cycle arrest, (Colman et al., 2000). 
Since p53 senses DNA damage, it is important in determining drug sensitivity. Non- 
genotoxic stress, such as oncogene activation, hypoxia and ribonucleotide depletion, 
can also induce activation of p53, (Pluquet & Hainaut, 2001).
Activation of p53 can occur by three separate pathways. Ionising radiation causes 
DNA damage that is sensed by ‘checkpoints’ that suspend progress through the cell 
cycle until the damage has been repaired. These checkpoint proteins include DNA- 
dependent protein kinase, ATM, Chkl and Chk2. These kinases activated by DNA 
damage, phosphorylate p53 at amino-terminal sites close to the Mdm2-binding region 
of the protein, blocking its interaction with Mdm2 and leading to stabilisation of the 
protein (Vogelstein et al., 2000). Aberrant growth signals, caused by oncogenes such 
as ras and myc, leads to activation of p53 by p M ^ .  These oncogenes stimulate the 
transcription of the pi 4 ^  protein, which then binds to Mdm2 and inhibits its activity. 
Activation of p53 by cytotoxic drugs, UV and protein kinase inhibitors is mediated by 
ATR kinase and casein kinase II (Figure 1.10).
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Figure 1.10 p53 activation and downstream functions
1.6.3 Regulation of p53
Accumulation of p53 is regulated by an autoregulatory negative feedback loop 
involving Mdm2. Mdm-2 gene expression is controlled by p53 and is overexpressed 
in many tumours (Gallagher and Brown, 1999). When p53 levels are high in the cell, 
Mdm-2 is transcribed and translated. Mdm-2 binds to the amino-terminal 
transactivation domain of p53 in the nucleus, preventing its interaction with TATA 
binding protein (TBP)-associated factors necessary for the regulation of transcription 
of p53 genes. A leucine-rich area in the Mdm-2 protein, which is a nuclear export 
signal, causes transport of the Mdm-2:p53 complex into the cytoplasm. Mdm-2 can 
then induce p53 degradation through ubiquitin-mediated proteolysis, (Colman et al, 
2000). This can be seen in Figure 1.11. When p53 is inactive, the protein is unstable 
and in a conformation whereby the C-terminal domain blocks function of the DNA- 
binding domain (Pluquet and Hainaut, 2001). The disruption of the Mdm2 pathway is 
the most important mechanism for stabilisation and accumulation of p53 (Zeimet et al.,
2000).
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Figure 1.11 The p53 autoregulatory feedback-loop mechanism (Lane & Lain, 
2002)
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1.6.4 Cell cycle arrest and p53
When DNA is damaged, the activation of p53 occurs which stops the cell cycle to 
allow for DNA repair. The protein product of the Wafl/Cipl gene is p21. This gene 
is a transcriptional target of p53, with two p53-binding sites. p2iWAF1/CIP1 has a major 
role to play in p53-mediated cell cycle arrest (Gallagher and Brown, 1999). G1 arrest 
in response to DNA damage is caused by inhibition of CDKs by cyclin-dependent 
kinase inhibitors (CKIs). P21 is a CKI induced by p53, p63 and p73. Without CDKs 
the retinoblastoma protein (Rb) cannot become phosphorylated. Phosphorylation of Rb 
allows E2F to be released, leading to continuation of the cell cycle. Gadd45a (growth 
arrest and DNA damage) is also induced with Cdc2 and PCNA, which are associated 
with the cell cycle, and involved in DNA repair and G2/M cell cycle arrest (Cadwell 
and Zambetti, 2001).
1.6.5 Apoptosis
The p53 gene family are involved in all pathways of apoptosis. When DNA damage 
cannot be repaired, p53 can induce programmed cell death or apoptosis. Apoptosis can 
be triggered intrinsically or extrinsically. Within the cell, a death signal can cause 
release of cytochrome C from the mitochondria, which can interact with apaf-1 to 
activate caspases, the executioners of apoptosis. From outside the cell, certain ligands 
can bind death receptors on the cell surface, and this interaction can also lead to the 
activation of caspases. Whether apoptosis or cell cycle arrest is the p53 function 
carried out depends on the stimulus that activated p53, on the cell type (Bunz, 2001) 
and also on the environment surrounding the cell (Gallagher and Brown, 1999). 
Apoptosis can also occur by p53-independent pathways. Some of the main proteins 
involved in apoptosis are under the transcriptional control of wild-type p53. Members 
of the Bel family of proteins can regulate apoptosis in the cell. Pro-apoptotic members 
heterodimerise with anti-apoptotic members, and relative levels of these proteins 
decide the fate of the cell. The BAX gene, whose protein is pro-apoptotic, is 
transcribed by p53, since its promoter contains a p53 recognition motif. In addition, the 
expression of the Bcl-2 protein, which is anti-apoptotic, is repressed by wild-type p53 
(Gallagher and Brown, 1999), as is the expression of c-myc, a proto-oncogene 
(Cadwell and Zambetti, 2001). Overexpression of Bcl-2 can block p53-mediated 
apoptosis (Levine, 1997). Wild-type p53 also upregulates other pro-apoptotic proteins
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like the insulin-like growth factor binding protein IGF-BP3, killer/DR5 and fas/apol 
which are membrane receptors in the tumour necrosis factor receptor (TNFR) family 
(Cadwell and Zambetti, 2001). When p53 is mutated, less pro-apoptotic proteins are 
produced and proteins such as Bcl-2 and c-myc are expressed, leading to improper 
signalling and cell growth (Cadwell and Zambetti, 2001).
1.6.6 Invasion and metastasis and p53
Inhibition of metastasis may be partly controlled by p53 inducing expression of genes 
that block ECM degradation. The expression of two serpins (inhibitors of serine 
proteases), Maspin and PAI1 are regulated by p53 (Harms et al., 2004). PAI1 inhibits 
urokinase-type plasminogen activator (u-PA). U-PA usually leads to the activation of 
plasmin, which degrades ECM proteins. However, maspin is not thought to inhibit 
migration or metastasis in vivo. KAI1 is a target of p53 and has been shown to inhibit 
metastasis. The metastasis suppressor gene Nm23-Hl, a nucleoside diphosphate 
kinase, is also induced by p53 (Harms et al., 2004).
1.6.7 Mutations in p53
Mutant p53 is also capable of acting as a transcriptional activator, and can upregulate 
proteins such as MDR-1 (multiple drug resistance), PCNA, Bagl and c-myc (Cadwell 
and Zambetti, 2001). Along with these proteins involved in intrinsic apoptosis, p53 
can sometimes induce CD95 expression on the cell surface of tumours, which can lead 
to extrinsic apoptosis (Ferreira et al., 1999). The most common mutation of p53 is 
missense mutation, which leads to a protein with a single amino acid substitution. 
These mutations are usually found within the sequence-specific DNA-binding domain 
(Pfeifer and Holmquist, 1997). In a study carried out by Jassem et al., (2001), on 332 
non-small cell lung cancer patients, 96 were found to have a p53 mutation. Of these 
mutations, more than half were located on either exon 5 or exon 8.
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There are three mechanisms by which p53 mutations affect its ability to suppress 
tumourigenesis (Cadwell & Zambetti, 2001):
(1) Loss of wild-type p53 tumour suppressor function
(2) Dominant-negative inhibition of wild-type p53 function
(3) Gain of function giving selective growth advantage to cells expressing 
mutant p53.
These can be seen schematically in Figure 1.12. Most p53 mutants are highly stable 
and accumulate in the cell, in contrast to wild-type p53. In dominant negative 
inhibition, both wild-type and mutant p53 are present, but wild-type p53 becomes 
overwhelmed by the formation of dysfunctional tetramers between wild-type and 
mutant p53 (Gallagher and Brown, 1999). Mutant p53 proteins may also gain 
oncogenic properties which are not dependent on inhibition of wild-type p53, such as 
the ability to transcribe different genes as mentioned earlier. Wild-type p53 function 
can be inactivated not only by mutations, but by cellular or viral proteins which can 
sequester or degrade the protein (Gallagher & Brown, 1999). Mdm2, the main 
regulator of p53 is an example of this since it can sequester p53.
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Figure 1.12 The role of p53 mutations in tumorigenesis (Cadwell & Zambetti,
2001)
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1.6.8 Family members
The proteins p63 and p73 are homologues of p53. They both transactivate p53 target 
gene expression and induce apoptosis when overexpressed. These family members, 
unlike p53, are rarely mutated in human cancer. While p53 has predominantly a single 
isoform, there are three isoforms of p63 and seven isoforms of p73. All of the family 
members contain at least one proline-rich domain. All p53 family members are 
activated and stabilised after DNA damage (Harms et al., 2004). The proteins are 
activated and stabilised in response to common and distinct signals, allowing them to 
function independently.
1.6.9 Role of p53 in Multiple Drug Resistance (MDR)
Mutation of p53 is thought to play a major role in conferring multiple drug resistance 
to cells. Since p53 can control apoptosis and the cell cycle, if the action of p53 is 
blocked, then apoptosis or cell cycle arrest may fail to occur in response to DNA 
damage caused by drug administration. If a cell fails to die after treatment with the 
drug, it has become resistant. In other words, resistance will develop with loss of the 
genes necessary for death (Krishna and Mayer, 2000). A study carried out by Sampath 
et al. (2001), found that mutant p53 strongly upregulates human MDR1, but does not 
activate MRP1 (multidrug resistance protein). MDR1 and MRP1 are two of the most 
commonly expressed drug resistance genes.
Taking into account the functions of p53, a contradictory two-possibility scenario 
emerges. On one hand, p53 can mediate apoptosis in response to DNA damage caused 
by chemotherapy, thereby helping the cell to die. On the other hand, by inducing cell 
cycle arrest and favouring DNA repair p53 has the potential to increase resistance by 
allowing cells to live after DNA has been damaged by chemotherapeutic agents 
(Ferreira et a l , 1999). This can be seen visually in Figure 1.13.
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Figure 1.13 Outlined of the proposed influence of p53 on cellular processes 
relevant to cytotoxic therapy, (Zunino et al., 1997).
Lowe et al., (1993) carried out a study exploring the effects of p53 expression on 
normal and oncogene expressing cells following irradiation and treatment with various 
chemotherapeutic agents, and found that p53 was required for the efficient activation 
of apoptosis after treatment. Cells not expressing p53 were found to be much more 
resistant to the agents. They also noted that p53-independent cytotoxicity was more 
prevalent at high doses of irradiation or chemotherapy. The role of p53 in cell cycle 
arrest and apoptosis was investigated following treatment of lymphoma cell lines with 
y-rays, etoposide, nitrogen mustard and cisplatin (Fan et al., 1994). y-rays and 
etoposide were found to induce strong G1 arrest in wild-type p53 cells but not in 
mutant p53 cells, and caused rapid accumulation of p53 and p2iWAF1/CIP1. Nitrogen 
mustard and cisplatin induced relatively little G1 arrest and a slower accumulation of 
p53. The conclusion drawn from the results was that p53 mutations are often
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associated with increased resistance to DNA damage and that this is related to evasion 
of p53-mediated apoptosis.
Zhu et al. (1999), compared two gastric cancer cell lines HKN28, (expresses mutant 
p53), and AGS (expresses wild-type p53), for their response to treatment with the 
nonsteroidal anti-inflammatory drug (NSAID) indomethacin. It was found that the 
wild-type p53 cell line was more sensitive to growth inhibition and that in this cell 
line, indomethacin-induced apoptosis occurred more readily than in the mutant p53 
cell line. Interestingly, neither cell line showed cell cycle phase alteration in response 
to drug treatment.
The involvement of the Fas/FasL system in drug-induced apoptosis in lung cancer cells 
was investigated (Ferreira et al., 2000). It was found that although a functional Fas 
pathway existed in the cells, an independent apoptosis pathway occured after cisplatin, 
gemcitabine, topotecan and paclitaxel exposure. The study also showed that by 
comparing fas expression in wild-type and mutant p53 cell lines, Fas is probably under 
transcriptional control of wild-type p53.
Galmarini et al. (2001) studied the role of p53 in the cytotoxicity of tubulin binding 
agents on cancer cells. Tubulin-binding agents, i.e. vinca alkaloids and taxanes, are 
used regularly in treatment of cancer. This study was carried out on the breast cancer 
cell line MCF-7 and used drugs such as vinblastine and paclitaxel. The results 
obtained show that inactivation of p53 with a dominant negative mutant p53 is 
associated with resistance to the chemotherapeutic agents used.
Whether p53 status influences the level of induction of MRP family members in 
response to prooxidants was investigated in a study on the MRP family by Lin-Lee et 
al., (2001). MRP1, as mentioned earlier, is a protein associated with drug resistance, 
and is overexpressed in many cancers. The study observed that mutations in p53 were 
associated with increased expression of MRP 1 in some of the colorectal cancer cells 
examined. The mechanisms by which p53 regulated the expression of MRP 1 have not 
been discovered. It was shown that wild-type p53 can suppress MRP1, since null-p53 
cell lines express more MRP1 that wild-type p53 cell lines (Lin-Lee et al., 2001).
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A study by Qin and Ng (2002) investigated cisplatin-induced apoptosis and its effect 
on the cell cycle. The study involved two hepatoma cell lines, HepG2 (wild-type p53) 
and Hep3B (deleted p53). It was found that in wild-type p53 cells, a low dose of 
cisplatin induced transient G1 arrest, S phase block and upregulation of p53 and 
p21 wafi cipi protejns However a high dose of cisplatin led to cell growth inhibition 
and apoptosis in both cell lines. In p53 null cells there was no evidence of G1 arrest or 
accumulation of p53 or p2 i WAF1/CIP1 (Qin and Ng, 2002). This study importantly 
shows that cisplatin is capable of inducing apoptosis by p53 dependent and 
independent pathways. Most studies carried out have found that a mutation in p53 is 
connected with increased resistance to chemotherapy.
Interestingly, a few studies have found that p53 mutations can have the opposite effect. 
For example, Hawkins et al. (1996), investigated the role of p53 mutations on efficacy 
of chemotherapeutic drugs and found that a lack of p53 conferred sensitivity to the 
cells. Das et al., (2001) compared the effect of taxol on two lung cancer cell lines: 
A549 which expresses wild-type p53, and H1299 which does not express p53. Taxol 
was found to induce apoptosis in both cell lines efficiently at low doses, but the 
process was more regulated and maximum apoptosis reached at a lower drug 
concentration in the presence of p53. G2/M arrest was induced in both cell lines, 
independent of p53.
1.6.10 The role of p53 in treatment of cancer
Mutations of p53 in tumours are associated with bad prognosis. The tumours tend to 
be aggressive, with early metastasis, and lead to low survival rates. Since p53 plays a 
major role in response to chemotherapy, restoration of wild-type p53 function in 
tumour cells could increase the cells sensitivity to chemotherapy. Gene therapy is one 
of the most promising areas of cancer treatment. It involves the delivery of the wild- 
type p53 gene into tumour cells in vivo. The aim is that wild-type p53 function could 
be restored to the tumour cells so that they will become more sensitive to drug-induced 
DNA damage. The requirements for this kind of gene therapy are that there must be an 
efficient delivery system to get the genes to the tumour cells. After this there must be 
sufficient expression of the wild-type protein to mediate cell cycle arrest or cell death 
or increase sensitivity to anti-cancer agents (Gallagher and Brown, 1999).
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Many groups have transfected a wild-type p53 gene into cancer cell lines to try to 
restore its function. While there is an apparent problem with isolating clones that 
express exogenous wild-type p53, some groups have been successful in this.
For example, Wang and Beck (1998), transfected HI 299 with wild-type p53 to 
investigate the relationship between p53 and MRP. They checked for p53 protein 
expression by western blot. More recently, Liu et al., (2004) transfected H1299 with 
wild-type p53. The transfection used a GFP-tagged p53 plasmid, and p53 expression 
was observed under a fluorescent microscope.
The first group to report growth suppression induced by high level expression of 
exogenous wild-type p53 in lung cancer cells, which express normal endogenous p53 
was Cajot et al. (1992). Both wild-type and mutant p53 were transfected into the cell 
line Hut292DM using the polybrene-dimethyl sulphoxide technique. Expression of 
exogenous wild-type p53 inhibited growth of the cell line, so that low transfection 
efficiency resulted, whereas expression of exogenous mutant p53 had no apparent 
effect on the transfection efficiency. They were unable to isolate any wild-type p53- 
transfected clones that stably expressed normal exogenous p53, whereas exogenous 
mutant p53 was stably expressed in all mutant-transfected clones. They did isolate 
stable transfection clones expressing various truncated forms of p53, detected by PCR 
and northern blotting, but these clones did not affect in vitro growth properties.
Baker et al. (1990) found similar results working with two colorectal carcinoma lines- 
SW837 and SW480 which express mutant p53. They transfected wild-type cDNA and 
mutant cDNA-containing vectors into these cell lines. Of the mutant p53-transfected 
cells, 38% were found to express exogenous mutant p53 mRNA, while no expression 
of wild-type p53 mRNA was seen in any transfected clones. Clones isolated from 
wild-type p53-transfected cells were found to contain deleted or rearranged exogenous 
p53 sequences. The group concluded that the wild-type p53 gene was incompatible 
with proliferation of these cell lines.
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Examination of wild-type p53 for suppression of growth of lung cancer cells, and how 
mutations of single amino acids changes the biological effects of the wild-type p53 
gene was carried out (Takahashi et al., 1992). They worked with two cell lines, NCI- 
H358, which is p53 null and NCI-H23, which expresses mutant p53, and transfected 
each with a wild-type p53 expression vector, and a mutant p53 expression vector. 
They found that expression of exogenous wild-type p53 was incompatible with cell 
growth in the p53 null cell line, while stable expression of the mutant protein was 
found in the mutant p53-transfected clones. Again, this group isolated no wild-type 
p53-transfected clones that contained an intact p53 gene. Introduction of wild-type 
p53 into the mutant p53-expressing cell line had no significant effect, suggesting the 
mutant protein was sufficient to inactivate the growth suppressive effect of wild-type 
p53. In the mutant-p53 cell line, exogenous wild-type p53 was stably expressed after 
transfection, but at a lower level than the endogenous mutant p53.
Matsumoto et al. (1997), looked at the relationship between p53 functions and cellular 
thermosensitivity using murine fibroblasts transfected with either wild-type p53 or 
mutant p53 or cells with no p53 expression. Cells transfected with wild-type p53 were 
approximately two-fold more sensitive to heat than cells transfected with mutant p53. 
Also G1 arrest was observed in all cell lines in response to heat but it was more 
prominent in wild-type p53-transfected cells.
In a similar study, Ota et al. (2000) confirmed that cancer cells show p53-dependent 
heat sensitivity through an apoptosis-related mechanism in cells with different p53 
status. The cell line SAS was used which have a point mutation at codon 336 of exon 
10 of the p53 gene, but expresses a wild-type p53 phenotype. A stable transfection of 
a mutant p53 gene, which produces a dominant negative mutant p53 protein, was 
carried out by electroporation. The parent cells were found to be more sensitive to 
heat than clones expressing the mutant p53 gene. It was also found that the rate of 
apoptosis was approximately seven-fold higher in the parent cell line than in the 
mutant clonal cell line.
Shaw et al. (1992) investigated the function of wild-type p53 by studying effects of 
wild-type p53 re-expression in the human colon tumour cell line EB, which is deficient 
in endogenous p53. Expression of the p53 gene was induced by induction of the
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metallothionein promoter. They found that induction of wild-type p53 expression 
prevented tumour formation in nude mice, and also that two months of wild-type p53 
expression resulted in elimination of established tumours in mice.
More commonly, p53 function has been restored using adenovirus-mediated gene 
transfer. For example, Inoue etal. (2000) constructed a recombinant adenoviral vector 
expressing wild-type p53 and applied this vector with anti-cancer drugs to three human 
NSCLC cell lines -  one with wild-type p53, one with mutated p53 and one with 
deleted p53. The major finding was that Ad-p53 infection combined with anticancer 
drugs can induce G1 arrest, cell growth inhibition and possibly apoptosis, especially in 
the deleted p53 cell line. In a similar study, the efficiency of adenovirus-mediated 
transfer of p53 gene with anti-cancer agents in vitro and in vivo was investigated 
(Osaki et al., 2000). It was found that expression of p53 influenced chemosensitivity. 
Several drugs were tested for their suitability in combination with gene transfer, and it 
was decided that CPT-11 and 5-FU would be successful in NSCLC, (Osaki et al., 
2000). They also noted that the presence of mutant p53, rather than the loss of wild- 
type p53 protein, confers a selective growth advantage and promotes clonal expansion 
of tumour cells.
Liu et al. (1995) examined the mechanism of growth suppression by wild-type p53 
overexpression induced via adenovirus-mediated gene transfer. A wild-type p53- 
containing adenovirus Ad5CMV-p53 was used to infect two cell lines Tu-138, which 
expresses mutant p53, and MDA 686LN, which expresses wild-type p53. They found 
that growth suppression occurred in cells after p53 gene transfer and that this 
suppression was independent of the endogenous p53 status. However, growth 
suppression occurred earlier and was more profound in the Tu-138 cell line, which 
expresses endogenous mutant p53. The wild-type p53 gene was introduced into H358 
cells, which are p53 null, using an adenoviral vector (Fujiwara et al., 1994). They 
determined that this increases the cells sensitivity to a chemotherapy drug, in vitro and 
in vivo.
The efficacy of adenovirus-mediated p53 gene therapy in combination with paclitaxel 
against a number of tumour cell lines was examined by infecting cell lines expressing 
mutant p53, or with no p53 expression with an adenovirus containing the wild-type
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p53 gene (Ad-p53) (Nielsen et al., 1998). They found that paclitaxel had a synergistic 
or additive effect in combination with Ad-p53 independent of whether cells expressed 
mutant p53 or no p53 protein.
Huang et al. (2000) examined levels of p53, p21, BAX, Bcl2, MDM-2 and pRb after 
transfection of Ad5-p53 into three cervical cancer cell lines in order to discover how 
the cell decides between p53 dependent apoptosis versus cell cycle arrest. In the cell 
line expressing mutant p53, the levels of exogenous wild-type p53 were much higher 
than levels of endogenous mutant protein after transfection. Overall, the transfection 
resulted in restoration of wild-type p53 function, causing G1 arrest and also apoptosis 
in these cell lines.
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1.7 Microarrays
Each cell in the body contains a full set of chromosomes containing identical genes. 
At any given time only a fraction of these genes are expressed. It is this group of 
expressed genes that makes each cell type unique. Aberrant gene expression profiles 
are responsible for many diseases. The completion of the Human Genome project 
(HGP) in 2003 has led to a huge amount of information becoming available about 
almost every gene in the genome, and is necessary to understand more about the 
functions of these gene products. New advances in technology, for example, the 
development of full genome expression microarrays, have allowed researchers to study 
the expression of almost every gene simultaneously. It is important to note, however, 
that we may not yet have identified all genes correctly, from the sequence data, and 
certainly our knowledge of the range of splice variants is incomplete.
1.7.1 Introduction to microarray technology
Microarrays are artificially constructed grids of DNA such that each element of the 
grid contains a specific oligodeoxynucleotide probe. This enables researchers to 
simultaneously measure the expression of thousands of genes in a given sample. 
Microarray experiments rely on the ability of RNA to bind specifically to a 
corresponding sequence-complementary probe. DNA microarrays are classified based 
on the DNA molecule that is immobilised on the slide. There are two basic types: 
either “oligodeoxynucleotide” or “cDNA” arrays. Oligodeoxynucleotide arrays are 
typically made up of 25-80 mer oligodeoxynucleotides while cDNA arrays are printed 
with 500-5000 base pair PCR products.
Microarray technology can be used to detect specific gene changes in, for example 
diseased tissue compared to normal healthy tissue, or the changing gene expression 
profiles of developing tissues at incremental time points. These types of experiments 
have the potential to explain not only why a disease occurs, but also how best to 
overcome it by enhancing our understanding of the mechanisms behind diseases, their 
development and progression.
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The steps of a microarray experiment are shown in Figure 1.14. This is an example of
an affymetrix genechip experimental workflow:
1. Total RNA is isolated from the cells being studied
2. The RNA is enzymatically converted into a double stranded DNA copy known 
as a complementary DNA (cDNA). This is done through reverse transcription 
(RT).
3. The cDNA is allowed to go through in vitro transcription (IVT) to RNA (now 
known as cRNA). This RNA is labelled with Biotin by incorporating a biotin- 
labelled ribonucleotide during the IVT reaction.
4. This labelled cRNA is then fragmented in to pieces anywhere from 30 to 200 
base pairs in length by metal-induced hydrolysis.
5. The fragmented, Biotin-labelled cRNA is then hybridized to the array for 16 
hours.
6. The array is then washed to remove any unhybridized cRNA and then stained 
with a fluorescent molecule streptavidin phycoerythrin (SAPE), which sticks to 
Biotin.
7. Lastly, the entire array is scanned with a laser and the information is 
automatically transferred to a computer for analysis of what genes were 
expressed and at what approximate level.
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Figure 1.14 Steps in a microarray experiment (www.affymetrix.com)
1.7.2 Microarray analysis
Microarray experiments generate vast amounts of data in a short period of time. For 
the results of a microarray experiment to be acceptable, the raw data from the 
experiment must be validated. Good experimental design is the first step. It is 
important that the proper controls and replicates are included in each experiment. 
Replicates are particularly important since the methods used to identify differentially 
expressed genes are predominantly statistical. Microarray data is normalised to 
measure real biological changes by minimising processing variation. This process 
standardises the data so that the gene expression levels are comparable.
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Quality control checks must also be included at all stages of the experiment. These 
checks would usually include quality checks on the initially isolated RNA and 
processed sample at regular intervals, e.g. Agilent Bioanalyzer. The Agilent 
Bioanalyzer analyses sample RNA in order to determine quality. Detailed information 
about the condition of RNA samples is displayed in the form of highly sensitive 
electropherograms. Post-experimental quality control checks include the chip controls 
shown in Table 1.3.
Table 1.3 Array quality control measures
QC measure Result
Background Measure of non-specific binding
375’ Ratio Indicates how well IVT reaction has proceeded
Hybridisation controls Checks spike controls added to each sample
Percentage present All samples should have comparable % genes present
Noise The electrical noise from scanner
Scale factor Measures the brightness of array- All chips in an experiment 
should have scale factors within 3-fold of each other
The ideal format for reporting microarray data was reported by Brazma et al. (2001), 
and is called the “minimum information about a microarray experiment” (MIAME). 
MIAME has two general principles. The first is that there should be sufficient 
information recorded about each experiment to allow interpretation of the experiment, 
comparison to similar experiments and replication of the experiment. The second 
principle is that the data should be structured to allow automated data analysis and 
mining.
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1.7.3 Affymetrix GeneChips
The microarray experiments carried out in these studies employed the Affymetrix 
Genechip system, which are oligodeoxynucleotide microarrays. Affymetrix probes are 
designed using publicly available information (NCBI database). The probes are 
manufactured on the chip using photolithography, which is adapted from the computer 
chip industry. Each genechip contains approximately 1,000,000 features. Each probe 
is spotted as a pair, one being a perfect match (PM), the other with a mismatch at the 
centre (MM). Each gene or transcript is represented on the genechip by 11 probe pairs 
(PM+MM). This can be seen in Figure 1.15. As well as helping estimate and 
eliminate background, with 22 different probes in total, researchers can be sure that the 
microarray is detecting the correct piece of RNA. The amount of light emitted at 
570nm from stained chip is proportional to the amount of labelled RNA bound to each 
probe. Therefore, after scanning, the initial computer file generated ( DAT) contains a 
numerical value for every probe on the array.
Figure 1.15 Perfect match and mismatch probe pairs on Affymetrix GeneChips 
(www.afTymetrix.com)
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1.7.4 Bioinformatics
Bioinformatics is the collection, organization and analysis of large amounts of 
biological data, using networks of computers and databases. Software packages are 
available to analyse microarray data e.g. Genespring and Spotfire. The data analysis 
software used for the analysis of these microarray experiments was dChip, (Lin et a l, 
2004). This software is capable of probe-level and high-level analysis of Affymetrix 
gene expression arrays. High-level analysis in dChip includes comparing samples and 
hierarchical clustering in order to identify differentially expressed genes. Hierarchical 
clustering displays the relationships among genes or samples. These are represented 
by a tree where the length of the branches reflect the degree of similarity between the 
objects (Eisen et al., 1998). An example of a cluster can be seen in Figure 1.16.
Other bioinformatics software available facilitates pathway analysis of genes 
differentially regulated in the systems studied.
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Figure 1.16 Example of a hierarchical cluster of microarray samples
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1.7.5 Microarrays and cancer
Microarray technology is and has been used intensively to better understand the 
development of resistance to chemotherapeutic agents, both in vivo and in vitro. 
Whiteside et al. (2004) reported a novel method using time-course cDNA microarray 
analysis designed to evaluate which differentially expressed genes are directly 
involved in the development of drug resistance. The study used two lung cancer cell 
lines; one which readily developed resistance to cisplatin and another which after 
treatment with cisplatin did not display stable resistance. They identified seven genes 
that are likely to be involved in cisplatin resistance; three of them are newly identified 
in terms of cisplatin resistance.
Microarray analysis was used to identify differentially expressed genes associated with 
the development of resistance against adriamycin, cisplatin or 5-fluorouracil in gastric 
cancers (Kang et al., 2004). Analysing the resistant cell lines, they identified eight 
genes that were differentially expressed in more than one of three drug subsets.
Using cDNA microarrays the expression of 9216 genes in 39 human cancer cell lines 
treated with various anticancer drugs were investigated (Dan et al., 2002). They 
observed that susceptibility of cancer cells to a particular drug is determined by many 
factors. Fifty-five agents were tested and these were grouped together on the basis of 
mode of action. They noted that fifty genes were associated with greater than ten of the 
drugs and that genes associated with drugs of similar action clustered together. The 
study concluded that expression levels of up and down regulated genes could be used 
as a predictive marker of drug efficacy and could be used to predict mode of action of 
a novel compound.
Chen and his co-workers identified genes which are related to invasion and metastasis 
(Chen et al., 2001). They used cDNA microarrays on human lung adenocarcinoma 
cell lines with varying invasive abilities and metastatic potentials to identify 
metastasis-associated genes. They also confirmed that the cell lines had equivalent in 
vivo invasiveness. They identified hundreds of genes that were differentially 
expressed in their model cell lines. Many of these genes had already been found to 
play a role in metastasis, for example keratin-18 and Mts-1.
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Another study focused on differences in gene expression profiles between tumour cell 
lines and normal lung tissue using high-density oligonucleotide arrays (Sugita et al., 
2002). They found that fourteen genes were overexpressed only in SCLC, four genes 
were overexpressed only in NSCLC and two genes were overexpressed in both. They 
discovered that a large proportion of the genes overexpressed were cancer/testis 
antigens, and that these could possibly be used as biomarkers.
A 7685-element microarray was employed to create expression profiles for lung 
tumours and cell lines (Virtanen et al., 2002). Hierarchical clustering resulted in 
tumour samples and cell lines forming two distinct groups. Within the tumour group, 
SCLC and NSCLC grouped separately. Most SCLC cell lines grouped with the SCLC 
tumour samples. Smilarly, most of the squamous cell carcinomas clustered together. 
None of the adenocarcinoma cell lines tested grouped with adenocarcinoma tumour 
tissue.
Comparison of expression profiles of twenty-one SCLC cell lines and eight 
xenografted tumours from these cell lines to expression profiles of seventeen normal 
adult tissues using microarray technology was carried out in order to find tumour- 
specific genes (Pedersen et al., 2003). The results indicate that the cell lines expressed 
a set of genes not expressed in tumours, and that tumour samples are contaminated 
with normal tissue. The study yielded a set of genes expressed specifically in SCLC. 
This set of genes includes neuroendocrine markers, oncogenes and genes involved in 
proliferation and division.
Amundson et al. (2000) compared basal levels of ten transcripts of the sixty cell lines 
used in the National Cancer Institute in vitro anticancer drug screen (NCI-ACDS). 
The transcripts were chosen according to their known role in the response to cellular 
damage or cancer biology and as potential modifiers of toxicity. They included BAX, 
BCL-Xl, MDM2 and cMYC. The most significant finding of this study was that BCL- 
Xl protected all cancer types against p53-mediated apoptosis.
cDNA microarrays were also used to monitor mRNA expression in breast cancer cells 
selected for resistance to doxorubicin (Kudoh et al., 2000). They studied two breast
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cell lines, MCF-7 and MCF-7/D40, a doxorubicin resistant variant. These cell lines 
were compared after transient treatment with the drug. The results show that the 
resistant cell line showed far fewer changes in gene expression after treatment than the 
parent cell line. The group found that a subset of genes that are transiently induced by 
doxorubicin intersects with a distinct set of genes that are overexpressed in the stably 
resistant cell line. These genes may represent a signature profile of doxorubicin 
resistance.
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1.8 RNA Interference
RNA interference is the biological mechanism by which double-stranded RNA 
(dsRNA) induces gene silencing at the level of translation by targeting complementary 
mRNA for degradation. RNAi has the potential to help elucidate the complex issues 
involved in eukaryotic development, to aid in dissecting cellular pathways, and to 
identify targets for chemotherapeutic intervention that otherwise would remain 
unidentified
1.8.1 Introduction to siRNA technology
The phenomenon of post translational gene silencing (PTGS) was first discovered in 
plant studies. A major study into the silencing of specific genes in C. elegans by the 
introduction of dsRNA by Fire and Mello in 1998 showed that the presence of just a 
few molecules of dsRNA was sufficient to almost completely abolish the expression of 
a gene that was homologous to the dsRNA (McManus and Sharp, 2002).
A four-step mechanism of the RNAi pathway has been suggested by experiments 
conducted in Drosophila. The first step is that long dsRNA is cleaved in a ATP- 
dependent manner into 21-25nt double stranded fragments, termed small interfering 
RNAs (siRNAs). These siRNAs are incorporated into a protein complex. ATP- 
dependent unwinding of the siRNA duplex leads to activation of the complex to an 
RNA-induced silencing complex (RISC). The RISC can recognise and cleave a target 
RNA complementary to the guide strand of the siRNA (Hutvagner and Zamore, 2002). 
A schematic diagram of the mechanism of RNAi can be seen in Figure 1.17. Dicer, a 
member of the RNase III family of endonucleases is responsible for the production of 
siRNAs. Certain structural features are important for entry of siRNAs into the RNAi 
pathway, such as a 5’ phosphate and 3’ hydroxyl termini and two single-stranded 
nucleotides on the 3 ’ ends.
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The enzymatic machinery for generating siRNA also appears to be used for the 
production of a second class of endogenously encoded small RNA molecules termed 
microRNAs. These miRNAs are a newly identified and large family of RNAs with 
highly conserved expression patterns. Hundreds of miRNAs have been found in C. 
elegans, plants and mammals. A common feature throughout miRNAs, but not seen in 
siRNAs is that the sequences of miRNAs are found in the stem of a stem-loop 
structure (Kim, 2003). Many of the miRNA targets identified so far are transcription 
factors or proteins involved in cell growth and development (Ke et ah, 2003). The 
specificity of miRNA (through Watson & Crick base pairing) and the rapidity at which 
miRNAs can be generated (when compared to the time taken to synthesise regulatory 
proteins), result in regulatory molecules that are ideally suited for the precise temporal 
control required during development. miRNAs might even explain the diversity of 
phenotypes among higher organisms despite a limited number of protein coding genes.
The PTGS mechanisms of siRNA and miRNA are largely identical, as demonstrated 
by the fact that endogenously encoded human miRNAs can cleave exogenously added 
RNA substrates with fully complimentary target sites while siRNAs can repress 
translation without RNA cleavage when there are slight central mismatches (Zeng et 
al., 2003).
1.8.2 Applications of RNAi
With the advent of the Human Genome Project (HGP) completion and the 
development of microarray technology, there are thousands of genes whose sequences 
are fully known, but whose function is unknown. Gene silencing using siRNA is 
quickly becoming the most common method to study the function of these genes. 
Other methods of knocking down expression of a gene (e.g. antisense and ribozymes) 
are laborious and time-consuming. Libraries of siRNAs and automatic screening 
systems are now available which make it possible to screen large sections of the 
human genome simultaneously.
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It is clear that siRNA may have multiple applications in disease therapy. Diseases that 
could benefit from RNAi technology include viral infections, cancer and genetic 
disorders (Kim, 2003). The dosage of the siRNA applied is a crucial point for 
therapeutic applications considering the fact that siRNAs applied at a concentration of 
100 nM were found to nonspecifically induce the expression of a number of genes 
involved in apoptosis and cellular stress responses, reduction of the dosage to 20 nM 
eliminated this effect however (Semizarov et al., 2003). In the case of cancer, siRNA 
could theoretically be used to target oncogenes such as mutant p53 for example 
(Martinez et al., 2002) or a host of other targets, but it is more likely that it will be 
used in conjunction with chemotherapy, in fact siRNA could be used to sensitise 
tumours to chemotherapy through repression of drug resistance proteins e.g. MDR1 
(Wu et al., 2003). In order for siRNA to become a potential therapy, problems with 
delivery must be overcome.
1.8.3 Problems associated with RNAi
Long dsRNA has been found to induce an immune response when introduced into 
mammals (Bridge et al., 2003; Sledz et al., 2003), leading to induction of the IFN 
response, which triggers the PKR pathway to inhibit protein translation and activates 
RNase L. In mammalian systems this can be overcome by introduction of synthetic 
siRNAs.
In early studies using RNAi, there was questions regarding siRNA specificity. In a 
study by Jackson and colleagues (2003), using gene expression profiling, it was 
revealed that there was direct silencing of non-targeted genes (some containing as little 
as 11 contiguous nucleotides homology to the siRNA). This is similar to the finding 
that siRNAs can suppress expression of off-target proteins even with 3-4 base 
mismatches and additional G-U mismatches (Saxena et al., 2003). Scacheri et al., 
(2004) also described changes in the levels of p53 and p21 protein in cells that were 
transfected with siRNA against the MEN1 gene. These genes are considered sensitive 
markers of cell state and the effects do not appear to be part of an IFN mediated 
response. This effect may be due to a partial complimentary sequence matches that 
result in miRNA-like inhibition of translation. Interestingly, this group discovered that
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the levels of actin were not affected by this non-specific silencing indicating perhaps 
that unaffected actin levels are not an ideal control in siRNA experiments.
These results are disputed however in a study by Chi et al (2003), where DNA 
microarray analysis demonstrated the precise sequence specificity of siRNA 
constructs. In general, it is recognized that good siRNA design will result in no “off- 
target” effects, and that many failures in RNAi experiments may have been caused by 
lack of experiment optimisation.
1.8.4 Delivery of siRNA
The most widely used technique for RNAi is siRNA transfection. Design of siRNAs is 
crucial for an experiment to work. Choice of target site, transfection method and 
turnover rate of the protein must be taken into consideration. There are certain 
guidelines available for siRNA design. Secondary structures and mRNA binding 
proteins may influence the ability of an siRNA to bind its target. Companies such as 
Ambion create siRNAs using algorithms that overcome these issues. The choice of 
transfection reagent and conditions, such as cell density, also play a major role in the 
success of an siRNA transfection. Transfection of synthetic siRNA duplexes at low 
concentration can help to avoid the IFN response of cells (Kim et al., 2004). This 
method of siRNA delivery is relatively transient and inhibition is lost after a number of 
days. To allow the expression of short hairpin RNAs (shRNAs, these undergo post- 
transcriptional processing into 21nt duplex siRNAs by Dicer), plasmids have been 
designed using promoters based on RNA polymerase II or in  e.g. Sui et al., 2002. The 
plasmids can contain a selectable marker so that clonal populations of cells with 
permanently silenced target genes can be isolated. Viruses are excellent vehicles for 
siRNA delivery, especially retroviruses (Devroe & Silver, 2004). Other viral delivery 
vehicles include HIV based, lentivirus based vectors (Stewart et al, 2003) or 
adenoviruses (Shen et al, 2003). A lentiviral vector capable of expressing a siRNA 
against GFP was used to silence GFP in a transgenic mouse that had stable expression 
of GFP (Tiscomia et al, 2003).
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1.9 Aims of Thesis
1. The first aim of this work was to study p53 in order to determine its role 
in the development of resistance. Most chemotherapeutic drugs cause 
DNA damage that is sensed by p53, which either arrests the cell cycle 
to allow DNA repair or induces apoptosis. The role of p53 in drug 
resistance is unclear in the literature. Pulse-selection of cell lines with 
differing p53 status was carried out to discover if p53 status is a factor 
in the development of resistance in vitro. Wild-type p53 was also 
transfected into a number of lung cancer cell lines in order to 
investigate changes in resistance to chemotherapeutic agents and 
invasion in the p53 expressing cell lines.
2. The second aim was to identify mechanisms of the development of 
resistance to the chemotherapeutic agents, taxol and carboplatin in lung 
cancer cell lines. This was achieved by pulse-selecting lung cancer cell 
lines with pharmacologically relevant levels of taxol and establishing 
variants which display resistance to a clinically relevant degree. These 
cell lines were used as models for the study of taxol resistance by 
microarrays. Functional studies on a number of target genes identified 
by microarray analysis to be associated with taxol treatment were 
performed using siRNA technology.
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Section 2.0: Materials and Methods
2.1 Preparation of cell culture media
Ultrapure water (UHP) was purified to a standard of 12-18 Mil/cm resistance by a 
reverse osmosis system (Millipore Milll-RO 10 Plus, Elgastat UHP). Glassware 
required for cell culture related applications were soaked in a 2% RBS-25 (AGB 
Scientific) for 1 hour, washed in an industrial dishwasher, using Neodisher detergent 
and rinsed twice with UHP. All thermostable solutions, water and glassware were 
sterilised by autoclaving at 121°C for 20 minutes at 15 bar (Thermolabile solutions 
were filtered through 0.22 jam sterile filters (Millipore, Millex-GV SLGV025BS)).
All IX basal media were prepared in-house as follows: 10X media was added to sterile 
UHP water, buffered with HEPES (N-(2-Hydroxyethyl) piperazine-N-(2- 
ethanesulfonic acid) and NaHCC>3 as required and adjusted to pH 7.5 using sterile 1.5 
N NaOH or 1.5 N HC1. The media was then filtered through sterile 0.22(im bell filters 
(Gelman, 12158) and stored in sterile 500ml bottles at 4°C. Sterility checks on all 
media bottles for bacterial, yeast and fungal contamination were made using Colombia 
blood agar (Oxoid, CM217), Sabauraud dextrose (Oxoid, CM217) and Thioglycolate 
broths (Oxoid, CM 173) respectively. All sterility checks were then incubated at both 
25°C and 37°C. Basal media were stored at 4°C for up to three months in the dark. 
Complete media was then prepared as follows: supplements of 2mM L-glutamine 
(Gibco, 11140-0350) for all basal media and 1ml 100X non-essential amino acids 
(Gibco, 11140-035) and lOOmM sodium pyruvate (Gibco, 11360-035) were added to 
MEM. Other components were added as described in Table 2.1. Complete media was 
stored at 4°C for a maximum of one month in the dark.Preparation for cell culture
Table 2.1 Additional components in media.
Cell Line Basal Media FCS (%) Additions
A549 ATCC 5 N/A
NCI-H1299 RPM I1640 5 Sodium pyruvate
NCI-H460 RPMI 1640 5 Sodium pyruvate
SKLU-1 MEM 5 Sodium pyruvate, non-essential amino
acids
DLKP-SQ ATCC 5 N/A
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2.2 Cells and Cell Culture
All cell culture work was carried out in a class II laminar airflow cabinet (Holten 
LaminAir). All experiments involving cytotoxic compounds were conducted in a 
cytogard laminar airflow cabinet (Holten LaminAir Maxisafe). Before and after use 
the laminar airflow cabinet was cleaned with 70% industrial methylated spirits (IMS). 
All items brought into the cabinet were also swabbed with IMS. Only one cell line 
was used in the laminar air-flow cabinet at a time and upon completion of work with 
any given cell line the laminar air-flow cabinet was allowed to clear for at least 15 
minutes before use to eliminate any possibilities of cross-contamination between the 
various cell lines. The cabinets were cleaned weekly with the industrial disinfectant 
Virkon (Antech International, P0550). Details pertaining to the cell lines used for the 
experiments detailed in this thesis are provided in Table 2.2. All cells were incubated 
at 37°C and where required, in an atmosphere of 5% CO2. Cells were fed with fresh 
media or subcultured (see Section 2.5.1) every 2-3 days in order to maintain active cell 
growth. All of the cell lines listed in Table 2.5.1 are anchorage-dependent cell lines.
Table 2.2 Cell lines used in this thesis
Cell Line Details Source
A549 Lung adenocarcinoma ATCC
A549-tax Taxol-selected variant of A549 NCTCC
A549-cpt Carboplatin-selected variant of A549 NCTCC
NCI-H1299 Lung large cell carcinoma ATCC
HI 299-tax Taxol-selected variant of HI 299 NCTCC
H1299-cpt Carboplatin-selected variant of HI 299 NCTCC
NCI-H460 Lung large cell carcinoma ATCC
H460-tax Taxol-selected variant of H460 NCTCC
H460-cpt Carboplatin-selected variant of H460 NCTCC
SKLU-1 Lung adenocarcinoma ATCC
SKLU-1-tax Taxol-selected variant of SKLU-1 NCTCC
SKLU-1-cpt Carboplatin-selected variant of SKLU-1 NCTCC
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2.2.1 Subculturing of cell lines
The cell culture medium was removed from the tissue culture flask and discarded into 
a sterile bottle. The flask was then rinsed out with 1ml of trypsin/EDTA solution 
(0.25% trypsin (Gibco, 043-05090), 0.01% EDTA (Sigma, E9884) solution in PBS 
(Oxoid, BRI4a)) to ensure the removal of any residual media. Trypsin was added to 
the flask, which was then incubated at 37°C, for approximately 5 minutes, until all of 
the cells detached from the inside surface of the flask. The amount of trypsin used 
varies with flask size, i.e., 1ml for T25, 2ml for T75 and 5ml for T175. The trypsin 
was deactivated by adding an equal volume of complete media to the flask. The cell 
suspension was removed from the flask and placed in a sterile universal container 
(Sterilin, 128a) and centrifuged at lOOOrpm for 5 minutes. The supernatant was then 
discarded from the universal and the pellet was suspended in complete medium. A cell 
count was performed and an aliquot of cells was used to re-seed a flask at the required 
density.
2.2.2 Assessment of cell number and viability
Cells were trypsinised, pelleted and resuspended in media. An aliquot of the cell 
suspension was then added to trypan blue (Gibco, 525) at a ratio of 5:1. The mixture 
was incubated for 3 minutes at room temperature. A lOpil aliquot of the mixture was 
then applied to the chamber of a glass coverslip enclosed haemocytometer. Cells in 
the 16 squares of the four grids of the chamber were counted. The average cell 
numbers per 16 squares were multiplied by a factor of 104 and the relevant dilution 
factor to determine the number of cells per ml in the original cell suspension. Non- 
viable cells stained blue, while viable cells excluded the trypan blue dye as their 
membrane remained intact, and remained unstained. On this basis, percentage 
viability was calculated.
2.2.3 Cry op reservation of cells
Cells for cryopreservation were harvested in the log phase of growth and counted as 
described in Section 2.5.2. Cell pellets were resuspended in a suitable volume of foetal 
calf serum (FCS). An equal volume of a 10 -  20% Dimethylsulphoxide (DMSO)/FCS
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solution was added dropwise to the cell suspension. Volumes of 1ml of this 
suspension was then aliquoted into cryovials (Greiner, 122278), and immediately 
placed in the vapour phase of a liquid nitrogen container, which was equivalent to a 
temperature of -80°C. After a period of four hours, vials were removed from the 
vapour phase and transferred to the liquid phase for long-term storage (- 196°C).
2.2.4 Thawing of cryopreserved cells
A volume of 5ml of fresh warmed growth medium was added to a sterile universal. 
The cryopreserved cells were removed from the liquid nitrogen and thawed at 37°C 
quickly. The cells were removed from the vials and transferred to the aliquoted media. 
The resulting cell suspension was centrifuged at 1,000 rpm for 5 minutes. The 
supernatant was removed and the pellet resuspended in fresh culture medium. An 
assessment of cell viability on thawing was then carried out (Section 2.2.2). Thawed 
cells were then added to an appropriately sized tissue culture flask with a suitable 
volume of growth medium and allowed to attach overnight. The following day, flasks 
were fed with fresh media to remove any non-viable cells.
2.2.5 Monitoring of sterility of cell culture solutions
Sterility testing was performed in the case of all cell culture media and cell culture 
related solutions. Samples of prepared basal media were incubated at 37°C for a 
period of seven days. This ensured that no bacterial or fungal contamination was 
present in the media.
2.2.6 Serum Batch Testing
Batch to batch variation is a major problem associated with the use of FCS in cell 
culture. In extreme cases this variation may result in a lack of cell growth, whereas in 
more moderate cases growth may be retarded. To avoid the effects of the above 
variation, a range of FCS batches were screened for growth of each cell line. 
Screening involved seeding cells in 96 well plates and determining growth as a 
percentage of a serum with known acceptable growth rate.
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2.2.7 Isolation of Clonal Populations by Clonal Dilution
Clonal populations were isolated by plating cells in 96-well plates at a concentration of
1 cell per 3 wells. After 2 days, the 96-well plates were monitored for single cells in 
wells. Single cell wells were marked and then allowed to grow until they reached 
levels that would allow them to be scaled up initially into 24-well plates.
2.3 Mycoplasma analysis of cell lines
Cell lines were tested for possible mycoplasma contamination by Ms. Aine Adams and 
Mr. Michael Henry at the National Cell and Tissue Culture Centre. The protocol used 
is detailed in the following Sections 2.6.1 and 2.6.2. All cell lines described in this 
thesis were free from mycoplasma contamination.
2.3.1 Indirect staining procedure for Mycoplasma analysis
Mycoplasma negative NRK (Normal rat kidney fibroblast) cells were used as an 
indicator cells for this analysis. The cells were incubated with a sample volume of 
supernatant from the cell lines in question and then examined for Mycoplasma 
contamination. A fluorescent Hoechst stain was used in this analysis. The stain binds 
specifically to DNA and so stains the nucleus of the cell in addition to any 
Mycoplasma present. Mycoplasma infection was indicated by fluorescent bodies in the 
cytoplasm of the NRK cells.
2.3.2 Direct staining procedure for Mycoplasma analysis
Direct staining for Mycoplasma analysis involved inoculating samples on to a 
Mycoplasma culture broth (Oxoid, CM403). This was supplemented with 16% serum, 
0.002% DNA (BDH, 42026), 2jig/ml fungizone (Gibco, 042 05920), 2xl03 units 
penicillin (Sigma, Pen-3) and 10ml of a 25% yeast extract solution. Incubation was 
carried out at 37°C for a period of 48 hours. Samples of this broth were then streaked 
onto plates of Mycoplasma agar base (Oxoid, CM401) which had been supplemented 
as described above. The plates were incubated for three weeks at 37°C while exposed
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to C02. The plates were examined microscopically every 7 days. The appearance of 
small oval shaped colonies indicated the presence of Mycoplasma infection.
2.4 In vitro toxicity assays
Cells in the exponential phase of growth were harvested by trypsinisation as described 
in Section 2.5.1. Cell suspensions containing lxlO4 cells/ml were prepared in cell 
culture medium. Volumes of lOO^l/well of these cell suspensions were added to 96- 
well plates (Costar, 3599) using a multichannel pipette. Plates were agitated gently in 
order to ensure even dispersion of cells over the surface of the given well. Cells were 
then incubated overnight at 37°C in an atmosphere containing 5% CO2. Cytotoxic 
drug dilutions were prepared at 2X their final concentration in cell culture medium. 
Volumes of the drug dilutions (lOOpil) were then added to each well using a 
multichannel pipette. Plates were then mixed gently as above. Cells were incubated 
for a further 6-7 days at 37°C and 5% CO2 until the control wells had reached 
approximately 80-90% confluency. Assessment of cell survival in the presence of 
drug was determined by the acid phosphatase assay (Section 2.4.2). The concentration 
of drug which caused 50% cell kill (IC50 of the drug) was determined from a plot of the 
% survival (relative to the control cells) versus cytotoxic drug concentration.
2.4.1 Combination toxicity assays
Cells for combination assays were set up as for in vitro toxicity assays (Section 2.4). 
Following overnight incubation of cells, cytotoxic drug dilutions and non-steroidal 
anti-inflammatory drug (NSAED) dilutions were prepared at 4X their final 
concentration in media. Volumes of 50fj,l of the drug dilution and 50[j.l of the NSAID 
dilution were then added to each relevant well so that a total final volume of 200|il was 
present in each well. All potential toxicity-enhancing agents were dissolved in DMSO, 
ethanol or media. Stock solutions were prepared at approximately 15 mg/10ml media, 
filter sterilised with a 0.22|j,m filter (Millex-GV, SLGV025BS) and then used to 
prepare all subsequent dilutions. Cells were incubated for a further 6 days at 37°C in 
an atmosphere containing 5% CO2. At this point the control wells would have reached
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approximately 80-90% confluency. Cell number was assessed using the acid 
phosphatase assay (Section 2.4.2).
2.4.2 Assessment of cell number - Acid Phosphatase assay
Following the incubation period of 6-7 days, media was removed from the plates. 
Each well on the plate was washed twice with 100(j,l PBS. This was then removed and
lOOjal of freshly prepared phosphatase substrate (lOmM p-nitrophenol phosphate
(Sigma 104-0) in 0.1M sodium acetate (Sigma, S8625), 0.1% triton X-100 (BDH, 
30632), pH 5.5) was added to each well. The plates were then incubated in the dark at 
37°C for 2 hours. Colour development was monitored during this time. The 
enzymatic reaction was stopped by the addition of 50p.l of IN NaOH. The plate was 
read in a dual beam plate reader at 405nm with a reference wavelength of 620nm.
2.4.3 Statistical Analysis
Analysis of the significance of the difference in the mean IC50 value calculated from 
toxicity assays were performed using a student t-test (two-tailed with unequal 
variance), which was run on Microsoft Excel.
A p value > 0.05 was deemed not significant 
A p value <0.05 was deemed significant 
A p value < 0.005 was deemed highly significant
2.5 Safe handling of cytotoxic drugs
Cytotoxic drugs were handled with extreme caution at all times in the laboratory, due 
to the potential risks in handling these drugs. Disposable nitrile gloves (Medical 
Supply Company Ltd) were worn at all times and all work was carried out in cytotoxic 
cabinets (Holten LaminAir Maxisafe). All drugs were stored in a safety cabinet at 
room temperature or in designated areas at 4°C. The storage and means of disposal of 
the cytotoxic drugs used in this work are outlined in Table 2.3.
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Table 2.3 Storage and disposal details for chemotherapeutic agents
Cytotoxic Agent Storage Disposal
Adriamycin 4°C in dark Incineration
Taxol Room temperature in dark Incineration
Taxotere Room temperature in dark Incineration
Vincristine 4°C in dark Incineration
VP-16 Room temperature in dark Incineration
Carboplatin Room temperature in dark Incineration
Cisplatin Room temperature in dark Incineration
5-Fluorouracil Room temperature in dark Incineration
2.6 Pulse selection of parent cell lines
A number of drug resistant variants were established from the cell lines A549, H1299, 
SKLU-1 and H460 by pulse-selection with taxol or carboplatin.
2.6.1 Determination of drug concentration for pulse selection
Cells were seeded into twelve 25cm2 flasks at 1.5 x 105 cells per flask and allowed to 
attach overnight at 37°C. The following day media was removed from the flask and a 
range of concentrations of appropriate drug was added to the flasks in duplicate 
(concentrations based on miniaturised assays). Complete media was added to two 
flasks as a 100% survival control. Flasks were returned to the 37°C incubator for a 4 
hour incubation, after which the drug was removed, the flasks were rinsed and fed with 
fresh complete media. The flasks were then incubated for 5-7 days until the cells in 
the control flasks had reached approximately 80% confluency. At this point, medium 
was removed from the flasks and cells were trypsinised and counted in duplicate as 
described in Section 2.2.2. The concentration of drug that caused appropriate cell kill 
was determined from a plot of the percentage survival relative to the control cells 
versus cytotoxic drug concentration.
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Concentrations chosen for pulse selection of A549, H1299 and H460 gave an 80-90% 
kill, i.e. IC80 - IC90. SKLU-1 was pulsed at a concentration that gave a much lower 
kill, since these cells found it more difficult to recover from each pulse (Table 2.4).
Table 2.4 Concentrations for pulse-selection
Cell Line Taxol (ng/ml) Carboplatin (|j.g/ml)
A549 150 100
HI 299 150 50
SKLU-1 10 10
H460 50 50
2.6.2 Pulse selection
Cells at low confluency in 75cm2 flasks were exposed to the chosen concentration of 
taxol or carboplatin for 4 hours. After this period, the drug was removed and the flasks 
were rinsed and fed with fresh complete media. The cells were then grown in drug- 
free media for 6 days, refeeding every 2-3 days. This was repeated once a week for ten 
weeks. If the cells had not recovered sufficiently from the previous pulse, a week was 
skipped, but all cell lines received ten pulses.
2.7 In vitro invasion assays
Invasion assays were performed using the method of Albini (1998). Matrigel (Sigma 
E-1270) (llmg/ml) was diluted to lmg/ml in serum free culture media. Matrigel was 
kept ice cold at all times. Into each insert (Falcon 3097) (8.0|im pore size, 24 well 
format) lOOpi of lmg/ml Matrigel was placed. The insert and the plate were incubated 
for one hour at 37°C to allow the gel to polymerise. Cells were harvested and 
resuspended in culture media containing 5% FCS at the concentration of 1 x 106 
cells/ml. Excess media was removed from the inserts, and they were rinsed in culture 
media. Volumes of 1 OOja.1 of the suspension cells were added to each insert. A further 
100|j.l of culture media was added to each insert and 500^1 of culture media containing
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5% FCS was added to the well underneath the insert. Cells were incubated at 37°C for 
24 hours. After this time period, the inner side of the insert was wiped with a cotton 
swab dampened with PBS, while the outer side of the insert was stained with 0.25% 
crystal violet for 10 minutes and then rinsed in UHP and allowed to dry. The inserts 
were then viewed and photographed under the microscope. The invasion assays were 
quantified by counting cells within a graticule at 40X magnification.
2.8 Western blotting
2.8.1 Whole cell extract preparation
Cells were grown to 80-90% confluency in 75cm2 flasks. Media was removed and 
cells were trypsinised as described in Section 2.2.1. Cells were washed twice with ice 
cold PBS. All procedures from this point forward were performed on ice. Cells were 
resuspended in 100-200(4,1 of NP-40 lysis buffer and incubated on ice for 30 minutes. 
Table 2.5 below provides the details of the lysis buffer. Immediately before use, 10pj.l 
of the 100X stocks listed in Table 2.6 were added to 1ml of lysis buffer.
Table 2.5 NP-40 lysis buffer
Addition required per 500ml stock Final concentration
425ml UHP water -
25ml 1M Tris-HCl (pH 7.5) 50mM Tris-HCl (pH 7.5)
15ml 5M NaCl 150 mM NaCl
2.5ml NP-40 0.5% NP-40
Table 2.6 NP-40 lysis buffer 100X stocks
100X stock Preparation instructions
lOOmM DTT 154mg in 10ml UHP
lOOmM PMSF 174mg in 10ml 100% ethanol
100X Protease inhibitors 2.5 mg/ml leupeptin, 2.5 mg/ml aprotinin, 15 mg/ml 
benzamidine and 1 mg/ml trypsin inhibitor in UHP water
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After incubation on ice, lysates were centrifuged on a bench centrifuge at 14000rpm 
for 15 minutes at 4°C. Supernatant containing extracted protein was transferred to a 
fresh chilled eppendorf tube. Protein concentration was quantified using the Biorad 
assay as detailed in Section 2 .8 .2 . Samples were then stored in aliquots at -80°C.
2.8.2 Protein Quantification
Protein levels were determined using the Bio-Rad protein assay kit (Bio-Rad, 500- 
0006) as follows. A 2mg/ml bovine serum albumin (BSA) solution (Sigma, A9543) 
was prepared freshly in lysis buffer. A protein standard curve (0, 0.2, 0.4, 0.6, 0.8 and 
l.Omg/ml) was prepared from the BSA stock with dilutions made in lysis buffer. The 
Bio-Rad reagent was diluted 1:5 in UHP water. A 20(0.1 volume of protein standard 
dilution or sample (diluted 1 :10) was added to 980^1 of diluted dye reagent and the 
mixture vortexed. After 5 minutes incubation, absorbance was assessed at 570nm. 
The concentration of the protein samples was determined from the plot of the 
absorbance at 570nm versus concentration of the protein standard.
2.8.3 Gel electrophoresis
Proteins for analysis by Western blotting were resolved using SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE). The Atto dual mini slab kit was used (AE 6450). The 
stacking and resolving gels were prepared as illustrated in Table 2.7. The gels were set 
in clean 9cm x 8cm gel cassettes, which consisted of 2 glass plates separated by a 
rubber gasket to a width of 1mm. The resolving gel was added to the gel cassette and 
allowed to set. Once the resolving gel had set, stacking gel was poured on top. A 
comb was placed into the stacking gel after pouring, in order to create wells for sample 
loading (maximum sample loading volume of 15-20^1).
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Table 2.7 Preparation protocol for SDS-PAGE gels (2 x 0.75mm gels)
Components 10% Resolving Gel 5% Stacking Gel
Acrylamide stock 4.6 ml 670|il
UHP water 5.6ml 2.7ml
1.875 MTris-HCl pH 8.8 3.5ml -
1.25 M Tris-HCl pH 6.8 - 500|il
10% SDS 140(xL 40\xL
10% NH4- persulfate 140|iL 40|aL
TEMED 5.6(j,L 4|iL
The acrylamide stock in Table 2.7 consists of a 30% (29:1) ratio of acrylamide:bis- 
acrylamide (Sigma, A2792). In advance of samples being loaded in to the relevant 
sample wells, 20|jg of protein was diluted in 10X loading buffer. Molecular weight 
markers (Sigma, C4105) were loaded alongside samples. The gels were run at 250V 
and 45 mA until the bromophenol blue dye front was found to have reached the end of 
the gel, at which time sufficient resolution of the molecular weight markers was 
achieved.
2.8.4 Western blotting
Western Blotting was performed by the method of Towbin et al. (1979). Once 
electrophoresis had been completed, the SDS-PAGE gel was equilibrated in transfer 
buffer (25mM Tris (Sigma, T8404), 192mM glycine (Sigma, G7126), pH 8 .3-8.5) for 
approximately 30 minutes. Five sheets of Whatman 3mm filter paper were soaked in 
freshly prepared transfer buffer. These were then placed on the cathode plate of a 
semi-dry blotting apparatus (Bio-rad). Air pockets were then removed from between 
the filter paper. PVDF membrane (Boehringer Mannheim 1722026) or nitrocellulose 
membrane (Amersham Pharmacia Biotech, RPN 303D), which had been equilibrated 
in the same transfer buffer, was placed over the filter paper on the cathode plate. Air 
pockets were once again removed. The gels were then aligned on to the membrane. 
Five additional sheets of transfer buffer soaked filter paper were placed on top of the 
gel and all air pockets removed. The proteins were transferred from the gel to the
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membrane at a current of 34mA at 15V for 30-40 minutes, until all colour markers had 
transferred. Following protein transfer, membranes were stained using Ponceau 
(Sigma, P7170) to ensure efficient protein transfer. The membranes were then blocked 
overnight using 5% milk powder (Cadburys; Marvel skimmed milk) in PBS at 4°C. 
The membranes were washed with PBS prior to addition of the primary antibody.
Membranes were treated with primary antibody for 2-3 hours at room temperature (or 
overnight at 4°C) and a negative control where the membrane was exposed to antibody 
diluent was also performed. Antibodies were prepared in 1% Marvel in PBS. Primary 
antibody was removed after this period and the membranes rinsed 3 times with PBS 
containing 0.5% Tween 20 (Sigma P1379) for a total of 15-30 minutes. Secondary 
antibody (1 in 1,000 dilution of anti-mouse IgG peroxidase conjugate (Sigma, A4914) 
in PBS, was added for 1.5 hour at room temperature. The membranes were washed 
thoroughly in PBS containing 0.5% Tween for 15 minutes.
Table 2.8 List of Primary antibodies and dilutions
Primary Antibody Dilution
p53 (Calbiochem, OP43) 1 1000
P73 (Calbiochem, OP 109) 1 200
MDM2 (Calbiochem, OP 144) 1 200
ß-actin (Sigma, A5441) 1 10,000
Pgp (Santa Cruz, SC-13131) 1 200
MRP1 (Santa Cruz, SC-1883 5) 1 200
ID3 (Santa Cruz, SC-490 1 200
CRIP1 (BD Biosciences, 610976) 1 200
2.8.5 Enhanced chemiluminescence (ECL) detection
Immunoblots were developed using an Enhanced Chemiluminescence kit (Amersham, 
RPN2109), which facilitated the detection of bound peroxidase-conjugated secondary 
antibody. Following the final washing membranes were subjected to ECL. A layer of 
parafilm was flattened over a glass plate and the membrane placed gently upon the
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plate. A volume of 3ml of a 50:50 mixture of ECL reagents was used to cover the 
membrane. The ECL reagent mixture was completely removed after a period of one 
minute and the membrane wrapped in clingfilm. All excess air bubbles were removed. 
The membrane was then exposed to autoradiographic film (Kodak, X-OMATS) for 
various times (from 10 seconds to 30 minutes depending on the signal). The exposed 
autoradiographic film was developed for 3 minutes in developer (Kodak, LX-24). The 
film was then washed in water for 15 seconds and transferred to a fixative (Kodak, FX- 
40) for 5 minutes. The film was then washed with water for 5-10 minutes and left to dry 
at room temperature.
2.9 RT-PCR analysis
2.9.1 Preparation of materials for RNA analysis
Due to the labile nature of RNA and the high abundance of RNase enzymes in the 
environment a number of precautionary steps were followed when analysing RNA 
throughout the course of these studies.
• General laboratory glassware and plasticware are often contaminated by RNases.
To reduce this risk, glassware used in these studies were baked at 180°C
(autoclaving at 121 °C does not destroy RNase enzymes) for at least 8hours. Sterile, 
disposable plasticware is essentially free of RNases and was therefore used for the 
preparation and storage of RNA without pre-treatment. Polyallomer ultracentrifuge 
tubes, eppendorf tubes, pipette tips etc., were all autoclaved before use. All 
spatulas which came in to contact with any of the solution components were baked, 
chemicals were weighed out onto baked aluminium-foil and a stock of chemicals 
for "RNA analysis only" was kept separate from all other laboratory agents. All 
solutions (which could be autoclaved) that came in to contact with RNA were all 
prepared from sterile ultra-pure water and treated with 0.1% diethyl pyrocarbonate 
(DEPC) (Sigma, D5758) before autoclaving (autoclaving inactivates DEPC).
• Disposable gloves were worn at all times to protect both the operator and the
experiment (hands are an abundant source of RNase enzymes). This prevents the
introduction of RNases and foreign RNA/DNA in to the reactions. Gloves were 
changed frequently.
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2.9.2 Total RNA extraction from cultured cell lines
Adherent cells were grown in 75cm2 flasks until approximately 80% confluent. 
Media was then removed and 1ml per 75cm2 flasks of TRI reagent (Sigma, T-9424) 
was added to the flask for 5 minutes ensuring that all cells were covered with the 
solution. TRI reagent is a mixture of guanidine thiocyanate and phenol in a mono­
phase solution. It effectively dissolves DNA RNA and protein on lysis of cell culture 
samples. After addition of the reagent, the cell lysate should be passed several times 
through a pipette to form a homogenous lysate. To ensure complete dissociation of 
nucleoprotein complexes, the sample was allowed to stand for 5 minutes at room 
temperature. A volume of 200(il of chloroform (not containing isoamyl alcohol or 
any other additive) per ml of TRI reagent was added to the cell lysate. The sample was 
covered tightly, shaken vigorously for 15 seconds and allowed to stand for 2-15 
minutes at room temperature. The resulting mixture was centrifuged at 13,000rpm for 
15 minutes at 4°C. Centrifugation separated the mixture into 3 phases: an organic 
phase (containing protein), an interphase (containing DNA) and a colourless upper 
aqueous phase (containing RNA). The aqueous phase was then transferred to a fresh 
tube and 0.5ml of isopropanol per ml of TRI reagent used in sample preparation and 
mixed. The sample was then allowed to stand for 5-10 minutes at room temperature. 
The sample was then centrifuged at 13,000rpm for 10 minutes at 4°C. The RNA 
precipitate formed a pellet on the side and the bottom of the tube. The supernatant was 
removed and the RNA pellet was washed by adding 1ml (minimum) of 75% ethanol 
per 1ml of TRI reagent. The sample was vortexed and centrifuged at 8000rpm for 5 
minutes at 4°C. Samples can be stored in ethanol at 4°C for at least 1 week and up to 
one year at -20°C. The RNA pellet was air-dried briefly. Approximately 30fil DEPC 
treated FfeO was added to the pellet. The RNA was then stored at -80°C until required 
for PCR analysis.
2.9.3 RNA quantification using Nanodrop
RNA was quantified spectrophotometrically at 260nm and 280nm using the Nanodrop. 
A 1 |o.l aliquot of suitably diluted RNA was placed on the nanodrop. The software 
calculated the amount of RNA present using the fact that an optical density of 1 at
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260nm is equivalent to 40mg/ml RNA. The ratio of A260/A280 was used to indicate the 
purity of the RNA.
2.9.4 Reverse transcription of RNA isolated from cell lines
The following components were used in the reverse transcriptase (RT) reaction for 
RNA isolated from cell lines: lp.1 oligo (dT)i2-is primers (l(og/ml) (Promega, Cl 101); 
2(0.1 of total RNA (0.5(og/ml) and 2|ol of DEPC-H2O were mixed together and heated at 
70°C for 10 min and then chilled on ice to remove any RNA secondary structure 
formation and allow oligo (dT) primers to bind to the poly (A)+ tail on the mRNA. To 
this, 4(ol of a 5X buffer (consisting of 250mM Tris-HCL, pH 8.3, 375mM KC1 and 
15mM MgCl2), 2(xl of DTT (lOOmM), l\i\ of dNTPs (lOmM each of dATP, dCTP, 
dGTP and dTTP), 7 (0,1 of water and 1 |0.1 of Moloney murine leukaemia virus-reverse 
transcriptase (MMLV-RT) (Sigma, M1302) was then added to the heat-denatured 
RNA complex and the mixture was incubated at 37°C for 1 hour to allow the MMLV- 
RT enzyme catalyse the formation of cDNA on the mRNA template. The enzyme was 
then inactivated and the RNA and cDNA strands separated by heating to 95°C for 2 
minutes. The cDNA was used immediately in the PCR reaction or stored at -20°C 
until required for analysis.
2.9.5 Polymerase Chain Reaction (PCR) analysis of cDNA formed from mRNA 
isolated from cell lines
PCR reactions were set up as 50(ol volumes using 5 (ol of cDNA formed during the RT 
reaction (see Section 2.9.4). Complemetary DNA (cDNA) was amplified for varying 
cycle numbers but where possible amplification was carried out in the exponential 
phase of amplification. The sequences of all primers used for PCR in this thesis are 
shown in Table 2.9. Each PCR reaction tube contained: 5(ol 10X buffer (lOOmM Tris- 
HC1, pH 9.0, 50mM KC1, 1% Triton X-100); 2|ol 25mM MgCl2; ljol of first strand 
target primer* (250ng/|ol); l|ol of second strand target primer* (250ng/|ol); 0.5(ol of 
first strand endogenous 3-actin control primer* (250ng/jol); 0.5|ol of second strand 
endogenous (3-actin control primer* (250ng/|ol) and 35.5|ol UHP. A volume of 5|ol of
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cDNA (pre-heated to 95°C for 3minutes to separate strands and remove any secondary 
structure if the sample had been stored at -20°C) was added. The mixture was heated 
to 94°C for 5minutes (reduces non-specific binding of primers to template). A volume 
of 1 (j.1 of lOmM dNTP (Sigma, DNTP-100), and 0.5|_il of Taq DNA Polymerase 
enzyme (Sigma; D4545) and water to a total volume of 8.5|il was then added. The 
cDNA was then amplified by PCR (Techne; PHC-3) using the following program:
• 94°C for 3min (denature double stranded DNA)
• 25-35 cycles 94°C for 30sec (denature double stranded DNA);
X°C for 30sec (anneal primers to cDNA);
72°C for 30sec (extension);
• 72°C for 7min (extension).
• Storage at 4°C
Table 2.9 Sequences of primers used for PCR
Gene Length
(bp)
Tm
(°C)
Size
(bp)
Sequence
P-actin
(large)
29
22
55 383 GAA ATC GTG CGT GAC ATT AAG -GAG AAG CT 
TCA GGA GGA GCA ATG ATC TTG A
P-actin
(small)
23
22
55 142 TGG ACA TCC GCA AAG ACC TGT AC 
TCA GGA GGA GCA ATG ATC TTG A
p53 26
26
55 293 CAG CCA AGTCTG TGA CTT GCA CGT AC 
CTA TGT CGA AAA GTG TTT CTG TCA TC
A 10|il aliquot of tracking buffer, consisting of 0.25% bromophenol blue (Sigma, 
B5525) and 30% glycerol in water, was added to each tube of amplified cDNA 
products. A volume of 20|o.l of cDNA products from each tube were then separated by 
electrophoresis at lOOmV through a 2% agarose (Sigma, A9539) gel containing 
ethidium bromide (Sigma, E8751), using TBE (22.5mM Tris-HCl, 22.5mM boric acid 
(Sigma, B7901) and 0.5mM EDTA) as running buffer. Molecular weight markers “(j)- 
X I74” Hae III digest (Sigma, P0672) were run, simultaneously, as size reference. The
71
resulting product bands were visualised as pink bands (due to the intercalation of the 
cDNA with the ethidium bromide) when the gels were placed on a transilluminator 
(UVP Transilluminator). The gels were photographed.
2.10 Transfection of Mammalian Cells with Exogenous DNA
In order to understand the role of p53 more clearly, it was found necessary to introduce 
foreign DNA into host cells to increase the level of expression of the p53 gene by 
transfecting with an expression plasmid. Sufficient plasmid was produced by 
transforming JM109 with the plasmid required, growing up a large stock of these cells 
and isolating the plasmid from them. This isolated plasmid was then transfected into 
the chosen cell line.
2.10.1 Plasmid details
A 2kb Bam HI fragment was digested and purified from a p53 clone (ATCC) and 
subcloned into the Bam HI site of pcDNA3.1 Zeo+. This was carried out by 
Invitrogen.
2.10.2 MgCU / CaCU Transformation of JM109 Cells
A bacterial cell suspension (100|xl) of competent JM109 (Promega, L2001) was mixed 
with 20ng DNA and placed on ice for 40min after which the mixture was heat-shocked 
at 42°C for 90 seconds and then placed on ice for 3 minutes. LB broth (1ml) ((10g 
Tryptone (Oxoid, L42), 5g Yeast Extract (Oxoid, L21) 5g NaCl (Merck, 
K1880814))/litre LB, autoclaved before use) was added to the competent cell 
suspension and incubated at 37°C for 40min. A volume of 400|j,l of this suspension 
was spread on a selecting agar plate (LB agar containing appropriate antibiotic conc.) 
and incubated overnight at 37°C. Single colonies, which grew on these selecting 
plates, were further streaked onto another selecting plate and allowed to grow 
overnight at 37°C.
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2.10.3 DNA miniprep of plasmid DNA
To determine and select the colonies containing the inserted DNA sequence, a 
miniprep of the plasmid DNA was carried out. Plasmid DNA was isolated using the 
QIAprep spin miniprep kit (Qiagen, 27104). Single colonies were selected off the 
plates (Section 2.10.2) and incubated in universals containing 5mls LB/Amp shaking 
at 180rpm at 37°C overnight. After incubation, the cells were centrifuged at 8,500rpm 
for 3 minutes. Pelleted cells were resuspended in 250(41 of buffer PI and the cell 
suspension was transferred to an microcentrifuge tube. To this solution, 250(il buffer 
P2 was added and mixed gently. A volume of 350(41 buffer N3 was added to the 
solution and the tube was mixed immediately. This mixture was centrifuged for 10 
minutes at 13,000 rpm. The supernatant was applied to a QIAprep spin column and 
centrifuged for 60 seconds. The flow-through was discarded. The column was washed 
by adding 500(4.1 buffer PB and centrifuging for 60 seconds. The flow through was 
discarded. This step was repeated with 750|4,1 buffer PB. The column was centrifuged 
for a further 60 seconds to remove all of the wash buffer. The column was then placed 
in a clean microcentrifuge tube. To elute the DNA 50(j.l of buffer EB was added to 
the column. The column was let stand for 60 seconds and tehn centrifuged for 60 
seconds.
2.10.4 Restriction digest of plasmid
After miniprep of the plasmid in E. Coli JM109 cells, a restriction digest of the 
pcDNA + p53 and the empty vector pcDNA plasmids was carried out to ensure that 
the plasmid was intact. Three digests were set up for each plasmid:
- No enzyme
- EcoRl
- BamHl
For each digestion the follwing was added to 2(41 DNA: 2(41 enzyme buffer; l|4l 
enzyme and 15(41 water. The samples were run out on a 1% agarose gel, together with 
3 (j,ls loading dye. From this information, samples were selected for large-scale 
plasmid preparation. The p53 plasmid was inserted in to the pcDNA vector at a 
BamHl cutting site. Subsequently, when the plasmid is cut with BamHl enzyme, two 
bands should result, one the size of the vector, and the other corresponding to the p53
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inserted fragment. Ligation with another enzyme like EcoRl only results in one band 
since it doesn’t separate the p53 fragment.
2.10.5 Preparation/Purification of plasmid DNA
Plasmid DNA was purified using an endofree plasmid maxi kit (Qiagen, 12362). A 
single colony from selecting plates (Section 2.10.2) was used to inoculate 5 ml 
LB/Amp broth. This was incubated for 8 hours at 300rpm and 37°C. This culture was 
diluted 1/500 (400(j.l into 200mls) into selective media and incubated overnight at 
300rpm and 37°C. The bacterial cells were harvested by centrifugation at 6,000rpm 
for 15 minutes at 4°C. The pellet was resuspended in 10ml buffer PL To this, 10 ml 
buffer P2 was added, mixed gently and incubated at room temperature for 5 minutes. 
A volume of 10ml chilled buffer P3 was added to the lysate and mixed immediately 
and gently. The lysate was poured into the barrel of the QIAfilter cartridge and 
incubated at room temperature for 10 minutes. The cap from the QIA filter outlet 
nozzle was removed and the plunger was gently inserted in to the cartridge, The cell 
lysate was filtered into a 50ml tube. To the lysate, 2.5ml buffer ER was added and 
mixed by inverting repeatedly. This was incubated on ice for 30 minutes. A qiagen- 
tip 500 was equilibrated by applying 10ml buffer QBT and the column was allowed to 
empty by gravity flow. The filtered lysate was tehn applied to the qiagen-tip and 
allowed to enter the resin by gravity flow. The qiagen-tip was washed twice with 30ml 
buffer QC. The DNA was eluted by addition of 15ml buffer QN and the eluate was 
collected in a 30ml tube. The DNA was precipitated by adding 10.5ml isopropanol to 
the eluated DNA. This was mixed and centrifuged at ~10,000rpm for 30 minutes at 
4°C. The DNA pellet was washed with 5ml of 70% ethanol and this was centrifuged at 
~10,000rpm for 10 minutes. The pellet was air-dried and dissolved in 500|ol buffer 
TE. The DNA concentration was determined by measuring the OD260nm-
2.10.6 Lipofectin transfection
Cells were seeded into a 25cm2 flask at a density of 1 x 105 cells per flask in 4 mis 
culture medium. The cells were then incubated overnight at 37°C overnight. For each 
transfection, 2\xg DNA was diluted into 100|il of serum free media (SFM). For each
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transfection, 20(^ 1 lipofectin reagent (Invitrogen, 18292-011) was diluted into 100fj.l 
SFM and left at room temperature for 30-45 minutes. The two solutions were then 
combined and incubated at room temperature for 10-15 minutes. The cells were 
washed with 2 ml SFM. To the DNA-lipofectin mixture, 1,8ml SFM was added. This 
solution was mixed gently and overlaid onto the cells. The cells were then incubated 
for a further 24 hours. After this time, the DNA containing media was replaced with 
serum-containing growth media and incubated for a further 48 hours. The cells were 
subcultured 1:5 into zeocin-containing media.
2.10.7 Selection and Isolation of Clones
In order to study the true effect of transfection studies, single clones of stably 
transfected cells were selected and isolated. The selection process was carried out by 
feeding the “transfected” cells with media containing zeocin (Invitrogen R250-01), the 
plasmids used had a zeocin-resistant gene, therefore, only those cells containing the 
plasmid will survive treatment with zeocin. Two days after transfection the cells were 
fed with media containing zeocin. The concentration of the drug was increased until a 
concentration known to kill untransfected cells was reached. At this stage the cells 
were plated at clonal density and clonal populations were propagated as described in 
Section 2.2.7. Transfected cells were periodically challenged with zeocin to establish 
stability of transfectants.
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Figure 2.1 shows a schematic of the gene expression workflow.
2.11 Microarrays
1. Isolation of Total RNA from cell lines/clinical samples
----►
r
Nanodrop,
Bioanalyser
2. cDNA synthesis from Total RNA
3. cDNA Cleanup
4. cRNA synthesis from cDNA (IVT Amplification)
5. cRNA Cleanup
— ►
r
Nanodrop,
Bioanalyser
6. Hybridisation of cRNA to chip
7. Fluidics on chip
8. Chip Scanning
Figure 2.1 Gene expression workflow
76
2.11.1 Isolation of total RNA from cell lines
Total RNA was extracted from cells using the RNeasy Mini prep kit (Qiagen, 74104). 
Cells were lysed in 600|ol buffer RLT (2-P-mercaptoethanol was added prior to use - 
10^1/ml). Cells were homogenised by passing samples five times through a 20-gauge 
needle fitted to an RNase-free syringe. One volume (600|il) 70% ethanol was added 
and the lysate was applied to an RNeasy column. Samples were centrifuged for 15 
seconds at 10,000rpm and flow through was discarded. A volume of 700(il Buffer 
RW1 was added. Samples were centrifuged for 15 seconds at 10,000rpm and flow 
through and collection tube were discarded. A volume of 500|ol Buffer RPE was 
pipetted onto the column, and samples were centrifuged for 15 seconds at 10,000rpm 
and flow through was discarded. A further 500^1 Buffer RPE was added. The 
columns were centrifuged for 2 min at 10,000rpm. The column was transferred to a 
new 1.5ml tube and the RNA was eluted with 20 [0,1 RNase free water. A 1:4 dilution 
of the eluted RNA was applied to the nanodrop to quantify the RNA (Section 2.9.3).
2.11.2 Determination of RNA purity using Bioanalyser
The RNA 6000 Nano assay™ was used to ensure RNA samples subjected to 
microarray analysis were of good quality. A 550|ol aliquot of RNA 6000 Nano gel 
matrix was placed into a spin filter tube and centrifuged at 1500g for 10 minutes. The 
filtered gel was aliquoted into 65(0.1 amounts. During the 10 minute spin, 2[ol aliquots 
of suitably diluted RNA samples (see Section 2.11.1) and RNA ladder were prepared 
in 0.5|il RNase free tubes and heated to 70 °C for at least 2 minutes followed by 
cooling on ice for 1 minute. The dye concentrate was allowed to equilibrate to room 
temperature for 30 minutes, then vortexed for 10 seconds and 1 (0,1 of the dye was added 
to 65(0,1 of filtered gel matrix. The solution was vortexed well and centrifuged for 10 
minutes at 13,200rpm. A new chip was placed on the chip priming station and 9|ol of 
the gel dye mix was pipetted into the well marked with the bold G. The Chip priming 
station was closed gently and the plunger pressed and held in place by the clip. After 
exactly 30 seconds, the plunger was released by pressing the clip. After a further 30 
seconds, 9(ol of gel dye mix was pipetted into the remaining wells marked G. RNA 
6000 Nano Marker (5(il) was loaded into the well marked with the ladder and into all 
the 12 sample wells. If any well remained unused, 6^ ,1 Nano Marker was added to
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those wells. l|o,l of each sample prepared earlier (Section 2.11.1) was added into each 
of the sample wells. The chip was placed in the special vortex adapter and vortexed at 
2400 rpm for 1 minute. The chip was then run on the Agilent Bioanalyzer within 5 
minutes.
2.11.3 cDNA synthesis from total RNA
Synthesis of cDNA was carried out using the One-cycle cDNA synthesis kit 
(Affymetrix, 900431). Total RNA (10|j.g) was placed in a 0.5ml tube. To each tube, 
2|ol of diluted poly-A RNA controls were added along with 2\x\ of 50(iM T7-01igo(dT) 
Primer. RNase-free water was added to a final volume of ll|o.l. The tubes were 
flicked to mix and then centrifuged briefly. This reaction was incubated for 10 
minutes at 70°C. The sample was then cooled to 4 °C for at least 2 minutes. The first 
strand mastermix was assembled, allowing for an extra half a sample. For a single 
reaction the master mix contained, 4[0.1 5X 1st strand reaction mix, DTT (0.1M), dNTP 
(lOmM). A volume of 7|j,l of mastermix was added to each reaction tube to a final 
volume of 18|jJ. The tubes were mixed by flicking, and then centrifuged briefly and 
placed immediately at 42°C for 2 minutes. To each RNA sample, 2j_tl of SuperScript II 
was added. The tubes were mixed well and centrifuged briefly. The tubes were 
incubated at 42°C for 1 hour and then cooled at 4°C for 2 minutes. The second strand 
mastermix was assembled containing: 91(j.l RNase-free water; 30|al 5X 2nd strand 
reaction mix; 3 jj.1 dNTP(lOmM); l|al E.coli DNA ligase; 4|il E.coli DNA polymerase I 
and 1 (j.1 RNase H. To each first strand synthesis sample, 130jal of second-strand 
mastermix was added. The tubes were mixed and centrifuged briefly and incubated for
2 hours at 16°C. After incubation, 2|il of T4 DNA Polymerase was added to each 
sample, and incubated for 5 minutes at 16°C. To stop any further reaction, 10|xl of 
EDTA (0.5M) was then added to each tube
2.11.4 cDNA cleanup
Synthesized cDNA was cleaned-up using a sample clean-up module (Affymetrix, 
900371). cDNA binding buffer (600^1) was added to each double-stranded cDNA
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synthesis preparation and mixed by vortexing for 3 seconds. A volume of 500|_l1 of the 
sample was then applied to a cDNA cleanup spin column sitting in a 2ml collection 
tube. The columns were centrifuged for 1 minute at 10,000rpm and the flow through 
was discarded. The column was loaded with the remaining sample and centrifuged as 
above. The collection tube and flow through were discarded. The spin column was 
placed in a clean 2ml collection tube. To the column, 750(ol of cDNA wash buffer was 
added and centrifuged for 1 minute at 10,000rpm. The columns were then centrifuged 
with the caps open for 5 minutes at 13,000rpm to allow the membrane to dry. The spin 
columns were placed in a 1.5ml tube and 14(_il of cDNA elution buffer was pipetted 
directly onto column membrane. The tubes were centrifuged for 1 minute at 
13,000rpm. Eluted cDNA was stored at -80°C.
2.11.5 cRNA synthesis from cDNA
Genechip IVT labelling kit (Affymetrix, 900449) was used to prepare cRNA. To each 
0.5ml tube, 6(0,1 of cDNA was added. For the IVT reaction the following reagents were 
added to the cDNA: 14(0.1 RNase-free water; 4(0.1 10X IVT labelling buffer; 12(ol 
labelling NTP mix and 4|ol IVT labelling enzyme mix. These reagents were mixed 
carefully and centrifuged briefly. The reaction tubes were then incubated for 16 hours 
at 37°C.
2.11.6 cRNA cleanup
Synthesized cRNA was cleaned-up using a sample clean-up module (Affymetrix, 
900371). To the labelled cRNA 60|ol of RNase-free water was added and mixed by 
vortexing for 3 seconds. After mixing, 350|ol of IVT cRNA binding buffer was added 
and again mixed by vortexing for 3 seconds. A volume of250|ol of ethanol (96-100%) 
was added and pipetted up and down to mix. This sample was applied to an IVT 
cRNA cleanup spin column sitting in a 2ml collection tube. This was centrifuged for 
15 seconds at 10,000rpm and the flow through discarded. To the column, 500(ol of 
80% (v/v) ethanol was added and centrifuged for 15 seconds at 10,000rpm. The flow 
through was discarded and the column was centrifuged for 5 minutes at 13,000rpm 
with the cap open to allow the membrane to dry. The column was transferred to a
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1.5ml tube and ll|ol of RNase-free water was applied directly to the membrane. The 
column was centrifuged for 1 minute at 13,000rpm. A further 10(ol of RNase-free 
water was applied to the membrane and centrifuges again for 1 minute at 13,000rpm. 
The eluted cRNA was diluted 1:100 for quantification using the Nanodrop (Section 
2.9.3). A 1:2 dilution of the cRNA was also analysed on the Bioanalyser (Section 
2.11.2).
2.11.7 Hybridisation of cRNA to genechips
Fragmentation of the labelled cRNA was carried out prior to hybridisation onto the 
array using the sample clean up module (Affymetrix, 900371). This was achieved by 
incubating 15jag of cRNA with 5X fragmentation buffer at 94°C for 35 minutes. To 
each tube of fragmented RNA, 270|ol of hybridisation cocktail was added which 
contained per reaction: 5|o.l control oligonucleotide B2 3nM (Hybridization control kit, 
Affymetrix, 900454); 15(ol 20X eukaryotic hybridisation controls (Hybridization 
control kit, Affymetrix, 900454); 3(0.1 Herring sperm DNA lOmg/ml (Promega, 
D1811); 3|ol BSA 50mg/ml (Invitrogen, 15561-020); 150^1 2X Hybridisation buffer 
(Hybridization control kit, Affymetrix, 900454); 30(0.1 DMSO (Sigma, D5879) and 
34(j.l water. The genechips were placed at room temperature 30 minutes before use to 
allow the rubber septa to equilibrate to room temperature. This prevents leakage of the 
sample. The genechips used were Affymetrix U133 Plus 2.0 chips. The arrays were 
wetted by filling with 200jol of IX hybridisation buffer and incubated at 45°C for 15 
minutes at a rotation speed of 60rpm. The hybridisation cocktail was heated to 99°C 
for five minutes and then cooled to 45 °C for 5 minutes and then centrifuged at 
13,000rpm for 5 minutes. The buffer solution was removed from the genechips and 
replaced with 300|ol of hybridisation cocktail and sample. The genechips were then 
placed into the hybridisation oven at 45°C at a rotation of 60rpm for 16 hours.
2.11.8 Array washing and staining
After hybridisation, the hybridisation buffer was removed from the chips and replaced 
with non-stringent wash buffer. Streptavidin phycoerythrin (SAPE) stain solution was 
freshly prepared: 600|o.l 2X stain buffer (lOOmM MES stock buffer, 1M Na+, 0.05%
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Tween-20); 48|xl 50mg/ml BSA (Invitrogen, 15561-020); 12|il lmg/ml SAPE 
(Molecular probes, S-866) and 540|il deionised (DI) water. This was divided into two 
aliquots per array. Antibody was prepared as follows: 300|il 2X stain buffer; 24|il 
50mg/ml BSA; 6[ol lOmg/ml goat IgG stock (Sigma, 15256); 3.6(il 0.5mg/ml 
biotinylated antibody (Vector Laboratories BA-0500) and 266.4(j.l DI water. The 
Affymetrix Genechip Operating Software™ (GCOS™) manages the fluidics protocol. 
The fluidics station was prepared by running a priming protocol. This step checks that 
the buffers are properly connected and fills the tubes with the appropriate fluid. When 
primed, each module was set up with one genechip, two vials of SAPE solution and 
one vial of antibody solution. The antibody amplification for eukaryotic targets 
protocol was initiated. The details of the protocol EukGE-WS2v4_450 can be seen in 
Table 2.10. This process takes approximately 75 minutes to complete.
Table 2.10 Details of fluidics protocol for staining probe array
Fluidics protocol - EukGE-WS2v4_450
Post-hyb wash #1 10 cycles of 2 mixes/cycle with wash buffer A at 25°C
Post-hyb wash #2 4 cycles of 15 mixes/cycle with wash buffer B at 50°C
Stain Probe array stained for lOmins in SAPE solution at 25 °C
Post-stain wash 10 cycles of 4 mixes/cycle with wash buffer A at 25°C
2nd Stain Probe array stained for lOmins in SAPE solution at 25°C
3rd Stain Probe array stained for lOmins in SAPE solution at 25°C
Final wash 15 cycles of 4 mixes/cycle with wash buffer A at 30°C
Hold Hold temperature of 25°C
2.11.9 Array scanning
After staining and washing, the chips were scanned using an affymetrix genechip 
scanner. Similarly to the fluidics station, GCOS manages the scanning protocol. The 
chips were placed in the scanner and scanned. The scan generated an initial image file 
(*.DAT), which contains the values for each gene probe. As there are 11 probes for 
each gene (one probe set), these values were averaged out into another file that is
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generated automatically by GCOS (*.CEL). GCOS can then generate another file from 
the .CEL file that will contain numerical values for each probe set (*.CHP).
Finally, a quality control report file (*.RPT) is generated which is used to check the 
reliability/QC of each sample.
2.11.10 Chip Quality Control
After carrying out the array experiments, some quality control must be carried out on 
the chips before continuing for analysis. GCOS generates a report for each chip that is 
scanned and a chip information form was filled out for each chip from this report with 
the following information:
■ Background -  level of non-specific binding
■ 3 75 ’ Ratio -  how well labelling reaction has proceeded
■ Hybridisation controls - comparable sample levels added
■ Percentage present
■ Noise -  electrical noise from scanner
■ Scale factor -  brightness of array
Once a chip report was deemed satisfactory, the data from the chip was transferred into 
the analysis software, dChip.
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2.12 Bioinformatics
2.12.1 Raw data transfer into dChip
DNA-Chip Analyzer (dChip) is a software package for analysis of microarray data. 
The CEL files generated by GCOS (Section 2.11.9) were imported into dChip. These 
CEL files contain all of the intensity values from the genechips scanned. In order to 
make sense of these files, a Chip Description File (CDF) file was also imported into D- 
Chip which specifies which arrays were used and what each probe on the array 
represents. A sample information file was also brought into dChip that contained more 
detailed information on each sample on the arrays. This facilitated interpretaion of the 
data in dChip.
2.12.2 Normalisation in dChip
Dchip is a software package implementing model-based expression analysis of 
oligonucleotide arrays (Li and Wong, 2001) and several high-level analysis 
procedures. This model-based approach allowed probe-level analysis on multiple 
arrays. By pooling information across multiple arrays, it was possible to assess 
standard errors for the expression indexes. In this normalisation procedure an array 
with median overall intensity was chosen as the baseline array against which other 
arrays were normalised at probe level intensity. Subsequently a subset of PM probes, 
with small within-subset rank difference in the two arrays, served as the basis for 
fitting a normalisation curve. This approach also allowed automatic probe selection in 
the analysis stage to reduce errors due to cross-hybridizing probes and image 
contamination. High-level analysis in dChip included comparative analysis and 
hierarchical clustering. Normalisation of the data was performed to adjust the 
brightness of the arrays to a comparable level. The array with the median overall 
intensity was taken as the baseline and the other arrays were normalised at probe 
intensity level. All low-intensity values were truncated to 1. The chips were also 
viewed in dChip to ensure that the overall appearance of the chip was of even 
intensity.
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2.12.3 Hierarchical clustering
Hierarchical clustering is a quality control step that was carried out in dChip. It 
allowed comparison of the list of gene expression values for each sample and shows 
which are most similar to each other. At this point, before further analysis it was 
ensured that the triplicate samples had clustered correctly. Hierarchical clustering was 
used to represent the relationship between replicate samples and different sets of 
replicate samples. The tree represents relationships amongst genes in which, branch 
lengths represent degrees of similarities. This method was useful in its ability to 
represent varying degrees of similarity and distant relationships among groups of 
closely related genes. The computed tree was used to organize genes in the original 
data table, so that genes with similar expression patterns were adjacent.
2.12.4 Data analysis
In dChip samples were compared in triplicate e.g. baseline vs experiment. This 
created genelists in Microsoft Excel of differentially expressed genes in the two 
groups. These genelists contained information on baseline and experiment intensity, 
fold change and p value. Each parent cell line was compared, in triplicate, to its taxol- 
resistant variant. Genelists created contained genes that were differentially expressed 
in the triplicates of the two cell lines using certain filtering parameters. The filtering 
parameters used were a fold change of >1.2, a difference of intensity of >100 and a p 
value <0.05. These comparison criteria require the fold change between the group 
means to exceed 1.2; the absolute difference between the two group means to exceed 
100 and that the difference of the means is statistically significant using an unpaired 
two-tailed t-test so that p-value <0.05.
2.12.5 Comparison of genelists
The genelists created in dChip were compared using Microsoft Access. A database 
was created to compare genes that were differentially expressed in two or more 
genelists from dChip. Firstly a list of genes that were differentially regulated in all 
four taxol-resistant variants, compared to parent cell lines was created. Secondly, a 
genelist that contained genes differentially regulated in three of the four taxol-resistant 
variants was created. This genelist was shortened to only include only genes that were
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upregulated in three of the four taxol-resistant variants, or downregulated in three - f  
the four taxol-resistant variants
2.12.6 Pathway analysis
Pathway analysis was carried out using Pathway Assist software. Genelists to be 
studied in Pathway Assist were imported in the form of *txt files. Pathway Assist is a 
product aimed at the visualisation and analysis of biological pathways, gene regulation 
networks and protein interaction maps. It comes with a comprehensive database that 
gives a snapshot of all information available in PubMed, with the focus on pathways 
and cell signalling networks. This product was useful in assisting in the interpretation 
of Microarray results. It allowed visualisation of results in the context of pathways, 
gene regulation networks and protein interaction maps. This was done using curated 
and automatically created pathways. Graph drawing, layout optimisation, data filtering, 
pathway expansion and classification and prioritization of proteins were all possible. 
Pathway Assist worked by identifying relationships among genes, small molecules, cell 
objects and processes and built pathways based on these relationships.
2.13 RNA interference (RNAi)
RNAi using small interfering RNAs (siRNAs) was carried out to silence specific 
genes. The siRNAs used were chemically synthesized and purchased from Ambion 
Inc. These siRNAs were 21-23 bps in length and were introduced to the cells via
rni, f __ T*\/i
reverse transfection with the transfection agent siPORT TVeoFX (Ambion inc., 
4511).
2.13.1 Transfection optimisation
In order to determine the optimal conditions for siRNA transfection, an optimisation 
with a siRNA for kinesin (Ambion Inc., 16704) was carried out for each cell line. Cell 
suspensions were prepared at lxlO4, 2.5xl04 and 5xl04 cells per ml. Solutions of 
negative control and kinesin siRNAs at a final concentration of 30nM were prepared in 
optiMEM (Gibco™, 31985). NeoFX solutions at a range of concentrations were 
prepared in optiMEM in duplicate and incubated at room temperature for 10 minutes.
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After incubation, either negative control or kinesin siRNA solution was added to each 
neoFX concentration. These solutions were mixed well and incubated for a further 10 
minutes at room temperature. Replicates of lOfil of the siRNA/neoFX solutions were 
added to a 96-well plate. The cell suspensions were added to each plate at a final cell 
concentration of lxlO3, 2.5xl03 and 5xl03 cells per well. The plates were mixed 
gently and incubated at 37°C for 24 hours. After 24 hours, the transfection mixture 
was removed from the cells and the plates were fed with fresh medium. The plates 
were assayed for changes in proliferation at 72 hours using the acid phosphatase assay 
(Section 2.4.2). Optimal conditions for transfection were determined as the 
combination of conditions which gave the greatest reduction in cell number after 
kinesin siRNA transfection and also the least cell kill in the presence of transfection 
reagent. The optimised conditions for the cell lines are shown in Table 2.11.
Table 2.11 Optimised conditions for siRNA transfection
Cell line Seeding density per well Volume NeoFX per well (nl)
A549 and variants 2.5 x 10J 0.2
H1299 and variants 5x  103 0.3
H460 and variants 1 x 103 0.1
2.13.2 Proliferation effects of siRNA transfection
Using the optimised conditions in Table 2.11, each of the siRNAs was tested to see 
changes in proliferation of the cells after transfection. Two separate siRNAs were 
used for each target gene (Table 2.12), with the exception of ABCB1 since a validated 
siRNA was available for this target. All siRNAs were purchased from Ambion Inc. 
Solutions of siRNA at a final concentration of 30nM were prepared in optiMEM 
(Gibco™, 31985). NeoFX solution was prepared in optiMEM and incubated at room 
temperature for 10 minutes. After incubation, an equal volume of neoFX solution was 
added to each siRNA solution. These solutions were mixed well and incubated for a 
further 10 minutes at room temperature. Replicates of 10|il of the siRNA/neoFX 
solutions were added to a 96-well plate. The cell suspensions were added to each plate 
at the appropriate final cell concentration (Table 2.11). The plates were mixed gently
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and incubated at 37°C for 24 hours. After 24 hours, the transfection mixture was 
removed from the cells and the plates were fed with fresh medium. The plates were 
assayed for changes in proliferation at 72 hours using the acid phosphatase assay 
(Section 2.4.2).
Table 2.12 List of siRNAs used
Target name Ambion IDs
Scrambled Negative control #2
ABCB1 4123 (Validated)
CTGF 146149, 146150
ID3 122173, 122294
CRIP1 145761, 215088
IGFBP6 44812, 44907
EMP1 145889, 145890
CRYZ 112817, 146128
GULP1 121783, 121784
SCP 27500, 27593
FSTL1 136252, 146149
2.13.3 Toxicity assays on siRNA transfected cells
To assay for changes in sensitivity to chemotherapeutic agents, siRNA experiments in 
96-well plates were set up as in Section 2.13.2. Transfection medium was removed 
after 24 hours and replaced with fresh growth medium. Concentrations of the 
chemotherapeutic agent (2X) were added to the plates in replicates of four 48 hours 
after transfection. The plates were assayed for changes in proliferation at 96 hours 
using the acid phosphatase assay (Section 2.4.2).
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Section 3.0: Results
3.1 p53
3.1.1 Transfection with wild-type p53
In order to better understand the role of p53 in drug resistance, a wild-type p53 plasmid 
was introduced to the cell lines in table 3.1.1.
Table 3.1.1 p53 status of parent cell lines
Cell line p53 status
A549 Wild-type
H1299 Null
DLKP-SQ Mutant
3.1.2 Restriction digest of plasmid
Restriction digest of the pcDNA + p53 and the empty vector pcDNA plasmids was 
carried out to ensure that the plasmid was intact. Three digests were set up for each 
plasmid:
No enzyme
- EcoRl
- BamHl
The p53 plasmid was inserted in to the pcDNA vector at a BamHl cutting site. 
Subsequently, when the plasmid is cut with BamHl enzyme, two bands should result, 
one the size of the vector, and the other corresponding to the p53 inserted fragment. 
Ligation with another enzyme like EcoRl only results in one band since it doesn’t 
separate the p53 fragment. The results seen in Figure 3.1.1 show that the plasmid 
obtained from the large scale preparation is intact, so the transfection can be carried out.
88
00
VO
orac*i
w
K*
£Ui
r*
o’
era
09
o
5"
3a■a
»■aM■*S9
M  •es
1*
• t
1111'
11
4<l
li
II1
CONTROL
VECTOR-UNCUT
VECTOR-EcoRl
VECTOR-BamHl
P53-UNCUT
P53 — EcoRl
P53 -B am H l
Figure 
3.1.1 
M
ap 
of plasm
id
+
f -
Nhe I 
Pme I 
Aft II 
Mnd III 
Kpn I 
BamH I 
SsiX I 
EcoR I 
Pstl 
EcoR V 
Bs(X I 
Noti 
Xho I 
Xba I 
/Apa I 
Pme I
»
M?el 
Pme I 
Apa I 
Xbal
X /70  I
Not I 
Bs£K I 
EcoR V 
EcoR I 
BsCKI 
BamH I 
Kpn I 
H/nd III 
Afì II 
Pme I
3.1.3 Lipofectin transfection
The wild-type p53 plasmid was transfected into four cell lines using lipofectin reagent. 
Three transfections were carried out per cell line
• No plasmid
• pcDNA empty vector
• pcDNA + p53
These controls ensure that any changes observed in the cell lines after transfection are 
due to the p53 expression and not caused by the transfection procedure itself.
3.1.4 Changes in sensitivity to chemotherapeutic drugs in mixed populations
Initially the mixed populations of the transfected cell lines were tested for any changes 
in sensitivity. The empty vector (EV) control transfected cell lines were also included in 
this analysis. Some changes in sensitivity were observed in both EV-transfected and 
p53-transfected cells as seen in Table 3.1.2.
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Table 3.1.2 IC50s of mixed population transfection
Adr (ng/ml) Taxol (ng/ml) Carbo (ng/ml)
A549-parent 15.4 + 4.2 1.1 ±0.2 6.7 ±0.4
A549-ev mp 13.6 ±3.1 1.7 ±0.5 12.4 ±3.8
A549-p53 mp 25.5 ±1.4 2 ±0.2 15.5 ±0.7
HI299-parent 31 ±0.8 4.3 ±0.1 5.4 ±0.2
H1299-ev mp 13.2 ±1.1 4.2 ±0.6 4.1 ±0.2
H1299-p53 mp 14.6 ±2.6 2.8 ±0.4 3.1 ±0.3
SQ parent 10.9 ±0.8 2.2 ±0.2 2.3 ±0.2
SQ -  ev mp 15.7 ± 1.4 2.2 ±0.1 3.3 ±0.2
SQ -  p53 mp 10.3 ±0.7 1.6 ±0.2 2.2 ±0.3
(Results are expressed as IC50 ± SD, n=3)
ev -  empty vector control transfection 
p53- p53 transfection 
mp -  mixed population
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3.1.5 Analysis of p53 function
In non-drug treated cells (control) wild-type p53 protein should be present in small 
amounts because it is degraded rapidly by the cell. However, when cells are subjected to 
stress, such as DNA damage induced by drug treatment, wild-type p53 protein should 
accumulate, if the gene is functional. To test the function of the introduced gene 
transfected cells were treated with a range of different adriamycin concentrations with 
subsequent analysis of p53 protein content.
3.1.5.1 A549
A549 cells express endogenous wild-type p53, therefore accumulation of p53 is present 
in untransfected cells. Figure 3.1.3 shows the presence of p53 in A549 and the mixed 
population of p53-transfected A549 (A549-p53 mp) before and after treatment with 
adriamycin at 15, 30, 45 and 60ng/ml. There is an increased amount of wild-type p53 
protein in the mixed population, demonstrating that the p53 gene is functional. An 
increase in p53 accumulation after DNA damage would demonstrate that exogenous 
p53 is functional. The mixed population was subsequently cloned out and ten individual 
clones isolated. Some of these clones show variances in the amount of p53 protein 
expressed as shown in Figure 3.1.4.
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Figure 3.1.3 Western blot analysis of p53 expression in A549 parent and p53- 
transfected mixed population before and after adriamycin treatment
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Figure 3.1.4 Western blot of A549 parent and transfected clones
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3.1.5.2 H1299
H1299 parent cells have a p53 deletion which results in no endogenous p53 mRNA or 
protein expression. Western blot analysis revealed no p53 protein expression before or 
after drug treatment in the H1299-p53 mixed population. However, the cells were 
resistant to zeocin proving that the transfection was successful. After cloning out the 
mixed population and screening them for p53 protein expression clone 8 demonstrated 
the presence of p53 protein (Figure 3.1.6). p53 mRNA was present in two of the p53- 
transfected clones, 6 and 8 (Figure 3.1.5)
Figure 3.1.7 shows this cell line H1299-p53 clone 8 before (-) and after (+) adriamycin 
treatment. The p53 protein expressed in H1299-p53 clone 8 does not accumulate after 
DNA damage caused by the chemotherapeutic agent adriamycin.
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Figure 3.1.5 RT-PCR mRNA expression of p53 in H1299-p53 transfected clones
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Figure 3.1.7 p53 expression in H1299-p53 clone 8 after drug treatment
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3.1.6 Changes in sensitivity of p53 clones to chemotherapeutic drugs
In order to determine the role of p53 in resistance to chemotherapeutic agents, the p53 
transfected clones were tested for differences in sensitivity to the agents adriamycin, 
taxol and carboplatin.
3.1.6.1 A549
It was expected that p53 would sensitise cells to chemotherapeutic drugs, however the 
general trend in the A549-p53 transfected cells was an increase in resistance with the 
introduction of p53 as shown in table 3.1.3. Some clones (e.g. clone 3) showed 
increased sensitivity to adriamycin with no significant change in resistance to taxol or 
carboplatin graphically shown in Figure 3.1.8.
Table 3.1.3 IC50s for some chemotherapeutic drugs in A549 transfected clones
Cell Line Adriamycin
(ng/ml)
Taxol
(ng/ml)
Carboplatin
(Hg/ml)
A549 parent 15.43 ±4.2 1.1 ±0.1 6.7 ±0.4
A549 EV mp 13.6 ±3.1 1.7 ± 0.5 12.4 ±3.8
A549 EV clone 1 9.9 ±0.4 2.2 ±0.1 8.3
A549 EV clone 2 11 ±0.9 1.7 ±0.4 6.1 ±0.9
A549 EV clone 3 8.8 ±0.9 2.1 ±0.1 9.6 ±0.2
A549 p53 mp 25.5 ± 1.4 2.1 ±0.2 15.5 ±0.7
A549 p53 clone 1 14.2 ± 1.5 2.6 ±0.6 8.5 ±0.5
A549 p53 clone 2 14.9 ± 1.9 1.4 ±0.4 9.6 ± 1.2
A549 p53 clone 3 11.1 ±0.3 1.5 ±0.6 8.9± 1.4
A549 p53 clone 4 17.8 ±2.1 1.9 ± 0.1 13.5 ± 2.3
A549 p53 clone 5 20.5 ± 1.4 2.1 ±0.1 12.5 ± 1.7
A549 p53 clone 6 15.8 ± 1.7 2 ±0.2 18.6 ±2.2
A549 p53 clone 7 19.4 ±0.6 2 ±0.2 15.4 ±1.1
A549 p53 clone 8 24.2 ± 1.3 1.9 ±0.6 11.7 ± 2.6
A549 p53 clone 9 13.9 ± 1.5 1.1 ±0.5 8.9 ± 1.2
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Figure 3.1.8 IC50s for (a) Adriamycin, (b) Taxol and (c) Carboplatin in A549 
transfected clones
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3.1.6.2 H1299
In contrast to the A549 transfected cells the introduction of wild-type p53 sensitised 
most clones of the HI 299 transfected cell line. An increase in sensitivity to adriamycin, 
taxol and carboplatin was seen in all clones but H1299-p53 clone 3, which was more 
resistant to the drugs tested. However, the empty vector mixed population showed 
enhanced sensitivity, equivalent to the p5 3-transfected mixed population, so a role for 
p53 in the enhanced sensitivity is uncertain. No p53 protein was detected in the mixed 
population of H1299-p53 by western blot analysis. These results are shown in Table 
3.1.4 and Figure 3.1.9.
Table 3.1.4 lC50s of H1299 clones to the chemotherapeutic agents adriamycin, 
taxol and carboplatin.
Cell Line Adriamycin
(ng/ml)
Taxol
(ng/ml)
Carboplatin
(Hg/ml)
H1299 parent 31 ±0.8 4.3 ±0.1 5.4 ±0.2
H I299 EV mp 13.2 ± 1.1 4.2 ±0.6 4.1 ±0.2
H1299 EV clone 2 30.7 ±3.5 6 ±0.7 2.9 ±0.4
H1299 p53 mp 14.6 ±2.6 2.8 ±0.4 3.1 ±0.3
H1299 p53 clone 1 31.8 ± 1 2.4 ±0.3 1.3 ±0.2
H I299 p53 clone 2 24.5 ± 2.2 2.1 ±0.8 4 ±0.2
H1299 p53 clone 3 43.7 ±9.2 8.1 ±0.7 7.1 ±4.4
H1299 p53 clone 4 23.3 ±2.4 4.1 ±1.1 3.1 ±0.5
H1299 p53 clone 5 18.2 ± 1.5 3.6 ± 1.6 1.7 ±0.1
H1299 p53 clone 6 18 ±2.3 2.9 ± 1.1 1.9 ± 0.1
H1299 p53 clone 8 31.4 ±1.1 2 ±0.6 4.1 ±0.3
H I299 p53 clone 9 21.5 ±3.4 3.8 ± 1.5 4.8 ±0.7
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Figure 3.1.9 IC50s for (a) Adriamycin, (b) Taxol and (c) Carboplatin in H1299 
transfected clones
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3.1.6.3 DLKP-SQ
DLKP-SQ cells endogenously express mutant p53. It was expected that the introduction 
of wild-type p53 should increase the sensitivity of the cells to chemotherapeutic drugs 
The IC50s of the DLKP-SQ clones to some chemotherapeutic agents are shown in table 
3.1.5. Some of the p53-transfected clones show slight sensitisation to adriamycin and 
taxol, but not to carboplatin (Figure 3.1.10). However, an effect on sensitivity was again 
observed in the empty vector-transfected cells, so there is no clear evidence for the 
impact of wild-type p53 on drug sensitivity.
Table 3.1.5 IC50s of SQ clones to the chemotherapeutic agents adriamycin, taxol 
and carboplatin
Cell Line Adriamycin
(ng/ml)
Taxol
(ng/ml)
Carboplatin
(Hg/ml)
SQ parent 10.8 + 0.8 2.2 ±0.2 2.2 ±0.2
SQ EV mp 14.7+1.4 2.2 ±0.1 3.2 ±0.2
SQ EV clone 1 11.6 + 0.5 1.6 ± 0.2 3.8 ±0.1
SQ EV clone 3 14.4 + 0.1 1.3 ±0.3 4.6 ±0.3
SQ p53 mp 10.3+0.7 1.6 ±0.4 2.2 ±0.3
SQ p53 clone 1 12.2+1 1.2 ±0.1 2.3 ±0.5
SQ p53 clone 2 7.1 ±0.2 2.1 ±0.1 3.4 ±0.5
SQ p53 clone 3 10.3 + 1.5 1.2 ± 0.1 2.5 ±0.3
SQ p53 clone 5 9.2+ 0.4 1.1 ±0.1 2.7 ±0.1
SQ p53 clone 6 8.9 ±0.4 1.8 ±0.1 2.9
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3.1.7 Changes in sensitivity of H1299-p53 clone 8
The only p53-expressing clone 8 showed an increase in sensitivity to taxol. Other p53- 
transfected clones, which did not express detectable p53 protein, show some changes in 
sensitivity to these drugs. H1299-p53 clone 6 expresses p53 mRNA but does not 
express any protein and showed increased sensitivity to taxol and carboplatin and 
increased resistance to adriamycin (Figure 3.1.11).
■  Adr
■  Tax 
□  Cpt
Figure 3.1.11 Fold resistance of H1299-p53 clones to the chemotherapeutic agents 
adriamycin, taxol and carboplatin.
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3.1.8 Expression of p53 family members
The expression of p53 family members, p63 and p73 were determined by western 
blotting. Since the p53 expressed by H1299-p53 clone 8 does not accumulate after 
DNA damage (Figure 3.1.5), this cell must have alternate mechanisms in place for 
dealing with stress. It is possible that this is regulated in the H1299 cells by p63 or p73. 
The expression of p73 in H1299 cell lines is shown in Figure 3.1.12. This blot shows 
H I299 parent, control-transfected clones and H1299-p53 8 before (-) and after (+) 
treatment with adriamycin at 25ng/ml. All of the cell lines express the protein, although 
there is more expressed after DNA damage in H I299, but not in the transfected cell 
lines. The other family member p63 was not detected in any of the cell lines.
P-actin
Figure 3.1.12 Western blot of H1299 cell lines for p73 and P-actin
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3.1.9 Expression of Mdm2
Mdm2 is the major regulator of p53. Figure 3.1.13 shows the expression of Mdm2 in 
H1299 parent, control-transfected clones and H1299-p53 8 before (-) and after (+) 
treatment with adriamycin at 25ng/ml. Low levels of Mdm2 protein were detected in 
all of the H1299 cell lines (parental and clones) tested.
Mdm2
P-actin
Figure 3.1.13 Western blot of H1299 cell lines for Mdm2 and P-actin
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3.1.10 Changes in invasion of H1299-p53 clone 8
In order to see if p53 plays any role in invasion, H1299-p53 clone 8, the only clone 
expressing detectable p53 protein, was tested along with the parent cell line in the 
invasion assay. Invasive ability of these cell lines is shown in Figure 3.1.14 and Figure 
3.1.15. The p53-expressing clone appears considerably less invasive than the parental 
cells. However, these effects may be due to transfection since control transfected cells 
appear to have differing invasive potentials. Nevertheless, the decrease in invasion 
observed in H1299-p53 clone 8 is substantial and offers an opportunity to study genes 
and proteins involved in invasion.
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(a)
(b)
(c)
Figure 3.1.14 Invasion of: (a) H1299 parent; (b) H1299-p53 clone 6 and (c) H1299- 
p53 clone 8
106
(a)
(b)
(c)
Figure 3.1.15 Invasion of H1299-EV cells: (a) Clone 1; (b) Clone 2 and (c) Clone 3
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3.1.11 Microarray analysis of H1299-p53
Since one of the H1299-p53 transfected clones was found to express p53 protein (Figure 
3.1.4), it was chosen for microarray analysis. Three samples in triplicate were included 
in this experiment, H1299, H1299-EV and H1299-p53. For H1299-EV, three separate 
clones of this cell line were included as replicates. For H1299-p53, triplicate samples of 
H1299-p53 clone 8 were included.
The genechips used were Affymetrix U133 Plus 2.0 chips (Section 2.11).
3.1.11.1 Quality control
A number of quality control measures are carried out on microarray experiments before 
gene expression analysis begins. Firstly, a chip information form was filled out for each 
form. The information from these forms for all of the microarray chips run in this 
experiment can be seen in Table 3.1.6. For the experiments to be comparable there 
must be no more than 3-fold difference between the scaling factors for each chip. The 
lowest scaling factor in this group of chips is 0.632 and the highest is 1.106, which is a 
fold difference of 1.75.
Another quality control measure taken after the chip is satisfactory is hierarchical 
clustering. This clusters the samples based on their gene expression, and places the 
most similar samples in groups together. The hierarchical cluster generated by dChip 
for this experiment can be seen in Figure 3.1.16. It showed that the parent samples 
clustered correctly and the H1299-p53 samples clustered correctly but the control 
transfected H1299-EV samples did not cluster. Despite the result of the clustering, 
further analysis was carried out using d-chip.
These quality control measures are explained in more detail in Section 3.3.
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Table 3.1.6 Quality control on chips from p53 experiment
Sample name Scaling
factor
Noise Background % Present 375’ Ratio 
GAPDH
- -
H1299_l 0.867 1.8 52.13 45.9 1
H1299_2 0.729 2.26 66.41 43 0.95
H1299 3 0.847 1.63 49.2 45.1 1.14
H1299_EV_1 0.743 1.8 55.72 47 0.99
H1299_EV_2 0.723 2 62.14 44.4 0.96
H1299 E V 3 1.106 1.32 42.89 42.3 2.19
H1299_p53_l 0.683 2.2 69.53 43.8 0.95
H1299_p53_2 0.632 2.23 68.57 44.7 0.94
H1299_p53_3 0.765 1.94 59.43 44 0.98
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Figure 3.1.16 Hierarchical Cluster of p53 experiment samples
DChip software was used in the original generation of genelists. Using dChip, H1299 
was compared to H1299-EV, and H1299 was compared to H1299-p53. The parameters 
used were a fold change of 2, a difference of intensity of 100 and a p value of <0.05. 
The numbers of genes changed in these genelists are shown in Table 3.1.7.
Table 3.1.7 Number of genes differentially regulated
3.1.11.2 Generation of genelists
Genelist ¡No. ol‘genes
H1299 vs H1299-EV 221
H1299 vs H1299-p53 296
These genelists were compared to eliminate genes that were differentially expressed in 
the control-transfected cells from the p53 genelist. This comparison resulted in a 
genelist of 254 genes. Of this, 151 were upregulated genes and 104 were 
downregulated. These genelists are shown in Tables 3.1.8 and 3.1.9. The transfected 
gene p53, does not appear in these lists. In order to investigate this a genelist was 
generated in dChip using less stringent filtering criteria of a fold change of 1.2 and a 
difference in intensities of 50. In this list p53 was detected, however it appeared in both 
parent and transfected cell lines at intensities of 381 and 293 respectively. This 
represents a 1.3-fold downregulation of p53 in the transfected cells, which is directly 
conflicting the results observed earlier in RT-PCR (Figure 3.1.5) and western blotting 
(Figure 3.1.6). It is possible that the probes on the affymetrix chip are designed to a 
part of the p53 gene that was not present on the cDNA that was used for transfection, 
e.g. the untranslated region (UTR). Since the western blotting and RT-PCR results 
represent repeated experiments with the inclusion of controls, this result should be a 
true reflection of the p53 status of the transfected cells.
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Table 3.1.8 Upregulated genes in Hl299-p53
Gene fold change
Desmoplakin 2.72
Cysteine and glycine-rich protein 1 2.52
Protein tyrosine phosphatase type IVA, member 1 2.25
Methionine adenosyltransferase II, alpha 2.23
Myeloid cell leukemia sequence 1 (BCL2-related) 2.39
Thrombospondin 1 2.92
Thrombospondin 1 5.31
Thrombospondin 1 3.91
Inositol 1,4,5-triphosphate receptor, type 3 2.27
DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, X-linked 2.86
Rho GDP dissociation inhibitor (GDI) beta 6.43
Peptidylprolyl isomerase F (cyclophilin F) 2.54
Transforming growth factor, beta-induced, 68kda 2.3
Chloride intracellular channel 4 3.06
Podocalyxin-like 2.9
Caldesmon 1 2.23
Secreted frizzled-related protein 1 3.02
Laminin, gamma 2 2.53
Guanylate binding protein 1, interferon-inducible, 67kda 2.8
Chromosome 10 open reading frame 69 2.18
PALM2-AKAP2 protein 2.12
Alanyl (membrane) aminopeptidase 2.46
Interleukin 1 receptor, type I 3.99
Lysyl oxidase-like 2 5.32
Metastasis suppressor 1 2.23
Diphtheria toxin receptor 2.71
Death-associated protein kinase 3 2.51
GLI pathogenesis-related 1 (glioma) 2.43
Friend leukemia virus integration 1 2.59
Lysyl oxidase 2.58
SMAD, mothers against DPP homolog 7 (Drosophila) 3.84
Acyl-Coenzyme A oxidase 2, branched chain 2.1
TNF receptor-associated factor 1 2.74
Importin 8 2.11
Protein tyrosine phosphatase, non-receptor type 11 (Noonan syndrome 1) 3.32
Protein tyrosine phosphatase, non-receptor type 11 (Noonan syndrome 1) 2.71
Nucleolar and coiled-body phosphoprotein 1 2.15
Serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 8 2.22
Protein tyrosine phosphatase, receptor type, R 3.82
Tropomyosin 1 (alpha) 2.23
Pentaxin-related gene, rapidly induced by IL-1 beta 3.61
Adrenergic, beta-2-, receptor, surface 3.58
V-crk sarcoma virus CT10 oncogene homolog (avian)-like 2.59
Ras-gtpase activating protein SH3 domain-binding protein 2 2.28
Chromosome condensation 1 2.05
BCL2-like 1 2.36
Zinc finger protein 45 (a Kruppel-associated box (KRAB) domain polypeptide) 2.03
Phosphatidylinositol-4-phosphate 5-kinase, type I, alpha 2.03
Secretoglobin, family ID, member 1 2.2
Fibroblast growth factor 5 2.89
Sin3-associated polypeptide, 18kda 2.04
Inhibitor of DNA binding 1, dominant negative helix-loop-helix protein 2.31
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Growth arrest and DNA-damage-inducible, beta 2.34
Annexin A3 2.71
F-box and WD-40 domain protein 11 2.71
Kinesin family member Cl 2.28
Synovial sarcoma translocation, chromosome 18 2.15
Insulin-like growth factor binding protein 3 2.47
Peripheral myelin protein 22 3.58
Fibroblast growth factor 5 3.7
Fibroblast growth factor 5 3.62
Baculoviral IAP repeat-containing 3 2.61
Protein tyrosine phosphatase, receptor type, R 3.29
MAX protein 2.04
Notch homolog 2 (Drosophila) III Notch homolog 2 (Drosophila) 2.07
Phosphatidylinositol-4-phosphate 5-kinase, type I, alpha 3.49
CASP8 and FADD-like apoptosis regulator 2.08
Plasminogen activator, urokinase III plasminogen activator, urokinase 2.36
Cyclin E2 2.55
Ras homolog gene family, member B 2.04
KIAA0746 protein 2.5
DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, X-linked 2.26
KIAA0286 protein 2.81
Hypothetical protein H41 2.46
Snf2-related CBP activator protein 2.5
Met proto-oncogene (hepatocyte growth factor receptor) 2.9
Dehydrogenase/reductase (SDR family) member 2 2.69
Poliovirus receptor 2.28
Elongation factor, RNA polymerase II, 2 2.15
Microtubule-associated protein IB 2.04
Hypothetical protein dj462o23.2 2.23
Myotubularin related protein 1 2.1
BCL2-like 1 2.54
Integrin, alpha 6 2.01
Phosphatidylinositol binding clathrin assembly protein 2.05
Lysyl oxidase 2.67
Primase, polypeptide 2A, 58kda 2.35
Chromosome condensation 1 2.23
Gb:AK026847.1 /DB_XREF=gi: 10439802 /FEA=mma /CNT=1 81.68
Phosphoribosylglycinamide formyltransferase, 2.08
Sulfide quinone reductase-like (yeast) 2.06
Calcium/calmodulin-dependent protein kinase II 2.94
Lin-7 homolog C (C. Elegans) 2.12
Erythrocyte membrane protein band 4.1 like 4B 3.08
Tropomodulin 3 (ubiquitous) 2.45
Mitogen-activated protein kinase 2.66
Diphtheria toxin receptor 2.08
Ubiquitin-fold modifier 1 2.3
Paraspeckle component 1 2.31
Potassium channel tetramerisation domain containing 5 2
Chromosome 6 open reading frame 166 2.03
Dual specificity phosphatase 23 2.34
Guanylate binding protein 3 2.54
Normal mucosa of esophagus specific 1 4.18
Calcium binding protein 39 2.18
Dnaj (Hsp40) homolog, subfamily C, member 5 2.25
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Eukaryotic translation initiation factor 4E binding protein 2 2.05
Monoglyceride lipase 2.36
Myosin VB 2.44
Breast cancer membrane protein 101 3.69
Protocadherin 18 2.23
HTV-1 rev binding protein 2 2.51
Purine-rich element binding protein B 2.08
Chromosome 6 open reading frame 105 3.08
Ring finger protein (C3HC4 type) 159 2.08
Transcribed locus, highly similar to NP 058593.1 2.03
Dimethylarginine dimethylaminohydrolase 1 2.78
MRNA; cdna dkfzp564c0762 (from clone dkfzp564c0762) 2.09
Gb:AI361034/DB XREF=gi:4112655/DB XREF=qy03el0.xl 2.13
Gb:AA805622 /DB_XREF=gi:2874372 /DB_XREF=ocl9bll.sl 3.1
Hypothetical LOC388480 2.11
Guanylate binding protein 1, interferon-inducible, 67kda 3.27
Suppressor of Ty 16 homolog (S. Cerevisiae) 2.14
TNF receptor-associated factor 1 2.9
Hypothetical protein LOC285550 2.51
Transferrin receptor (p90, CD71) 3.44
Membrane associated DNA binding protein 2.61
Grpe-like 2, mitochondrial (E. Coli) 3.12
UL16 binding protein 2 2.27
Homo sapiens, clone IMAGE:3866695, mma 2.21
Zinc finger protein 566 2.08
Ras-gtpase-activating protein SH3-domain-binding protein 2.54
Microfibrillar-associated protein 3 2.93
Neuron navigator 3 2.5
Desmoglein 2 2.6
Dimethylarginine dimethylaminohydrolase 1 4.03
Ras homolog gene family, member B 3.19
Zinc finger protein 146 2.17
Dnaj (Hsp40) homolog, subfamily C, member 14 2.51
Inositol polyphosphate-5-phosphatase, 40kda 2.72
Primase, polypeptide 2A, 58kda 2.07
Fucosyltransferase 8 (alpha (1,6) fucosyltransferase) 2.97
Hypothetical protein HSPC129 2.32
V-ets erythroblastosis virus E26 oncogene homolog 1 (avian) 2.56
F-box and leucine-rich repeat protein 21 3.89
RNA binding motif protein 14 2.56
Keratin associated protein 2-4 4.11
Rho GDP dissociation inhibitor (GDI) beta 8.13
Solute carrier family 16 (monocarboxylic acid transporters), member 1 2.28
Catenin (cadherin-associated protein), alpha 1, 102kda 2.37
Gb:BC029166.1 /DB XREF=gi:23272920 /TID=Hs2.385583.1 /CNT=2 2.07
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Table 3.1.9 Downregulated genes in H1299-p53
Gene Fold change
SH3 domain binding glutamic acid-rich protein like -2.08
SH3 domain binding glutamic acid-rich protein like -2.18
Insulin induced gene 1 -2.19
Transducin (beta)-like lX-linked -2.32
Sterol regulatory element binding transcription factor 1 -2.81
Periplakin -4,64
Special AT-rich sequence binding protein 1 -2.45
Latrophilin 1 -3.62
Arginase, type II -3.42
Neurofilament, heavy polypeptide 200kda -3.61
Insulin receptor substrate 1 -2.57
O-6-methylguanine-DNA methyltransferase -2.11
Dual-specificity tyrosine-(Y)-phosphorylation regulated kinase IB -2.33
Chromosome X open reading frame 34 -2.03
Carboxypeptidase M -2.35
Cyclin-dependent kinase inhibitor 2A (melanoma, p i6, inhibits CDK4) -2.04
Phosphatidylethanolamine N -methyltransferase -2.31
Nuclear factor of activated T-cells 5, tonicity-responsive -3.15
Tetratricopeptide repeat domain 3 -2.22
Fatty acid desaturase 1 -2
Protein kinase C binding protein 1 -2.11
Paternally expressed 3 -10.83
Acetylserotonin O-methyltransferase-like -2.22
Nuclear receptor subfamily 2, group F, member 1 -2.85
Carboxylesterase 2 (intestine, liver) -2.08
Protein tyrosine phosphatase type IVA, member 3 -3.9
Secreted phosphoprotein 1 -5.87
V-rel reticuloendotheliosis viral oncogene homolog A -2.03
RPL13-2 pseudogene -2.22
Prostate tumor overexpressed gene 1 -2.23
Fatty acid synthase -2.05
Lipin 1 -2.16
Chromodomain helicase DNA binding protein 9 -2.25
Troponin Tl, skeletal, slow -2.08
F-box and leucine-rich repeat protein 7 -2.54
Transducin (beta)-like lX-linked -2.03
Pleckstrin homology domain containing, family C member 1 -2.08
Calreticulin -2.19
Potassium voltage-gated channel, subfamily G, member 1 -2.85
Likely ortholog of mouse zinc finger protein EZI -2.15
Sma4 -2.14
Olfactory receptor, family 7, subfamily E, member 18 pseudogene -2.05
Zinc finger protein 395 -2.25
Dnaj (Hsp40) homolog, subfamily D, member 1 -9.13
Host cell factor Cl regulator 1 (XPOl dependant) -2.04
Dapper homolog 1, antagonist of beta-catenin (xenopus) -3.89
Dipeptidase 3 -6.15
Regulator of G-protein signalling 17 -2.93
Chemokine-like factor -2.04
Nucleosomal binding protein 1 -5.5
SH2 domain containing 3A -2.95
Neurofilament, heavy polypeptide 200kda -3.38
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Cluster Incl. AA669799:ag36c04.sl Homo sapiens cdna, 3 end -2.22
Acetylserotonin O-methyltransferase-like -2
Host cell factor Cl regulator 1 (XPOl dependant) -2.38
Latrophilin 1 -2.03
Thyroid hormone receptor associated protein 3 -2.55
Kiaal333 -2.81
Gb:AA827878 /DB XREF=gi:2900241 /DB XREF=od56g09.sl -2.58
Gb:AFl 13016.1 /DB_XREF=gi:6642755 /FEA=flmma /CNT=30 -4.28
Nucleoporin like 1 -2.07
Metastasis associated lung adenocarcinoma transcript 1 (non-coding RNA) -3.09
Likely ortholog of rat vacuole membrane protein 1 -3.87
Nuclear factor I/A -2.43
RAB3D, member RAS oncogene family -2.04
Rho gtpase activating protein 18 -2.09
KIAA1280 protein -2.51
KIAA1160 protein III RAB43, member RAS oncogene family -2.15
Solute carrier family 25 (mitochondrial carrier; phosphate carrier), member 23 -2.31
Mitogen-activated protein kinase kinase 7 -2.05
Retinoic acid induced 1 -2.16
Metastasis associated lung adenocarcinoma transcript 1 (non-coding RNA) -3.15
Hypothetical protein BC001096 -2.1
Staufen, RNA binding protein, homolog 2 (Drosophila) -2.87
Gb:AI694536 /DB_XREF=gi:4971876 /DB_XREF=wd72dl2.xl -2.12
Spermatogenesis associated 11 -2.03
Zinc finger protein 595 -5,87
Hypothetical protein BC014339 -2.14
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 -2.11
Myo-inositol 1-phosphate synthase A1 -2.66
Gb:AI566130 /DB_XREF=gi:4524582 /DB_XREF=tn53g07.xl -2.15
Hypothetical protein FLJ37659 -112.09
Eomesodermin homolog (Xenopus laevis) -4.12
Chromosome 10 open reading frame 75 -2.11
MRNA; cdna dkfzp4341201 (from clone dkfzp4341201) -8.75
Pyruvate dehydrogenase phosphatase isoenzyme 2 -5.55
Gb:AF152528.1 /DB XREF=gi:5457102 /FEA=mma/CNT=l -2.92
CDNA: FLJ23566 fis, clone LNG10880 -2.36
Carboxypeptidase M -2.08
Shugoshin-like 2 (S. Pombe) -2.15
Hypothetical protein LOC150763 -2.62
Carboxypeptidase M -2.51
Cyclin-dependent kinase inhibitor 2B (pl5, inhibits CDK4) -2.71
Hypothetical gene LOCI33874 -3.32
Gb:AW083849 /DB XREF=gi:6039001 /DB XREF=xc46al2.xl -2.28
GbAV651242 /DB XREF=gi:9872256 /DB XREF=AV651242 -5.65
Gb:AW270845 /DB_XREF=gi:6657875 /DB_XREF=xs04h08.xl -2.3
Carboxypeptidase M -2.18
Gb:AI418253 /DB_XREF=gi:4264184 /DB_XREF=tf74b09.xl -2.59
Carboxypeptidase M -2.67
Chromosome 14 open reading frame 62 -4.61
Gb:AK057525.1 /DB_XREF=gi: 16553266 /TID=Hs2.401310.1 /CNT=6 -2.72
Hypothetical gene supported by AK056786 -3.05
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3.2 Pulse selection of cell lines
Four different lung cancer cell lines were chosen for the drug treatment (Table 3.2.1). 
The cell lines include two adenocarcinoma (AC) and two large cell carcinoma (LCC) 
cell lines. They were pulse-selected with taxol and carboplatin representing two drugs, 
which are used clinically for treating this type of cancer. The concentrations of each 
drug used for pulse selection can be seen in section 2 .6 .
Table 3.2.1 List of lung cancer cell lines and drugs used for the pulse-selections
Cell line Cell type Drugs used
A549 Adenocarcinoma taxol, carboplatin
SKLU-1 Adenocarcinoma taxol, carboplatin
NCI-H1299 (HI299) Large cell carcinoma taxol, carboplatin
NCI-H460 (H460) Large cell carcinoma taxol, carboplatin
Table 3.2.2 Concentrations for pulse-selection
Cell Line Taxol (ng/ml) Carboplatin (|xg/ml)
A549 150 100
H1299 150 50
SKLU-1 10 10
H460 50 50
3.2.1 Determination of sensitivity of the parent cell lines to chemotherapeutic 
agents
The parent cell lines were analysed using an in vitro toxicity assay to determine the 
IC50 (drug concentration killing half of the cell population) of the following 
chemotherapeutic drugs: adriamycin, taxol, carboplatin, cisplatin, 5-fluorouracil, VP- 
16 and vincristine. This was carried out as described in Section 2.4.
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Cell line Adriamycin
(ng/ml)
5-Fluoruracil
(ng/ml)
Taxol
(ng/ml)
Taxotere
(ng/ml)
A549
SKLU-1
H1299
H460
17.3 ±0.2 
27.1+0.4
30.3 ±0.9 
1 1 .1  ± 1.6
150.9 ± 13.8 
1223.3 ±73.7 
152.1 ± 15.2 
188.7 ± 17
1.1 ± 0.1 
1.2 ± 0.1 
4 ±0.3 
4.4 ±0.2
0.8 ±0.9
0.8 ± 0.1 
0.8 ± 0.2
Cell line Vincristine
(ng/ml)
VP-16
(ng/ml)
Carboplatin
(Hg/nil)
Cisplatin
(ng/ml)
A549 
SKLU-1 
HI 299 
H460
3.7 ±05 
0.7 ±0.3 
2.4 ±0.1
3.7 ±0.6
117.3 ± 18 
115.7 ± 5.9 
111.1 ± 12.3 
78.8 ± 8.6
5.9 ±0.2 
2.8 ± 0.2 
3.7 ±0.6 
2.4 ±0.2
584.4 ±32.3
405.7 ±21.2
436.8 ±29.6 
250.3 ±29.7
Table 3.2.3 IC50s of parent cell lines to a number of chemotherapy drugs 
(Results are expressed as IC50 ± SD, n=3)
Table 3.2.3 shows the IC50 concentrations for the parent cell lines. There is a 
considerable difference in sensitivity to the panel of drugs between each cell line and 
even between the same cell types. For example A549 is about twice as resistant to 
carboplatin compared to SKLU-1, whereas SKLU-1 is 8-fold more resistant to 5- 
fluorouracil compared to A549. Similarly within the group of large cell carcinomas, 
H I299 is more resistant to adriamycin and the platinum agents than H460.
3.2.2 Changes in resistance to chemotherapeutic drugs in selected variants
Pulse selection of the above cell lines with taxol and carboplatin resulted in the 
establishment of eight novel cell lines. These were denoted “-tax” for the taxol selected 
cells, and “-cpt” for the carboplatin selected cells. SKLU-1 was very sensitive to 
repeated drug treatment and pulse selection at high kill concentration resulted in total 
cell death after three pulses. Therefore, pulse selection was performed at a much lower 
concentration, which resulted in less cell death for the first three pulses and after that 
gave a 50% kill. These concentrations can be seen in Table 3.2.1.
All pulse-selected cell lines exhibited at least a 2-fold increase in resistance to the 
selecting drug. This level of resistance is relatively low compared to the high levels of 
resistance that can be achieved by a continuous treatment with the selecting 
chemotherapy drug. In the clinical setting patients receive chemotherapy treatment 
once every 1-3 weeks, therefore a weekly drug treatment for 4 hours (pulse selection) 
is more related to the in vivo situation. A number of the newly established cell lines 
exhibited multidrug resistance, becoming resistant to compounds other than the 
selecting drug. In general, cells pulsed with carboplatin show similar levels of cross­
resistance to cisplatin, both platinum-based drugs.
119
3.2.2.1 Changes in resistance in A549 pulse-selected variants
The IC50 values for the A549 pulse-selected variants can be seen in Table 3.2.4. Fold 
resistance information and p values are shown in Table 3.2.5 and Figure 3.2.1. A549- 
tax shows statistically significant increases in resistance to adriamycin, taxol, 
carboplatin, 5-FU, VP-16 and vincristine. These are low-level resistances, with the 
greatest change evident in resistance to taxol and VP-16. The only significant change 
in resistance observed in A549-cpt is a 0.5-fold resistance (or 2-fold increase in 
sensitivity) to taxol. This cell lines also displays changes in resistance to carboplatin 
and cisplatin, but these were not found to be statistically significant.
Table 3.2.4 IC50s of A549 variants
A549 A549-tax A549-cpt
Adriamycin (ng/ml) 17.3+0.2 31.9 ± 4.9 13.3 ± 1.8
Taxol (ng/ml) 1 .1  + 0.1 6 ±0.5 0.5 ±0.1
Taxotere (ng/ml) 0.8 ±0.9 1.5 ± 0.2 0.3 ±0.1
Carboplatin (|j.g/ml) 5.9 ±0.2 7.3 ±0.3 9.6 ±2.2
Cisplatin (ng/ml) 584.4 ±32.3 517.6 ±21.5 1377 ±427.4
5-FU (ng/ml) 150.9 ± 13.8 290.5 ± 10.2 204.6 ±26.5
VP-16 ng/ml) 117.3 ± 18 484.5 ±81.4 106 ± 11.5
Vincristine (ng/ml) 3.7 ±0.5 6 ± 0.2 4.4 ±0.9
(Results are expressed as IC50 ± SD, n=3)
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Table 3.2.5 Fold resistance of A549 pulse-selected variants
Chemotherapeutic
agent
A549 A549-tax P value 
A549-tax
A549-
cpt
P value 
A549-cpt
Adriamycin 1 1 .8 * 0.035 0 . 8 0.055
Taxol 1 5.5*** 0.003 0.5*** 0 . 0 0 2
Taxotere 1 1 . 8 0.365 0.3 0.397
Carboplatin 1 j 3 *** 0.004 1 . 6 0 . 1 0 2
Cisplatin 1 0.9* 0.049 2.4 0,084
5-FU 1 0 . 0 0 0 2 1.4 0.053
VP-16 1 4.1* 0.013 0.9 0.421
Vincristine 1 1 .6 ** 0.007 1 . 2 0.338
* p value <0.05
** p value <0.01
*** p value <0.005
6 -,
Adriamycin Taxol Taxotere Carboplatin Cisplatin 5-Fluorouracil VP-16 Vincristine
Chemotherapeutic Agent
Figure 3.2.1 Fold resistance of A549 pulse-selected variants
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3.2.2.2 Changes in resistance in H1299 pulse-selected variants
The IC50 values for the H1299 pulse-selected variants can be seen in Table 3.2.6. 
Fold resistance information and p values are shown in Table 3.2.7 and Figure 3.2.2.
HI 299-tax shows significant resistance to taxol, taxotere, carboplatin, 5-FU and 
vincristine. The greatest fold change was observed in taxol and taxotere, as was 
expected.
H1299-cpt shows significant resistance to taxol, carboplatin, cisplatin and VP-16. The 
most interesting increases in resistance are to carboplatin and cisplatin, however the 
resistance is very low at 2-fold and 1.5-fold respectively.
Table 3.2.6 IC50s of H1299 variants
H1299 H1299-tax H1299-cpt
Adriamycin (ng/ml) 30.3+0.9 29.8 ±1.3 27.4 ± 1.7
Taxol (ng/ml) 4 ±0.3 17.7 ±0.7 4.7 ±0.3
Taxotere (ng/ml) 0.8 ± 0.1 1.9 ±0.2 0.5 ±0.2
Carboplatin (pig/ml) 3.7 ±0.6 6.2 ±0.5 7.5 ±0.9
Cisplatin (ng/ml) 436.8 ±29.6 654.9 ± 196.2 673.1 ±86.4
5-FU (ng/ml) 152.1 ± 15.2 270 ± 10 148 ±2.1
VP-16 (ng/ml) 111.1 ± 12.3 122.4 ± 19.3 156.4 ±9.6
Vincristine (ng/ml) 2.4 ±0.1 5.4 ±1 1.8 ±0.3
(Results are expressed as IC50 ± SD, n=3)
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Table 3.2.7 Fold resistance of H1299 pulse-selected variants
Chemotherapeutic
agent
H1299 111299-
tax
P value 
HI299-tax
H1299-
cpt
P value 
H1299-tax
Adriamycin 1 1 0.620 0.9 0.074
Taxol 1 0.0003 1 .2 * 0.045
Taxotere 1 2 5*** 0.002 0.6 0.062
Carboplatin 1 0.004 2 ** 0.007
Cisplatin 1 1.5 0.192 1.5* 0.031
5-FU 1 1 .8** 0.001 1 0.693
VP-16 1 1.1 0.448 \ 4 ** 0.008
Vincristine 1 2.3* 0.031 0 .8* 0.045
* p value <0.05
** p value <0.01
*** p value <0.005
■  H1299
■  H1299-tax 
□  H1299-cpt
Adriamycin Taxol Taxotere Carboplatin Cisplatin 5-Fluorouracil VP-16 Vincristine
Chemotherapeutic Agent
Figure 3.2.2 Fold resistance of H1299 pulse-selected variants
!
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3.2.2.3 Changes in resistance in H460 pulse-selected variants
The IC50 values for the H460 pulse-selected variants can be seen in Table 3.2.8. Fold 
resistance information and p values are shown in Table 3.2.9 and Figure 3.2.3. 
H460-tax shows a significant increase in resistance of 2.4-fold to taxol, and 2.8-fold to 
taxotere. Interestingly, there is a decrease in sensitivity to carboplatin in this cell line. 
H460-cpt displays significant increases in resistance to taxol, carboplatin and 
vincristine. Unexpectedly, the greatest change in resistance was to vincristine at 2.9- 
fold.
Table 3.2.8 IC50s of H460 variants
H460 H460-tax H460-cpt
Adriamycin (ng/ml) 1 1 .1  ± 1.6 9.9 ±0.5 11 ±0.5
Taxol (ng/ml) 4.4 ±0.2 10.8 ±0.3 7 ±0.3
Taxotere (ng/ml) 0.8 ± 0.2 2.3 ±0.3 1.9 ±0.9
Carboplatin (|j.g/ml) 2.4 ±0.2 2 ± 0.1 5.6 ±0.9
Cisplatin (ng/ml) 250.3 ±29.7 163.3 ±94.1 413 ±266.4
5-FU (ng/ml) 188.7 ± 17 201 ± 12.2 166.7 ±22.3
VP-16 (ng/ml) 78.8 ± 8.6 77.1 ±4.6 68.3 ±3.6
Vincristine (ng/ml) 3.7 ±0.6 9.1 ±5.2 10.6 ± 1.2
(Results are expressed as IC50 ± SD, n=3)
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Table 3.2.9 Fold resistance of H460 pulse-selected variants
Chemotherapeutic
agent
H460 11460-
tax
P value 
H460-tax
H460-
cpt
P value 
H460-cpt
Adriamycin 1 0.9 0.344 1 0.925
Taxol 1 2  4 *** 0.0001 1 g*** 0.0005
Taxotere 1 2 .8 *** 0.003 2.3 0.178
Carboplatin 1 0 .8 * 0.023 2.3* 0.024
Cisplatin 1 0.7 0.246 1 . 6 0.401
5-FU 1 1 . 1 0.370 0.9 0.250
VP-16 1 1 0.858 0.9 0.157
Vincristine 1 2.5 0.208 2  9 *** 0.003
* p value <0.05
** p value <0.01
*** p value <0.005
3 .5
3
Adriamycin Taxol Taxotere Carfaoplatin Cisplatin 5- VP-16 Vincristine
Fluorouracil
Chemotherapeutic Agent
Figure 3.2.3 Fold resistance of H460 pulse-selected variants
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3.2.2.4 Changes in resistance in SKLU1 pulse-selected variants
The IC50 values for the SKLU1 pulse-selected variants can be seen in Table 3.2.10. 
Fold resistance information and p values are shown in Table 3.2.11 and Figure 3.2.4. 
SKLUl-tax shows increases in resistance to adriamycin (2.1-fold), taxol (5-fold), 
cisplatin (1.4-fold) and VP-16 (1.4-fold).
SKLUl-cpt displays significant increases in resistance to adriamycin, taxol, 
carboplatin, cisplatin and VP-16. Although this cell line was pulsed with carboplatin, 
it shows an 8.5-fold increase in resistance to taxol and only a 1.4-fold increase in 
resistance to carboplatin.
Table 3.2.10 IC50s of SKLU-1 variants
SKLU-1 SKLU-l-tax SKLU-l-cpt
Adriamycin (ng/ml) 27.1+0.4 55.8 ±5.1 78 ±10.8
Taxol (ng/ml) 1 .2 + 0.1 6.2 ±0.5 10.5 ±0.6
Carboplatin (|ig/ml) 2 .8 + 0.2 3.7 ±0.9 4 ±0.2
Cisplatin (ng/ml) 405.7 + 21.2 566 ±46.3 1176.7 ±75.1
5-FU (ng/ml) 1223.3 ±73.7 1210 ±215.2 553.3 ±7.6
VP-16 (ng/ml) 115.7 ±5.9 162 ± 17.1 239.7 ± 12.6
Vincristine (ng/ml) 0.7 ±0.3 1.3 ±0.1 1 ±0.3
(Results are expressed as IC50 ± SD, n=3)
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Table 3.2.11 Fold resistance of SKLU1 pulse-selected variants
Chemotherapeutic
agent
SKLU1 SKLU1-
tax
P value 
SKLUl-tax
SKLUl-
cpt
P value 
SKLUl-cpt
Adriamycin 1 2 .1 ** 0 . 0 1 0 2.9* 0.014
Taxol 1 0.003 8.5*** 0.001
Carboplatin 1 1.3 0.209 0.001
Cisplatin 1 1.4* 0.014 2  9 *** 0 . 0 0 2
5-FU 1 1 0.927 0  5 *** 0.004
VP-16 1 1.4* 0.032 2  i*** 0.001
Vincristine 1 1 . 8 0.058 1.4 0.265
* p value <0.05
** p value <0.01
*** p value <0.005
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Figure 3.2.4 Fold resistance of SKLU1 pulse-selected variants
3.2.3 Invasion assays
Invasion assays were used to determine invasion ability of a cell line in vitro. The 
cells are placed on artificial extracellular matrix (ECM) which is coated onto a porous 
membrane and inserted into a 24-well plate. Cells are considered invasive when they 
are able to migrate through the ECM gel and the porous membrane and subsequently 
attach to the underside of the membrane within 24 hours. Some cell lines are capable 
of detaching from the insert and attaching to the bottom of the 24-well plate. These 
cells are termed superinvasive.
3.2.3.1 Invasion of parent cell lines
The invasive abilities of the four parent cell lines used in this study are demonstrated 
in Figures 3.2 .5-3.2 .8. There was increasing invasion ability in the parent cell lines as 
follows: H460; A549; SKLU-1 and H1299. Additionally a certain cell population of 
SKLU-1 (Figure 3.2.7b) and H1299 (Figure. 3.2.8b) displayed the ability to super- 
invade. The images presented are representative of at least three separate experiments, 
are at a magnification of 10X and are stained with crystal violet (Section 2.7).
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(a)
Figure 3.2.5 Invasion of H460
(b)
Figure 3.2.6 Invasion of A549
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(a)
(b)
Figure 3.2.7 Invasion and superinvasion of SKLU1
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(b)
Figure 3.2.8 Invasion (a) and superinvasion (b) of H1299
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3.2.3.2 Changes in invasion capacity after pulse-selection
The H460 parent line was the least invasive cell line used in this study. After pulse 
selecting the cells for taxol and carboplatin, both variants showed decreases in invasion 
activity (Figure 3.2.10). This invasion was quantified by counting the number of 
invading cells. Figure 3.2.9 shows the decrease of invasion the pulse-selected H460 
variants.
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Figure 3.2.9 Quantified invasion of H460 variants
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Figure 3,2.10 Invasion of (a) H460, (b) H460-tax and (c) H460-cpt
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The parental A549 cells showed a significant ability to invade (Figure 3.2.12). The 
taxol-selected cells showed slightly increased invasion, whereas the selection with 
carboplatin show considerably decreased invasion activity (Figure 3.2.11). The latter 
cells also differ morphologically from the parent cells having become larger and 
elongated.
Figure 3.2.11 Quantified invasion of A549 variants
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(a)
(b)
(c)
Figure 3.2.12 Invasion of (a) A549, (b) A549-tax and (c) A549-cpt
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SKLU-1 parent cells were invasive and a few cells also super-invaded. In contrast to 
the results mentioned above, pulse-selected variants of SKLU1 were less invasive than 
the parent cell line (Figures 3.2.13 and 3.2.14).
Figure 3.2.13 Quantified invasion o f SKLU1 variants
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Figure 3.2.14 Invasion of (a) SKLU1, (b) SKLUl-tax and (c) SKLUl-cpt
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H1299 parent was the most invasive and superinvasive cell line used in this project. 
After taxol-selection the invasion capacity slightly increased, whereas the carboplatin- 
selected cells showed a decrease in invasion activity (Figures 3.2.15 and 3.2.16), 
similar to what was seen with A549 cells.
Figure 3.2.15 Quantified invasion of H1299 variants
(a)
(b)
Figure 3.2.16 Invasion of (a) H1299, (b) H1299-tax and (c) H1299-cpt
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3.2.4 Pgp expression
Pgp expression was detected in cell lines using western blotting. Only one of the cell 
lines, H1299, was found to express the protein. Figure 3.2.17 shows that P-gp was up- 
regulated in H1299-tax relative to H1299.
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Figure 3.2.17 P-gp expression in selected cell lines
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3.2.5 MRP1 expression
MRP1 protein was detected in the cell lines (Figure 3.2.18). A549 parental cells 
express high levels of the protein, which seems to remain relatively unchanged in the 
pulse-selected variants. In H1299 cells, MRP1 protein is expressed at a very low level 
in the H1299-cpt cell line. All of the H460 cell lines express MRP1, with less 
expression in the selected variants compared to the parent cell line. SKLU1 parent 
cells express very low levels of MRP 1, whereas the protein is much more abundant in 
SKLUl-tax and especially SKLUl-cpt.
Figure 3.2.18 MRP1 expression in selected cell lines
3.2.6 Combination assays
Toxicity assays were carried out in all cell lines with a combination of adriamycin and 
the NSAID sulindac, an MRP1 inhibitor or a combination of taxol with GF120918, a 
Pgp inhibitor. A summary of the results observed in all combination assays can be 
seen in Table 3.2.12.
Table 3.2.12 Summary of effects observed in combination assays
Cell line Sulindac and adriamycin GF120918 and taxol
A549 ++ -
A549-tax ++ +
A549-cpt ++ -
H1299 - ++
H1299-tax - +
H1299-cpt + ++
SKLU1 - -
SKLUl-tax - -
SKLUl-cpt - -
H460 ++ -
H460-tax - -
H460-cpt ++ +
++ definite effect; + some effect; - no effect
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3.2.6.1 Adriamycin and sulindac in A549
There was some synergy observed between adriamycin and sulindac in A549 cells. 
MRP1 protein was expressed in this cell line (see section 3.2.5). The greatest effect 
was observed at 2 0(j.g/ml sulindac combined with adriamycin (Figure 3.2.19). In 
A549-tax (Figure 3.2.20), while there is still an effect of combining the two drugs, it is 
much less than that observed in the parent. Figure 3.2.21 shows the effects of this 
combination in A549-cpt. MRP1 is more highly expressed in this cell line, so it is 
unsurprising that the effect of combining sulindac with adriamycin is greatest here.
Figure 3.2.19 Adriamycin and sulindac combination in A549
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Figure 3.2.20 Adriamycin and sulindac combination in A549-tax
Figure 3.2.21 Adriamycin and sulindac combination in A549-cpt
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3.2.6.2 Adriamycin and sulindac in H1299
The combination of adriamycin and sulindac in H1299, H1299-tax and H1299-cpt is 
shown in Figures 3.2.22, 3.2.23 and 3.2.24 respectively. MRP1 is expressed at very 
low levels in these cell lines (Figure 3.2.5). No strong effect of this combination is 
seen in any of the cell lines.
Figure 3.2.22 Adriamycin and sulindac combination in H1299
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Figure 3.2.23 Adriamycin and sulindac combination in H1299-tax
Figure 3.2.24 Adriamycin and sulindac combination in H1299-cpt
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3.2.6.3 Adriamycin and sulindac in SKLU1
The effect of combining adriamycin and sulindac is SKLU1, SKLUl-tax and SKLU1- 
cpt is shown in Figures 3.2.25, 3.2.26 and 3.2.27 respectively. The relationship 
between adriamycin and sulindac in the SKLU1 cell lines seemed to be additive.
There was no difference observed in the behaviour of the drug combination in the 
resistant cell lines compared to the parent cell line, despite an increase in MRP1 
expression in the selected variants.
Figure 3.2.25 Adriamycin and sulindac combination in SKLU1
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Figure 3.2.26 Adriamycin and sulindac combination in SKLUl-tax
Figure 3.2.27 Adriamycin and sulindac combination in SKLUl-cpt
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3.2.6.4 Adriamycin and sulindac in H460
The effect of combining adriamycin and sulindac is H460, H460-tax and H460-cpt is 
shown in Figures 3.2.28, 3.2.29 and 3.2.30 respectively. There is a slight increase in 
effect of the combination in H460 and H460-cpt. This effect is not observed in H460- 
tax, which correlated to MRP1 expression, since MRP1 appears to be downregulated 
in H460-tax compared to H460.
Figure 3.2.28 Adriamycin and sulindac combination in H460
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Figure 3.2.29 Adriamycin and sulindac combination in H460-tax
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Figure 3.2.30 Adriamycin and sulindac combination in H460-cpt
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3.2.6.5 Taxol and GF120918 in A549
The effect of the combination of taxol with the P-gp inhibitor GF120918 (Elacridar) in 
the cell lines A549, A549-tax and A549-cpt (Figures 3.2.31, 3.2.32 and 3.2.33) was 
investigated. This combination did not result in synergism in the A549 or A549-cpt 
cells. P-gp expression was not detected by western blotting. There appears to be a 
slight combination effect in A549-tax.
Figure 3.2.31 Taxol and GF120918 combination in A549
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Figure 3.2.32 Taxol and GF120918 combination in A549-tax
Figure 3.2.33 Taxol and GF120918 combination in A549-cpt
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3.2.6.6 Taxol and GF120918 in H1299
The effect of the combination of taxol with the P-gp inhibitor GF120918 in the cell 
lines H1299, H1299-tax and H1299-cpt (Figures 3.2.34, 3.2.35 and 3.2.36). Synergy 
was observed between these two drugs in the H I299 cell lines and this was expected 
since P-gp is expressed in these cell lines (Section 3.2.4). Interestingly, there is less of 
an effect in HI299-tax than in the parent, despite the fact that this cell line expresses 
more P-gp.
Figure 3.2.34 Taxol and GF120918 combination in H1299
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Figure 3.2.35 Taxol and GF120918 combination in H1299-tax
Figure 3.2.36 Taxol and GF120918 combination in H1299-cpt
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3.2.6.7 Taxol and GF120918 in SKLU1
The effect of the combination of taxol with the P-gp inhibitor GF120918 in the cell 
lines SKLU1, SKLUl-tax and SKLUl-cpt (Figures 3.2.37, 3.2.38 and 3.2.39) shows 
no positive effect with the combination of taxol and GF 120918 in SKLU1 cells. The 
taxol resistant variant showed only additive effects when treated with the combination. 
These results suggest low or no presence of P-gp in these cell lines and is consistent 
with western blotting results.
Figure 3.2.37 Taxol and GF120918 combination in SKLU1
155
Figure 3.2.38 Taxol and GF120918 combination in SKLUl-tax
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Figure 3.2.39 Taxol and GF120918 combination in SKLUl-cpt
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3.2.6.8 Taxol and GF120918 in H460
The effect of the combination of taxol with the P-gp inhibitor GF120918 in the cell 
lines H460, H460-tax and H460-cpt (Figures 3.2.40, 3.2.41 and 3.2.42) was 
investigated. Combination of taxol and GF120918 in H460 cells appeared to result in 
an additive effect, with some possible synergy in the carboplatin-resistant cell line, 
which is unusual. The taxol-resistant variant behaves similarly to the parent cell line.
Figure 3.2.40 Taxol and GF120918 combination in H460
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Figure 3.2.41 Taxol and GF120918 combination in H460-tax
Figure 3.2.42 Taxol and GF120918 combination in H460-cpt
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3.3 Microarray analysis of Taxol selections
3.3.1 RNA Quality
RNA integrity was examined using the Agilent Bioanalyser at two points in the 
microarray experiments (Section 2.11.2). Firstly the purity of isolated RNA was 
determined prior to sample processing. An example of this bioanalyser trace can be 
seen in Figure 3.3.1 (a). Intact 28S and 18S ribosomal RNA bands, which indicate 
good quality RNA, were observed in all samples. Secondly, the yield and size 
distribution of transcripts of biotin-labelled cRNA were analysed. An example of this 
bioanalyser trace can be seen in Figure 3.3.1 (b).
18S 28S
Figure 3.3.1 Example of Bioanalyzer traces of (a) initial isolated RNA and (b) 
Biotin-labeled cRNA after 1VT.
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3.3.2 GeneChip Quality Control
A number of quality control measures are carried out on microarray experiments 
before gene expression analysis begins. These were generated by GCOS in a report 
file (*rpt). A chip information form was filled out for each chip summarising this 
information. The information from these forms for all of the microarray chips run in 
this experiment can be seen in Table 3 .3 .1.
3.3.2.1 Scale factor
Each array has varying image intensity, and this intensity, or brightness, is measured 
by the “scaling factor”. In order to make an accurate comparison of multiple sets of 
array data the intensities of the arrays were brought to the same level. This process was 
performed by GCOS® (GeneChip Operating Software) using a mathematical 
technique known as ‘scaling’. Scaling worked by calculating the overall intensity of an 
array and averaging every probe set on the array (with the exception of the top and 
bottom 2% of the probe set intensities). The average intensity of the array was then 
multiplied by the scaling factor to ensure that all of the intensities on the given array 
went up or down to a similar degree. Scaling allowed normalisation of several 
experiments to one target intensity. For the experiments to be comparable, there must 
be no more than 3 fold difference between the scaling factors for each chip. The 
lowest scaling factor in this group of chips is 0.688 and the highest is 1.132, which is a 
fold difference of 1 .6 .
3.3.2.2 Noise
“Noise” measured the pixel-to-pixel variation of probe cells on the array. It was caused 
by small variations in the digital signal observed by the scanner as it sampled the array 
surface. As each scanner has a unique electrical noise associated with its operation, 
noise values among scanners vary. Therefore arrays that were scanned on the same 
scanner were expected to have similar noise values. All of the noise values for this set 
of arrays were between 1.5 and 2.3.
160
3.3.2.3 Background
Affymetrix have found that typical background values range from 20 to 100 and that 
arrays being compared should have similar background. The background values ranged 
from 47 to 66 for this set of arrays, which is acceptable. High background is usually 
caused by ethanol carryover during sample processing.
3.3.2.4 Present call
The percentage of genes present relates to the number of probe sets present relative to 
the total number of probe sets on the array. Replicate samples should have similar 
percentage present and normally vary between 40-60% for cell line samples. All of the 
replicates were within 5% of each other, ranging from 42.3-45.9%.
3.3.2.5 3’:5’ ratio
All of the arrays used actin and GAPDH to assess RNA sample and assay quality by 
having probes specific for the 3’, middle and 5’end of these genes. The ratio of signal 
intensity from 3’ probes to 5’probes was a measure of the number of cDNA synthesis 
reactions that went to completion. A ratio of 1 indicated full length transcript and was 
considered ideal. A cut-off value of 3 was applied, values above 3 indicated that some 
of the sensitivity of the assay had been lost. The range of 3’:5’ ratios in these 
experiments was 0.93-1.14.
3.3.2.6 Hybridisation controls
Spiked cRNAs were used as hybridization controls. BioB, bioC and bioD represent 
genes in the biotin synthesis family of E.coli, and Cre is the recombinase gene from 
the PI bacteriophage. They were spiked in increasing concentrations and the average 
difference values were expected to be present in increasing amounts, B being the least 
and Cre the most. Chips passed QC if the BioB control was deemed “present” by 
GCOS.
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3.3.2.7 Visual examination
After scanning the array chips were inspected for the presence of image artefacts. 
These include spots or regions on the chip with unusually high or low intensity, 
scratches or overall background. All of the chips used passed visual inspection.
3.3.2.8 Quality control by hierarchical clustering
Another quality control measure taken after the chip is satisfactory is hierarchical 
clustering. This clusters the samples based on their gene expression, and places the 
most similar samples in groups together. The hierarchical cluster generated by dChip 
for this experiment can be seen in Figure 3.3.2. The triplicate samples all cluster 
together, as expected. After this, the cell lines cluster together, with the parent cell 
lines being most similar to their taxol-resistant variant. The cluster also shows A549 
and H460 to be the most similar of the cell lines, with HI 299 being the most different 
from the group of cell lines. These are represented by a tree where the length of the 
branches reflect the degree of similarity between the objects
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Table 3.3.1 Quality control on chips from taxol experiment
Sample name Scaling
factor
Noise Background % Present 375’ Ratio 
GAPDH
H1299_l 0.867 1.8 52.13 45.9 1
H1299_2 0.729 2.26 66.41 43 0.95
H1299_3 0.847 1.63 49.2 45.1 1.14
H1299_Tax 1 0.943 1.85 55.74 44.1 0.99
H1299_Tax 2 0.798 1.74 51.75 45.3 0.97
H1299 Tax 3 0.878 1.62 48.21 44.8 0.96
A549_l 1.132 1.61 48.23 43 1 .1 1
A549_2 1.071 1.74 52.29 42.3 1.08
A549 3 0.814 1.71 50.21 45.1 1 .1 2
A549_Tax 1 0.822 1.83 52.76 44.7 0.96
A549_Tax 2 0.985 1.76 51.78 43.1 1
A549_Tax 3 0.86 1.83 54.26 43.2 0.97
H460_l 0.858 1.66 48.68 43.3 0.93
H460_2 0.872 1.58 47.13 44.2 0.99
H460 3 1.039 1.59 48.12 42.7 1.06
H460_Tax 1 0.712 1.78 52.25 43.9 0.93
H460_Tax 2 0.8 1.79 52.17 45.4 0.94
H460_Tax 3 0.782 1.88 55.95 42.4 0.97
SKLU1_1 0.874 1.56 47.35 44.1 0.92
SKLU12 0.688 1.9 57.2 44.3 0.89
SKLU13 0.702 1.96 60.01 45.1 0.87
SKLUl_Tax 1 0.721 1.98 60.31 46.7 0.97
SKLU1 JTax 2 0.897 1.68 51.76 46.5 0.95
SKLUl_Tax 3 0.849 1.65 51.58 47 0.92
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3.3.3 Genelists
Since the samples clustered as anticipated, gene expression analysis continued. DChip 
software was used in the original generation of genelists. Using dChip, each parent 
triplicate was compared to the triplicate of its taxol-resistant variant. The parameters 
used were a fold change of 1.2, a difference of intensity of 100 and a p value of <0.05. 
The numbers of genes changed in the taxol-resistant cell lines compared to the parent 
are shown in Table 3.3.2. The H460 cell line result stands out since only 829 genes 
were differentially regulated compared to nearly 3000 genes in all the other cell lines.
Table 3.3.2 Number of genes differentially expressed in parent vs taxol genelists
Genelist No. of genes
A549 -  parent vs taxol 2779
H I299 -  parent vs taxol 3329
H460 -  parent vs taxol 829
SKLU1 -  parent vs taxol 2970
The next step in the analysis was comparison of these genelists. This was carried out 
using Microsoft Access. When all four gene lists were compared, nineteen genes were 
shown to be common (Table 3.3.3). Two genes from this list were upregulated in all 
four cell lines. These genes are ATP-binding cassette, sub-family B (MDR/TAP), 
member 1 also known as Mdrl and phosphoglucomutase-2. These genes are 
highlighted in Table 3.3.3. Mdrl is highly upregulated (from 2 - 9  fold), while 
phosphoglucomutase-2 is 1.2 fold upregulated in all the cell lines. No genes were 
downregulated in all four cell lines.
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Table 3.3.3 List of genes significantly up- or down-regulated in all of the taxol 
selections compared to parent cell lines
Gene
CD59 antigen p i8-20 
interleukin 1 receptor, type I 
insulin-like growth factor binding protein
5'-nucleotidase, ecto (CD73)
B-cell CLL/lymphoma 3 
tumor necrosis factor receptor 
superfamily, member 1A 
Paraneoplastic antigen MA2 
ATP-binding cassette, sub-family B 
(MDR/TAP), member 1 
phosphoribosylglycinamide 
formyltransferase 
vascular endothelial growth factor 
A kinase (PRKA) anchor protein (gravin) 
12
Chromosome 14 open reading frame 78 
collagen, type VI, alpha 1 
G protein-coupled receptor 48 
FXYD domain containing ion transport 
regulator 5
tissue inhibitor of metalloproteinase 2 
mitogen-inducible gene 6 
phosphoglucomutase 2 
tissue inhibitor of metalloproteinase 2
A549 H1299 H460 SKLU1
-1.43 -1.69 -1.33 1.26
-1.34 3.12 -2.1 1.72
-1.83 -3.59 -1.45 1.55
-2.87 -1.37 -2.89 1.21
1.43 -2.18 -1.75 2.55
-1.38 -1.38 -1.29 1.26
-1.48 2.65 1.69 -6.43
9.07 2.7 6.62 8.7
1.3 1.59 1.3 -1.48
1.39 -1.58 -1.56 2.82
1.8 -1.98 2.28 2.53
-1.3 -2.71 -1.67 1.34
-1.89 -1.7 - 1.86 1.56
-1.56 2.56 -1.34 -1.54
-1.82 -2.9 -1.57 2.05
-4.18 -1.44 -1.32 1.61
1.44 -1.64 -1.72 -1.5
1.24 1.2 1.21 1.27
-3.64 -1.46 -1.37 1.46
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Genelists were then generated that represented genes up- or down-regulated in three of 
the four cell lines. The number of genes in each of these genelists is shown in Table 
3.3.4.
Table 3.3.4 Number of genes differentially regulated in three of four cell lines
Gcnclisl No. genes
A549 + H1299 + H460 69
A549 + H1299 + SKLU1 162
A549 + H460 + SKLU1 48
H1299 + H460 + SKLU1 60
These genelists were compared and this resulted in two genelists, one of upregulated 
genes and one of down regulated genes. Table 3.3.5 shows the upregulated genes. 
Thirty-two genes were upregulated significantly in three of the four taxol-resistant cell 
lines. Table 3.3.6 shows the downregulated genes. Forty-two genes were significantly 
downregulated in three of the four taxol-resistant cell lines.
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Table 3.3.5 List of genes significantly upregulated in three of four taxol selected
cell lines compared to parent cells
Gene A549 H1299 H460 SKLU1
A kinase (PRKA) anchor protein 
(gravin) 12
1.8 2.28 2.53
phosphoglucomutase 2 1.24 1.2 1.21 1.27
hypothetical protein DKFZp762Cl 112 1.36 1.23 1.3
heat shock 70kDa protein 9B (mortalin- 
2)
caldesmon 1
1.22 1.26 1.23
1.46 2.03 1.69
ATP-binding cassette, sub-family E 
(OABP), member 1
1.22 1.26 1.38
crystallin, zeta (quinone reductase) 1.59 1.49 1.25
ATP-binding cassette, sub-family F 
(GCN20), member 2
1.22 1.77 1.26
inhibitor of DNA binding 3, 1.28 2.74 2.32
ATP-binding cassette, sub-family B 
(MDR7TAP), member 1
9.07 2.7 6.62 8.7
phosphoribosylglycinamide
formyltransferase,
1.3 1.59 1.3
mitochondrial ribosomal protein L42 1.32 1.2 1.22
TIA1 cytotoxic granule-associated RNA 
binding protein
1.41 1.58 1.38
LIM protein (similar to rat protein 
kinase C-binding enigma)
1.52 1.5 2.56
GULP, engulfment adaptor PTB domain 
containing 1
1.21 1.71 1.55
cytochrome b-5 1.3 1,37 1.53
Bemardinelli-Seip congenital 
lipodystrophy 2 (seipin)
1.25 1,81 1.42
tissue factor pathway inhibitor 2 1.93 1.44 8,01
LIM protein (similar to rat protein 
kinase C-binding enigma)
1.43 1.45 2.23
zinc finger protein 238 1.62 1.39 1.33
stromal cell protein 1.25 1.28 1.26
hypothetical protein FLJ10656 1.5 1.65 1.45
similar to signal peptidase complex 
(18kD)
1.26 1.47 1.59
chromosome 20 open reading frame 30 1.23 1.53 1.35
hypothetical protein FLJ20421 1.44 1.35 1.65
chromobox homolog 4 (Pc class 
homolog, Drosophila)
1.21 1.41 1.41
CDNA FLJ33420 fis, clone 
BRACE2020028
1.25 1.67 1.85
RAB27B, member RAS oncogene 
family
1.54 2.17 2.15
influenza virus NS1A binding protein 1.37 1.25 1.33
Transcribed locus, weakly similar to 
NP 079012.2
1.45 1.37 3.51
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Table 3.3.6 List of genes significantly downregulated in three of four taxol
selected cell lines compared to parent cells
Gene A549 H1299 H460 SKLU1
serine (or cysteine) proteinase inhibitor, -1.24 -1.36 -1.49
G protein-coupled receptor 56 -1.55 -2.95 -1.82
testis derived transcript (3 LIM domains) -1.26 -1.32 -2.45
G protein-coupled receptor 48 -1.56 -1.34 -1.54
plasminogen activator -1.39 -3.81 -1.56
zinc finger protein 36, C3H type-like 1 -1.56 -1.67 -1.42
CD59 antigen p i8-20 -1.43 -1.69 -1.33
epithelial membrane protein 1 -6.22 -2.37 -1.86
fascin homolog 1 -1.29 -2.56 -1.29
S100 calcium binding protein A13 -1.27 -1.56 -1.38
solute carrier family 16 member 3 -19.5 -1.66 -1.52
insulin-like growth factor binding protein 6 -1.83 -3.59 -1.45
5'-nucleotidase, ecto (CD73) -2.87 -1.37 -2.89
potassium intermediate subfamily N, 
member 4
-1.68 -4.28 -1.87
cysteine-rich protein 1 (intestinal) -2.61 -30.87 -3.45
carbonyl reductase 3 -1.63 -1.68 -1.54
tumor necrosis factor receptor superfamily, 
member 1A
-1.38 -1.38 -1.29
Microtubule-associated protein IB -1.49 -1.58 -1.37
Chromosome 14 orf 78 -1.3 -2.71 -1.67
collagen, type VI, alpha 1 -1.89 -1.7 -1.86
solute carrier family 16 member 3 -31.72 -1.73 -1.43
EF hand domain containing 2 -1.6 -2.21 -1.45
FXYD domain containing ion transport 
regulator 5
-1.82 -2.9 -1.57
tissue inhibitor of metalloproteinase 2 -4.18 -1.44 -1.32
SH3-domain kinase binding protein 1 -1.82 -1.37 -1.25
solute carrier family 2 (facilitated glucose 
transporter), member 1
-1.51 -1.35 -1.8
myristoylated alanine-rich protein kinase C 
substrate
-1.3 -1.86 -1.45
laminin, gamma 2 -3.55 -23.11 -1.66
plasminogen activator, urokinase -1.54 -2.79 -1.73
follistatin-like 1 -1.29 -7.44 -1.49
PTEN induced putative kinase 1 -1.89 -1.7 -1.34
connective tissue growth factor -1.36 -2.37 -1.43
histone 1, H2bk -1.31 -1.23 -1.65
frizzled homolog 2 (Drosophila) -1.63 -1.73 -1.43
ribonuclease P 40kDa subunit -1.39 -1.42 -1.47
kinesin 2 60/70kDa -1.45 -1.78 -1.35
PTEN-like phosphatase -1.25 -1.6 -1.64
tissue factor pathway inhibitor -108.5 -1.36 -1.98
chromosome 6 open reading frame 145 -1.56 -1.86 -1.36
Tissue factor pathway inhibitor -122.41 -1.22 -1.48
mitogen-inducible gene 6 -1.64 -1.72 -1.5
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3.3.4 Upregulated genes in all four taxol selections
As mentioned above (Section 3.3.2), only two genes were upregulated in all four taxol- 
resistant cell lines. Figure 3.3.2 shows the relationship between Mdrl expression and 
the level of taxol resistance displayed by the cells. There is no obvious trend, with the 
least resistant cell line, A549, having the largest fold increase in Mdrl expression.
Figure 3.3.2 Relationship between taxol resistance and Mdrl expression
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3.3.5 Choice of genes for further analysis
Analysis of the genelists in Microsoft Access led to a genelist of interesting genes from 
this study of seventy-four genes (Thirty-two upregulated and forty-to downregulated, 
Section 3.3.4). This had to be narrowed down to a manageable number of genes to be 
analysed further. This was achieved by two methods. Firstly, any unannotated or 
poorly annotated genes were removed. Secondly the list was shortened by magnitude 
of fold change. The resulting genelist of “target genes” can be seen in Table 3.3.7.
Table 3.3.7 Fold changes in target genes chosen for further study
Gene name A549 H1299 H460 SKLU1
Epithelial membrane protein 1 -6.22 -2.37 -1.86
Cysteine-rich protein 1 -2.61 -30.87 -3.45
Follistatin-like 1 -1.29 -7.44 -1.49
Connective tissue growth factor -1.36 -2.37 -1.43
Insulin-like growth factor binding 
protein 6
-1.83 -3.59 -1.45
Crystallin, zeta 1.59 1.49 1.25
ATP-binding cassette, sub-family 
B (MDR/TAP), member 1
9.07 2.7 6.62 8.7
Inhibitor of DNA binding 3 1.28 2.74 2.32
GULP1 1.21 1.71 1.55
Stromal cell protein 1.25 1.28 1.26
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3.3.6 Expression of target genes
In the following results are presented as average intensity ± standard deviation of the 
three replicates for each sample.
Table 3.3.8 shows the intensity of expression for each of the target genes in A549 and 
A549-taxol. The gene with the highest fold change in this system is ABCB1 (Figure 
3.3.3). However this gene is expressed at very low levels in both cell lines relative to 
the expression of some of the other genes. For example, CRYZ has less than a 2-fold 
increase in expression, but the difference in intensity in this gene from A549 to A549- 
taxol is over 1000.
In Table 3.3.9 the intensity of expression for each of the target genes in H1299 and 
H1299-taxol is shown. CRIP1 displays the highest fold change in these cell lines, 
with a 30-fold decrease in H1299-taxol compared to H1299 (Figure 3.3.4). It is 
interesting to note that ABCB1 (P-gp) is expressed at a higher intensity in H1299 
parent cells than in any of the other parent cell lines, although it remains at a relatively 
low intensity.
The intensity of expression for each of the target genes in H460 and H460-taxol is 
shown in Table 3.3.10. Only six of the ten target genes were differentially expressed 
in this system. ABCB1 shows the greatest fold change in H460-tax compared to H460 
(Figure 3.3.5). H460-taxol cells appear to have the largest expression of ABCB1 of all 
the cell lines tested.
ABCB1 is again the gene with the greatest fold change in SKLUl-taxol cells 
compared to SKLU1 with an almost 9-fold change in intensity (Figure 3.3.6). Table 
3.3.11 shows the intensity of expression for each of the target genes in these cell lines. 
Only five of the ten target genes were differentially expressed in these cell lines.
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Table 3.3.8 Expression of target genes in A549 and A549-tax
Gene A549 expression A549-tax expression
EMPI 257 ± 22 41 ± 14
CRIP1 2458 ± 55 942 ± 68
FSTL1 1339 ±46 1035 ±73
CTGF 556 ±33 409 ± 38
IGFBP 6 1762 ±65 961 ±41
CRYZ 1731 ±54 2755 ± 89
ABCB1 14 ± 10 123 ± 12
1D3 2949 ± 55 3770± 176
GULP 777 ±38 941 ±28
SCP 665 ± 37 829 ± 28
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Figure 3.3.3 Fold change in expression of target genes in A549-taxol
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Table 3.3.9 Expression of target genes in H1299 and H1299-tax
Gene H I299 expression HI299-tax expression
EMPI 2688± 131 1134 ±80
CRIP1 361 ± 18 12 ± 17
FSTL1 335 ±27 45 ± 19
CTGF 1546± 129 654 ± 25
IGFBP 6 169 ± 17 47 ± 8
CRYZ 806 ±39 1204 ±44
ABCB1 62 ±7 167 ± 12
ID3 684 ±36 1878 ± 156
GULP 482 ± 60 825 ± 20
SCP 886 ± 62 1137 ±22
Figure 3.3.4 Fold change in expression of target genes in H1299-taxol
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Table 3.3.10 Expression of target genes in H460 and H460-tax
Gene H460 expression H460-tax expression
EMPI 352 + 26 190 ± 19
CRIP1 2393 +238 693 ± 58
IGFBP 6 407 + 24 280 ± 1 1
CRYZ 431 + 16 538 ± 19
ABCB1 46 + 6 306 ± 13
ID3 556 ±60 1290 ±81
Figure 3.3.5 Fold change in expression of target genes in H460-taxol
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Table 3.3.11 Expression of target genes in SKLU1 and SKLUl-tax
Gene SKLU1 expression SKLUl-tax expression
FSTL1 3373 ± 151 2270 ± 78
CTGF 1894+ 130 1323 ±51
ABCB1 15 + 8 128 ± 8
GULP 311 ±34 480 ± 23
SCP 497 ±11 626 ± 17
Figure 3.3.6 Fold change in expression of target genes in SKLUl-taxol
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3.3.7 Pathway Analysis of target genes
Pathway analysis on the ten target genes was carried out using Pathway Assist. The 
genelist was imported to the programme and from this information common pathways 
were built. Genelists to be studied in Pathway Assist were imported in the form of *txt 
files. Pathway Assist is a product aimed at the visualisation and analysis of biological 
pathways, gene regulation networks and protein interaction maps. It comes with a 
comprehensive database that gives a snapshot of all information available in PubMed, 
with the focus on pathways and cell signalling networks. Pathway Assist worked by 
identifying relationships among genes, small molecules, cell objects and processes and 
built pathways based on these relationships. Figure 3.3.7 shows how the ten genes are 
linked through common pathways. The genes coloured blue are the upregulated target 
genes and the genes coloured green are the downregulated target genes. The pink 
genes are the specified links from pathway assist.
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Figure 3.3.7 Common pathways of target genes
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Table 3.3.12 Abbreviations from common pathway (Figure3.3.7)
Abbreviation Gene name
ID3 Inhibitor of DNA-binding 3
ABCB1 ABC sub-family B member 1 (Mdrl)
Loc55974 Stromal cell protein (SCP)
CRYZ Crystallin, zeta (quinone reductase)
GULP1 Engulfment adapter protein
EMP1 Epithelial membrane protein 1
CRIP1 Cystein rich intestinal protein 1
CTGF Connective tissue growth factor
FSTL1 Follistatin-like 1
IGFBP6 Insulin-like growth factor receptor binding protein 6
JAK2 Janus kinase 2
TCF4 Transcription factor 4
IL6 Interleukin 6
TNF Tumour necrosis factor
CCL4 Chemokine ligand 4
MVP Major vault protein
LRP1 Low density lipoprotein-related protein 1
TGFpl Transforming growth factor, beta 1
CKM Creatine Kinase
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3.4 RNA interference
Ten targets were chosen from microarray studies on taxol-selected cell lines. Five of 
these targets were found to be upregulated in association with taxol resistance and five 
to be downregulated in association with taxol resistance. The targets are shown below. 
Two pre-designed siRNAs from Ambion were tested for each target. The cell lines 
chosen for the study were A549 and H1299 and their taxol-resistant variants.
3.4.1 Details of targets
Upregulated targets:
-  ABCB1 (p-glycoprotein)
-  ID3 (Inhibitor of DNA binding 3)
-  GULP1 (engulfment factor)
-  SCP (Stromal cell protein)
-  CRYZ (Quinone reductase)
It was expected that an increase in sensitivity to taxol would be observed in the taxol 
resistant cell lines after transfection with siRNAs to the above genes.
Downregulated targets:
-  EMP1 (Epithelial membrane protein 1)
-  CRIP1 (Cysteine-rich intestinal protein 1)
-  FSTL1 (Follistatin-like 1)
-  CTGF (Connective tissue growth factor)
-  IGFBP6 (Insulin-like growth factor binding protein 6)
It was expected that an increase in resistance to taxol would be observed in the 
parental cell lines after transfection with siRNAs to the above genes, since they are 
expressed at a lower level in the taxol-resistant cells.
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3.4.2 Effects of siRNA transfection on proliferation
In order to determine if transfection of a given siRNA had an effect on the sensitivity 
of a cell line to a chemotherapeutic agent, it was important to ensure that the 
transfection did not have an effect on the proliferation of the cells. Kinesin was 
included as a positive control. This gene plays an important role in cell division, so 
transfection of kinesin siRNA results in cell cycle arrest. Figures 3.4.1 and 3.4.2 show 
the effect of siRNA transfection of the targets in A549 and A549-tax cells respectively. 
Figures 3.4.3 and 3.4.4 show the effect of siRNA transfection of the targets in H1299 
and HI 299-tax cells respectively. Most of the siRNAs had little or no effect on the 
proliferation of the cell lines. However, a number of the siRNAs affected proliferation 
of the cell lines. In A549 and A549-tax, transfection of IGFBP6 siRNA (2) led to a 
considerable increase in proliferation. In H1299-tax, transfection of SCP siRNA (1) 
led to a considerable decrease in proliferation.
Transfection of siRNAs to specific genes was expected to transiently silence the target 
gene. Therefore, only modest phenotypic effects were expected with these 
experiments, since the protein would only be downregulated for a short period of time, 
and there would not be a total downregulation of protein.
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Figure 3.4.1 Effect of siRNA transfection on proliferation of A549 cells
Figure 3.4.2 Effect of siRNA transfection on proliferation of A549-tax cells
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Figure 3.4.3 Effect of siRNA transfection on proliferation of H1299 cells
Figure 3.4.4 Effect of siRNA transfection on proliferation of H1299-tax cells
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3.4.3 Effects of siRNA transfection on sensitivity to taxol
After determining the effect of transfection of the target genes siRNAs on 
proliferation, the role of these genes in determining sensitivity to taxol was 
investigated. Two siRNAs for each target gene were transfected into A549, A549-tax, 
H1299 and H1299-tax. The effect of the these siRNA transfections on taxol sensitivity 
was determined as described in Section 2.13,3. In each experiment, a control of either 
transfection reagent or a scrambled siRNA transfection was included to ensure that the 
effect was due to the gene being targeted. A summary of the results obtained can be 
seen in Table 3.4.1. More detailed results from each transfection follow in subsequent 
sections.
Table 3.4.1 Summary of results from transfection of target genes siRNA
Gene A549 A549-tax H1299 HI 299-tax
ABCB1 - + + +
ID3 + - + -
CRYZ - - - +
GULP1 - - - +
SCP - - - -
CTGF - - - -
CRIP! + + - -
IGFBP6 + - + -
EMP1 + + - -
FSTL1 + + - -
+ Indicates that an effect was observed 
- Indicates that no effect was observed
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3.4.3.1 Effect of transfection of ABCB1 siRNA
ABCB1 is a gene whose protein product is P-gp, the multidrug resistance protein. 
Transfection of ABCB1 siRNA has no effect on the sensitivity to taxol in A549 cells 
(Figure 3.4.5). However there is a slight increase in sensitivity of taxol in transfected 
A549-tax cells (Figure 3.4.6). This increase is relatively small considering that 
microarray analysis of these cells shows a 9-fold increase in Mdrl in the taxol-selected 
cells. Transfection of ABCB1 siRNA resulted in a slight increase in sensitivity to 
taxol in H1299 parent cells (Figure 3.4.7). The effect is much more significant in the 
taxol-selected cells (Figure 3.4.8), which were shown to have almost a 3-fold increase 
in Mdrl by microarray analysis.
Figure 3.4.5 Effect of transfection of ABCB1 siRNA in A549 cells
Figure 3.4.6 Effect of transfection of ABCB1 siRNA in A549-taxol cells
Figure 3.4.7 Effect of transfection of ABCB1 siRNA in H1299 cells
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Taxol Ong/ml Taxol 15ng/ml Taxol 20ng/ml Taxol 25ng/ml
Figure 3.4.8 Effect of transfection of ABCB1 siRNA in H1299-taxol cells 
3.4.3.2 Effect of transfection of ID3 siRNA
ID3 is Inhibitor of DNA-binding 3. ID3 was upregulated approximately 1.3-fold in 
taxol resistant cells by the microarray analysis. In A549 there is an increase in 
sensitivity to taxol after transfection with ID3 siRNA (Figures 3.4.9). There might 
also be slight sensitisation in A549-tax (Figure 3.4.10). ID3 was approximately 3-fold 
upregulated in HI 299-tax compared to the parent cells by the microarray analysis. 
Transfection of ID3 siRNA led to a slight increase in sensitivity to taxol in the parent 
cells (Figure 3.4.11), but appeared not to have an effect in H1299-tax (Figure 3.4.12).
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Figure 3.4.9 Effect of transfection of ID3 siRNA in A549 cells
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Figure 3.4.10 Effect of transfection of ID3 siRNA in A549-tax cells
188
Figure 3.4.11 Effect of transfection of ID3 siRNA in H1299 cells
Taxol Ong/ml Taxol 15ng/ml Taxol 20ng/ml Taxol 25ng/ml
Figure 3.4.12 Effect of transfection of ID3 siRNA in H1299-tax cells
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3.4.3.3 Effect of transfection of CRYZ siRNA
CRYZ is crystallin, zeta or quinone reductase. CRYZ was upregulated in taxol- 
selected cells. Transfection of CRYZ siRNA in A549 and A549-tax had no significant 
effect on sensitivity to taxol in either parental or selected cell lines (Figures 3.4.13 and 
3.4.14). CRYZ is 1.5 fold upregulated in H1299-tax compared to the parent cell line. 
Transfection of CRYZ siRNA resulted in a slight increase in sensitivity to taxol at 
lOng/ml in the parent cells (Figure 3.4.15). The effect is difficult to see at other 
concentrations and does not appear in the taxol selected cells (Figure 3.4.16)
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Figure 3.4.13 Effect of siRNA transfection of CRYZ in A549 cells
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Figure 3.4.14 Effect of transfection of CRYZ siRNA in A549-tax cells
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Figure 3.4.15 Effect of transfection of CRYZ siRNA in H1299 cells
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Taxol Ong/ml Taxol 15ng/ml Taxol 20ng/ml Taxo] 25ng/ml
Figure 3.4.16 Effect of transfection of CRYZ siRNA in H1299-tax cells
3.4.3.4 Effect of transfection of GULP1 siRNA
GULP1 is an engulfment factor. GULP1 is upregulated in the taxol-selected A549 
cells compared to parent A549, but had no effect on taxol sensitivity in either cell line 
(Figures 3.4.17 and 3.4.18). GULP1 is upregulated in taxol resistant H1299 cells. No 
major change in sensitivity was observed in the parent cell line transfected with 
GULP1 siRNA (Figure 3.4.19). However, an increase in sensitivity was noted in the 
H1299-tax cell line (Figure 3.4.20).
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Figure 3.4.17 Effect of transfection of GULP1 siRNA in A549 cells
Figure 3.4.18 Effect of transfection of GULP1 siRNA in A549-tax cells
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Figure 3.4.19 Effect of transfection of GULP1 siRNA in H1299 cells
Figure 3.4.20 Effect of transfection of GULP1 siRNA in H1299-tax cells
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3.4.3.5 Effect of transfection of SCP siRNA
SCP is stromal cell protein. SCP was upregulated in the taxol-selected A549 cells 
compared to A549, but had no effect on taxol sensitivity in either parent or resistant 
cell line (Figures 3.4.21 and 3.4.22). SCP was upregulated in H1299-tax cells, but had 
no effect on taxol sensitivity in either parent or resistant cell line (Figures 3.4.23 and 
3.4.24).
Figure 3.4.21 Effect of transfection of SCP siRNA in A549 cells
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TaxolOng/ml Taxol 5ng/ml Taxol lOng/ml Taxol 15ng/ml
Figure 3.4.22 Effect of transfection of SCP siRNA in A549-tax cells
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Figure 3.4.23 Effect of transfection of SCP siRNA in H1299 cells
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Figure 3.4.24 Effect of transfection of SCP siRNA in H1299-tax cells
3.4.3.6 Effect of transfection of CTGF siRNA
CTGF is connective tissue growth factor. CTGF was downregulated in the taxol- 
selected variant of A549. The transfection of CTGF siRNA had very little effect on 
either the parent or selected cell line (Figures 3.4.25 and 3.4.26). CTGF was 2-fold 
downregulated in H1299-tax compared to parent cells. Transfection of one of the 
siRNAs for CTGF resulted in a small increase in resistance to taxol in the parent cells 
(Figure 3.4.27), which would be expected. However, the other siRNA did not show 
this effect. The transfection of CTGF siRNA in H1299-tax did not change the 
sensitivity of the cells to taxol (Figure 3.4.28).
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Figure 3.4.25 Effect of transfection of CTGF siRNA in A549 cells
Taxol Ong/ml T a x d  5ng/ml Taxol lOng/ml Taxol 15ng/ml
Figure 3.4.26 Effect of transfection of CTGF siRNA in A549-tax cells
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Figure 3.4.27 Effect of transfection of CTGF siRNA in H1299 cells
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Figure 3.4.28 Effect of transfection of CTGF siRNA in H1299-tax cells
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3.4.3.7 Effect of transfection of CRIP1 siRNA
CRIP1 is cysteine-rich intestinal protein 1. CRIP1 was almost 3-fold downregulated in 
A549-tax compared to parent cells. In both parent and taxol-selected cells transfection 
of CRIP1 siRNA led to an increase in resistance (Figures 3.4.29 and 3.4.30). 111299- 
tax cells displayed a very large (30-fold) decrease in CRIP1 compared to the parent 
cells. Unlike A549 cells, siRNA transfection of CRIP1 did not lead to an increase in 
resistance (Figures 3.4.31 and 3.4.32). This is surprising considering the large fold 
change compared to the much lower fold change in A549. This result illustrates that 
there are probably multiple genes involved in taxol resistance and that the pathways in 
different cell types are different, so that changing levels of a protein is enough to 
change sensitivity to taxol in one cell line but not another.
Figure 3.4.29 Effect of transfection of CRIP1 siRNA in A549 cells
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Figure 3.4.30 Effect of transfection of CRIP1 siRNA in A549-tax cells
Figure 3.4.31 Effect of transfection of CRIP1 siRNA in H1299 cells
Taxol Ong/ml Taxol 15ng/ml Taxol 20ng/ml Taxol 25ng/ml
Figure 3.4.32 Effect of transfection of CRIP1 siRNA in H1299-tax cells
3.4.3.8 Effect of transfection of IGFBP6 siRNA
IGFBP6 is Insulin-like growth factor receptor binding protein 6 . IGFBP6 was down- 
regulated in taxol-resistant A549 and H1299 cells. Transfection of IGFBP6 siRNA 
had no effect on taxol sensitivity in either A549-tax or H1299-tax (Figures 3.4.34 and 
3.4.36). In the parent cell lines, there may be a slight increase in sensitivity to taxol. 
transfection of IGFBP6 siRNA caused an increase in survival in the control cells. 
Taking this into consideration, there seems to be an effect in the parent cells after 
transfection of IGFBP6 siRNA (Figures 3.4.33 and 3.4.35).
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Figure 3.4.33 Effect of transfection of IGFBP6 siRNA in A549 cells
Figure 3.4.34 Effect of transfection of IGFBP6 siRNA in A549-tax cells
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Taxol Ong/ml Taxol lOng/ml Taxol 15ng/ml Taxol 20ng/ml
Figure 3.4.35 Effect of transfection of IGFBP6 siRNA in H1299 cells
Figure 3.4.36 Effect of transfection of IGFBP6 siRNA in H1299-tax cells
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3.4.3.9 Effect of transfection of EMP1 siRNA
EMP1 is epithelial membrane protein 1. EMP1 is downregulated 6-fold in A549-tax 
compared to parent cells. Despite this, there was no change in sensitivity to taxol in 
either cell lines at low taxol concentration (Figures 3.4.37 and 3.4.38). At the highest 
concentration of taxol, there appears to be an increase in sensitivity, most noticeably in 
the parent cells. This increase in sensitivity is the opposite effect than expected, since 
EMP1 was found to be downregulated in taxol-resistant cells. EMP1 is downregulated 
2-fold in H1299-tax cells compared to parent cells. The transfection of EMP1 siRNA 
had no effect on taxol sensitivity in either cell line (Figures 3.4.39 and 3.4.40).
Figure 3.4.37 Effect of transfection of EMP1 siRNA in A549 cells
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Figure 3.4.38 Effect of transfection of EMF1 siRNA in A549-tax cells
Figure 3.4.39 Effect of transfection of EMP1 siRNA in H1299 cells
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Figure 3.4.40 Effect of transfection of EMP1 siRNA in H1299-tax cells
3.4.3.10 Effect of transfection of FSTL1 siRNA
FSTL1 is follistatin-like 1. FSTL1 was found by microarray analysis to be 
downregulated in A549-tax compared to the parent cell line. Conversely, transfection 
of FSTL1 siRNA led to an increase in sensitivity of both parent and taxol-selected 
cells at high taxol concentrations (Figures 3.4.41 and 3.4.42). FSTL1 was found by 
microarray analysis to be downregulated 7.5-fold in H1299-tax compared to the parent 
cell line. Transfection of FSTL1 siRNA did not notably affect taxol sensitivity in 
either H1299 orH1299-tax (Figures 3.4.43 and 3.4.44).
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Figure 3.4.41 Effect of transfection of FSTL1 siRNA in A549 cells
Figure 3.4.42 Effect of transfection of FSTL1 siRNA in A549-tax cells
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Figure 3.4.43 Effect of transfection of FSTL1 siRNA in H1299 cells
Figure 3.4.44 Effect of transfection of FSTL1 siRNA in H1299-tax cells
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3.5 Further analysis of target genes
Three of the ten targets chosen for siRNA analysis were chosen for further analysis 
based on the results from Section 3.4. The three targets were ABCB1, ID3 and CRIP1. 
Both ABCB1 and ID3 were upregulated in the taxol-selected cell lines and siRNA- 
mediated silencing of these genes led to an increase in sensitivity to taxol. CRIP1 was 
downregulated in the taxol-selected cell lines and silencing of CRIP1 led to a decrease 
in sensitivity to taxol in A549 cell lines.
3.5.1 ABCB1
Transfection of ABCB1 siRNA resulted in the greatest change in sensitivity to taxol, 
especially in the H1299-tax cell line (Section 3.4.3). H1299 and H1299-tax are the 
only cell lines in this study that express detectable levels of P-gp (Section 3.1.4). 
Transfection of ABCB1 siRNA was tested for its effect on sensitivity to taxotere, 
adriamycin and carboplatin in the cell lines H1299, H1299-tax, H460 and H460-tax, 
and to taxotere and carboplatin in A549 and A549-tax. The results are shown in 
figures 3.5.1-3.5.16. These results are summarised in Table 3.5.2.
Table 3.5.2 Summary of effects of transfection of ABCB1 siRNA
Cell line Taxotere Adriamycin Carboplatin
H1299 No change Small T resistance No change
HI 299-tax T sensitivity No change No change
A549 No change ND No change
A549-tax Small T sensitivity ND No change
H460 No change No change No change
H460-tax Small T sensitivity No change No change
ND -  not done
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Transfection of ABCB1 siRNA into the taxol resistant cell lines: A549-tax (Figure 
3.5.4); H1299-tax (Figure 3.5.2) and H460-tax (Figure 3.5.6) resulted in an increase in 
sensitivity to taxotere. This was expected and paralleled the results found with taxol.
In H I299 cells, there was a decrease in sensitivity to adriamycin with transfection of 
ABCB1 siRNA (Figure 3.5.7). The results obtained for adriamycin sensitivity after 
transfection with ABCB1 siRNA were surprising, since adriamycin is a P-gp substrate, 
similar results to those obtained for taxol and taxotere would have been expected. No 
effects were seen in any of the cell lines in carboplatin sensitivity after transfection of 
ABCB1 siRNA. This was expected since carboplatin is not a substrate for P-gp.
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Figure 3.5.1 Effect of transfection of ABCB1 siRNA on taxotere sensitivity in 
H1299 cells
Taxotere Ong/m 1 Taxotere 5ng/m 1 Taxotere 1 Ong/m 1 Taxotere 20ng/ml
Figure 3.5.2 Effect of transfection of ABCB1 siRNA on taxotere sensitivity in
H1299-tax cells
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Figure 3.5.3 Effect of transfection of ABCB1 siRNA on taxotere sensitivity in 
A549 cells
Figure 3.5.4 Effect o f transfection of ABCB1 siRNA on taxotere sensitivity in
A549-tax cells
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Figure 3.5.5 Effect of transfection of ABCB1 siRNA on taxotere sensitivity in 
H460 cells
■  Control
■  S cram bled  
□  ABCB1
Taxotere Ong/m] Taxotere 2ng/ml Taxotere 4ng/ml Taxotere 8ng/ml
Figure 3.5.6 Effect o f transfection of ABCB1 siRNA on taxotere sensitivity in
H460-tax cells
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Figure 3.5.7 Effect of transfection of ABCB1 siRNA on adriamycin sensitivity in 
H1299 cells
Figure 3.5.8 Effect of transfection of ABCB1 siRNA on adriamycin sensitivity in
H1299-tax cells
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Figure 3.5.9 Effect of transfection of ABCB1 siRNA on adriamycin sensitivity in 
H460 cells
Figure 3.5.10 Effect of transfection of ABCB1 siRNA on adriamycin sensitivity in
H460-tax cells
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Figure 3.5.11 Effect of transfection of ABCB1 siRNA on carboplatin sensitivity in 
H1299 cells
Figure 3.5.12 Effect of transfection of ABCB1 siRNA on carboplatin sensitivity in
H1299-tax cells
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Figure 3.5.13 Effect of transfection of ABCB1 siRNA on carboplatin sensitivity in 
A549 cells
Figure 3.5.14 Effect o f transfection of ABCB1 siRNA on carboplatin sensitivity in
A549-tax cells
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Figure 3.5.15 Effect of transfection of ABCB1 siRNA on carboplatin sensitivity in 
H460 cells
Figure 3.5.16 Effect o f transfection of ABCB1 siRNA on carboplatin sensitivity in
H460-tax cells
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3.5.2 ID3
Silencing of this gene resulted in an increase in sensitivity to taxol. This was observed 
in all the cell lines tested. Silencing of this gene was tested for its effect on sensitivity 
to taxotere, adriamycin and carboplatin in the cell lines H1299, H1299-tax, A549, 
A549-tax, H460 and H460-tax. The results are shown in Figures 3.5.19-3.5.1.34. 
These results are summarised in Table 3.5.2.
Table 3.5.2 Summary of effects of transfection of ID3 siRNA
Cell line Taxotere Adriamycin Carboplatin
H1299 Small T sensitivity No change Small T resistance
HI 299-tax No change No change Small T resistance
A549 No change ND Small T sensitivity
A549-tax No change ND No change
H460 No change No change No change
H460-tax No change No change No change
ND -  not done
H1299 and H1299-tax (Figures 3.5.19 and 3.5.20) show an increase in sensitivity to 
taxotere with silencing of ID3. There was little or no effect observed in the other cell 
lines. There was no effect on the sensitivity observed in any of the cell lines to 
adriamycin after transfection with ID3 siRNA.
Silencing of ID3 resulted in an increase in sensitivity to carboplatin in A549 (Figure 
3.5.31). Interestingly, there was a decrease in sensitivity to carboplatin observed in 
H1299 (Figure 3.5.29) and H1299-tax (Figure 3.5.30).
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A549 HI 299 H460 SKLU1
Figure 3.5.17 Expression of ID3 protein in selected cell lines 
(each cell line samples in the order: parent; -tax; -cpt)
Figure 3.5.18 Densitometry showing fold expression of ID3
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Figure 3.5.19 Effect of transfection of ID3 siRNA on taxotere sensitivity in H1299 
cells
Figure 3.5.20 Effect of transfection of ID3 siRNA on taxotere sensitivity in
H1299-tax cells
222
Figure 3.5.21 Effect of transfection of ID3 siRNA on taxotere sensitivity in A549 
cells
Figure 3.5.22 Effect of transfection of ID3 siRNA on taxotere sensitivity in A549-
tax cells
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Figure 3.5.23 Effect of transfection of ID3 siRNA on taxotere sensitivity in H460 
cells
Taxotere Ong/ml Taxotere 2ng/ml Taxotere 4ng/ml Taxotere 8ng/ml
Figure 3.5.24 Effect of transfection of ID3 siRNA on taxotere sensitivity in 11460-
tax cells
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Figure 3.5.25 Effect of transfection of ID3 siRNA on adriamycin sensitivity in 
H1299 cells
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Figure 3.5.26 Effect of transfection of ID3 siRNA on adriamycin sensitivity in
H1299-tax cells
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Figure 3.5.27 Effect of transfection of ID3 siRNA on adriamycin sensitivity in 
H460 cells
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Figure 3.5.28 Effect of transfection of ID3 siRNA on adriamycin sensitivity in
H460-tax cells
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Figure 3.5.29 Effect of transfection of ID3 siRNA on carboplatin sensitivity in 
H1299 cells
Carboplatin Oug/ml Carboplatin 1 Oug/ml Carboplatin 15ug/ml Carboplatin 20ug/ml
Figure 3.5.30 Effect of transfection of ID3 siRNA on carboplatin sensitivity in
H1299-tax cells
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Figure 3.5.31 Effect of transfection of ID3 siRNA on carboplatin sensitivity in 
A549 cells
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Figure 3.5.32 Effect of transfection of ID3 siRNA on carboplatin sensitivity in
A549-tax cells
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Figure 3.5.33 Effect of transfection of ID3 siRNA on carboplatin sensitivity in 
H460 cells
Figure 3.5.34 Effect of transfection of ID3 siRNA on carboplatin sensitivity in
H460-tax cells
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3.5.3 CRIP1
Transfection of CRIP1 siRNA resulted in a decrease in sensitivity to taxol. This effect 
was only seen in the A549 parental and taxol-resistant cells. The effect on sensitivity 
to taxotere, adriamycin and carboplatin in the cell lines H1299, H1299-tax, A549, 
A549-tax, H460 and H460-tax was tested after transfection with CREP1 siRNA. The 
results are shown in Figures 3.5.37-3.5.1.52. These results are summarised in Table 
3.5.3.
Table 3.5.3 Summary of effects of transfection of CRIP1 siRNA
Cell line Taxotere Adriamycin Carboplatin
H1299 Small T sensitivity Small T resistance t  resistance
HI 299-tax T sensitivity No change Small T resistance
A549 Small t  sensitivity ND Small t  sensitivity
A549-tax Small T sensitivity ND Small T resistance
H460 No change Small T resistance No change
H460-tax No change Small T resistance No change
ND -  not done
H1299 (Figure 3.5.37), H1299-tax (Figure 3.5.38), A549 (Figure 3.5.39) and A549-tax 
(Figure 3.5.40) all showed an increase in sensitivity to taxotere after transfection with 
CRIP1 siRNA. This was unexpected, especially in A549 cells considering that the 
opposite effect was observed in taxol sensitivity.
A decrease in adriamycin sensitivity was observed in H1299 (Figure 3.5.43) and H460 
(3.5.45) after transfection with CRIP 1 siRNA.
Similarly, a decrease in sensitivity to carboplatin was observed in H1299 (Figure 
3.5.47), H1299-tax (Figure 3.5.48) and A549-tax (Figure 3.5.50) after siRNA 
transfection with CRIP1. In contrast, there was a small increase in sensitivity to 
carboplatin observed in A549 (Figure 3.5.49).
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H1299 H460 SKLU1
Figure 3.5.35 Expression of CRIP1 protein in selected cell lines 
(each cell line samples in the order: parent; -tax; -cpt)
Figure 3.5.36 Densitometry showing fold expression of CRIP1
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Figure 3.5.37 Effect of transfection of CRIP1 siRNA on taxotere sensitivity in 
H1299 cells
Figure 3.5.38 Effect o f transfection of CRIP1 siRNA on taxotere sensitivity in
HI299-tax cells
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Figure 3.5.39 Effect of transfection of CRIP1 siRNA on taxotere sensitivity in 
A549 cells
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Figure 3.5.40 Effect of transfection of CRIP1 siRNA on taxotere sensitivity in
A549-tax cells
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Figure 3.5.41 Effect of transfection of CRIP1 siRNA on taxotere sensitivity in 
H460 cells
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Figure 3.5.42 Effect of transfection of CRIP1 siRNA on taxotere sensitivity in
H460-tax cells
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Figure 3.5.43 Effect of transfection of CRDP1 siRNA on adriamycin sensitivity in 
H1299 cells
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Figure 3.5.44 Effect of transfection of CRIP1 siRNA on adriamycin sensitivity in
H1299-tax cells
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Figure 3.5.45 Effect of transfection of CRIP1 siRNA on adriamycin sensitivity in 
H460 cells
Figure 3.5.46 Effect of transfection of CRIP1 siRNA on adriamycin sensitivity in
H460-tax cells
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Figure 3.5.47 Effect of transfection of CRIP1 siRNA on carboplatin sensitivity in 
H1299 cells
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Figure 3.5.48 Effect of transfection of CR1P1 siRNA on carboplatin sensitivity in
H1299-tax cells
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Figure 3.5.49 Effect of transfection of CRIP1 siRNA on carboplatin sensitivity in 
A549 cells
Figure 3.5.50 Effect of transfection of CRLP1 siRNA on carboplatin sensitivity in
A549-tax cells
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Figure 3.5.51 Effect of transfection of CRIP1 siRNA on carboplatin sensitivity in 
H460 cells
Figure 3.5.52 Effect of transfection of CRIP1 siRNA on carboplatin sensitivity in
H460-tax cells
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3.5.4 Screening of H1299-tax using siRNA library plates
In order to further identify genes whose expression might play a role in taxol 
resistance, a number of experiments were carried out in collaboration with Dr. Patrick 
Gammell on the cell line established in this project, HI299-tax. These experiments 
used commercially available library plates for high-throughput screening of siRNAs. 
The library plates used were from Ambion Inc. - Silencer® CellReady™ Popular Gene 
siRNA Library and Silencer® CellReady™ Popular Kinase siRNA Library.
Some genes of interest were determined from these assays. The results can be seen in 
Figures 3.5.53 and 3.5.54. Transfection of caspase 2, CDC2 and K ifll siRNAa were 
found to dramatically affect cell growth in H1299-tax. Kif 11 and PLK1 were found to 
affect cell growth on the kinase library plate. Kif 11 was the positive control included 
in all siRNA proliferation experiments.
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Figure 3.5.53 Transfection of “popular genes” siRNAs in H1299-tax
Plkl CDC2
Figure 3.5.54 Transfection of “kinase libraray” siRNAs in H1299-tax
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Section 4.0: Discussion
The work described in this thesis aimed to increase our understanding of the 
mechanisms of chemotherapeutic drug resistance in human lung cancer cell lines using 
three approaches:
1. Generation and characterising of wild-type p53 transfection of wildtype p53
(A549), mutant p53 (DLKP-SQ) and p53 null (H1299) lung cancer cell lines.
2. Generation and characterisation (especially by expression microarray analysis)
of taxol and carboplatin resistant variants of the lung adenocarcinoma cell lines 
A549 and SKLU1 and the large cell lung carcinoma cell lines H I299 and 
H460.
3. Using siRNA gene expression knockdown technology to investigate the
functional role of chosen genes from the microarray analysis in the taxol- 
resistant phenotype.
These results are discussed here in the context of previously published reports.
4.1 The role of p53 in drug resistance
The development of acquired drug resistance in tumours is believed to be based on 
drug-induced mutational changes in the cells. Mutations in tumour suppressor genes 
have been shown to be important in sensitivity changes to certain chemotherapy drugs.
One well characterised tumour suppressor gene is p53. It has been shown that it is 
mutated in more than half of all tumours of various types. However, the role of p53 in 
the development of multidrug resistance in cancer is complex and not yet fully 
understood. p53 acts as a sensor for DNA damage caused by a drug or any other 
mutational influence. On one hand, its presence might facilitate chemotherapy by 
sensing DNA damage and consequently inducing apoptosis of the cell. On the other 
hand, it might arrest the cell cycle allowing time for the cell to partially repair the 
damage then allowing mutated cells to continue growing.
Within lung cancer, mutation of the p53 gene is present in about 70% of SCLC and 
50% of NSCLC. In NSCLC mutations are more frequently found in squamous cell 
carcinomas than in adenocarcinomas. (Viktorsson et al., 2005).
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Many studies have shown that loss of p53 function confers drug resistance to the cells. 
Inactivation of p53 has been associated with upregulation of the multidrug resistance 
gene MDR-1 (Thottassery et al, 1997; Sampath et al., 2001). Wild-type p53 has been 
shown to have transcriptional control of MDR1 (Bahr et al., 2001; Bush & Li, 2002), 
leading to repression of this gene. Li et al. (1997) sought to clarify the relationship 
between p53 and Mdrl by introducing a wild-type p53 cDNA into a multidrug- 
resistant cell line. They found that wild-type p53-transfected cells displayed an 
increase in Mdrl mRNA and P-gp protein, however this was associated with a 
decrease in drug resistance. The p53 family members p63 and p73 have been found to 
activate rather than repress MDR1 transcription. This may be due to differences in the 
DNA-binding domains of these proteins (Johnson et al., 2005).
P53 has also been linked, at the transcriptional level, with expression of MRP 1. Wang 
and Beck (1998) demonstrated that the human MRP1 gene is negatively regulated at 
the transcriptional level by wild-type p53. Another group examined the expression of 
p53 and MRP1 in colorectal cancers. They found that p53-positive cells expressed 
MRP1 more frequently than p53-negative cells. The p53 detected is most likely 
mutant, since aberrant p53 expression leads to accumulation of the protein in the cell. 
The group concludes that MRP1 expression may be regulated by mutant p53 
(Fukushima et al., 1999). Using a temperature-sensitive p53 vector, which when 
transfected into cells can express mutant p53 at 38°C and wild-type p53 at 32°C, 
Sullivan et al. (2000) showed that MRP1 expression is regulated by the transcriptional 
ability of p53. When wild-type p53 was expressed they observed repression of MRP 1 
and when mutant p53 was expressed they observed increased expression of MRP1.
Aside from transcriptional regulations, other factors are in play. Loss of p53 has been 
associated with poor clinical prognosis in cancer treatment. Wild-type p53 was stably 
expressed in a p53-null cell line (SaOS-2) in order to examine the relationship between 
p53 expression and sensitivity to cisplatin (Fan and Bertino, 1999). Both p53- 
mediated drug resistance and p53-mediated drug sensitivity were observed in the same 
model under different growth conditions, implying that growth factors may be 
involved in p53-mediated gene regulation.
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Likewise, loss or inactivation of p53 has been correlated with genetic instability. 
Ceraline et al. (1998) took human normal human fibroblasts and inhibited p53 protein 
expression using antisense oligonucleotides. They found that this led to increased 
G2/M arrest and also to greater sensitivity to DNA-damaging agents. Hawkins and co­
workers (1996) also found that inactivation of p53 can increase the sensitivity of the 
cells to chemotherapeutic drugs.
In order to investigate the role of p53 status in clinical response to chemotherapy, 
another group examined the relationship between p53 gene mutations and response to 
taxol/cisplatin chemotherapy in patients with advanced ovarian cancer. They found 
that this combination of drugs was effective in tumours with p53 mutations. The 
overall response rate was significantly higher in patients with mutant p53 tumours than 
in patients with wild-type p53 tumours. (Lavarino et al., 2000). This suggests that 
mutant p53 is less effective in causing cell cycle arrest and repair as opposed to 
apoptosis.
P53 status is usually studied in association with response to DNA-damaging 
chemotherapeutic agents but may also be associated to non-DNA-damaging agents 
such as taxol. A study by Rakovitch et al. (1999) demonstrated increased sensitivity to 
taxol in cells with inactivated p53 compared to functional p53. This response was 
correlated with increased micronucleation and DNA fragmentation. They suggests that 
p5 3-independent apoptosis may be the main mechanism of action of taxol in this 
system, explaining why taxol had a lesser effect in p53 functional cells.
An interesting review of the literature on p53 and anticancer treatment, (Brown and 
Wouters, 1999) states that short-term assays are inefficient at determining the total cell 
kill caused by an anticancer agent. This is due to the fact that apoptosis can occur 
rapidly after exposure and short-term assays tend to underestimate overall killing in 
cells with mutant p53 or that do not undergo apoptosis, so that some of the studies in 
this area of research using this methods may not be reliable. This review concluded 
that genes effecting apoptosis such as p53 might not contribute significantly to the 
sensitivity of cancer cells to anticancer agents.
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4.1.1 Analysis of pulse selections in cell lines with differing p53 status
The first aim of this thesis was to study p53 in a number of lung cancer cell lines in 
order to determine its role in the development of drug resistance. A panel of lung cell 
lines were chosen according to their p53 status: A549 and H460 express wild-type 
p53; H1299 is p53 null; and SKLU1 expresses mutant p53. All cell lines were pulsed 
with taxol and carboplatin. Interestingly, no correlation was found between the p53 
status of the cells and their ability to develop resistance. No previous studies have 
analysed development of drug resistance in cell lines with differing p53 status. A 
study by Das et al., (2001) compared the effect of taxol on two lung cancer cell lines: 
A549 which expresses wild-type p53, and H1299 which does not express p53. Taxol 
was found to induce apoptosis in both cell lines efficiently at low doses, but the 
process was more regulated and maximum apoptosis was reached at a lower drug 
concentration in the presence of p53. G2/M arrest was induced in both cell lines, 
independent of p53.
4.1.2 Analysis of p53 transfection in lung cancer cell lines
In order to further investigate the role of p53 in drug resistance, three lung cancer cell 
lines with different p53 status were transfected with wild-type p53. The three cell lines 
were A549, which expresses wild-type p53, DLKP-SQ which expresses mutant p53 
and H I299 which is p53 null.
A549 cells express endogenous wild-type p53 protein. It was expected that 
introduction of exogenous wild-type p53 may increase the sensitivity of the cells to 
chemotherapeutic agents. This was based on the findings of many other groups that 
introduction of wild-type p53 enhances the cytotoxicity of chemotherapeutic agents in 
vitro (Inoue et al., 2000; Miyake et al., 2000). In the present study, A549 cells 
transfected with p53 were found to over-express functional, wild-type p53 (Section 
3.1.5.1). The presence of functional p53 was determined by inducing DNA damage 
and assaying for stabilisation and accumulation of the protein.
The changes in sensitivity of p53-transfected A549 cells was tested for the three 
chemotherapeutic agents adriamycin, taxol and carboplatin. Major changes in 
sensitivity were difficult to detect since transfection alone appeared to have an effect
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on the sensitivity of the cells, especially to taxol, where control-transfected cells 
displayed a 2-fold increase in resistance. Conversely, control-transfected A549 cells 
were similar to parent cells in their sensitivity to adriamycin. Individual p53- 
transfected A549 cells displayed up to a 2-fold increase in resistance to adriamycin. In 
general, these results demonstrate that introduction of wild-type p53 into the cell line 
A549 does not sensitise the cells to the chemotherapeutic agents tested. In fact, the 
reverse is true in several cases, where an increase in resistance was observed. The 
contradictory literature mentioned earlier in this area, Hawkins et al., (1996) found that 
inactivation of p53 can lead to sensitisation of cells to chemotherapy. It should also be 
realised that integration of foreign DNA in transfectants is random and in different 
clones, expression of different genes, some of which could affect drug sensitivity, may 
be altered.
Analysis of wild-type p53 expression in a mutant-p53 expressing cell line is the most 
difficult. Mutant p53 is much more stable than wild-type p53 and so is expressed at 
higher levels in the cell. The most popular method of screening for wild-type p53 
involves observing stabilisation and accumulation of the protein after DNA damage. 
Since the mutant p53 protein is so highly expressed, it is problematic to identify 
changes in expression of any wild-type protein co-expressed in the cells. Nevertheless, 
all of the DLKP-SQ transfected clones were tested for changes in sensitivity to 
adriamycin, taxol and carboplatin. Some of the transfected clones displayed minor 
changes in sensitivity to the drugs tested, however, similar changes were observed in 
control transfected cells, suggesting that any changes were more likely to be attributed 
to transfection, rather than specifically to expression of wild-type p53. Since no 
significant changes were observed, it is possible that the mutant protein present was 
sufficient to overpower any exogenous wild-type p53 introduced. A similar study 
found that, exogenous wild-type p53 was stably expressed in a mutant-p53 cell line 
after transfection, but at a lower level than the endogenous mutant p53 (Takahashi et 
al., 1992). Shaw et al, (1992) investigated the function of wild-type p53 by studying 
effects of wild-type p53 re-expression in the human colon tumour cell line EB, which 
is deficient in endogenous p53. Expression of the p53 gene was induced by induction 
of the metallothionein promoter. They found that induction of wild-type p53 
expression prevented tumour formation in nude mice, wild-type p53 expression 
eventually resulted in elimination of established tumours in mice.
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Many groups have observed the difficulty of expressing wild-type p53 in a cell model 
that does not express it endogenously. Takahashi et al, (1992), examined whether 
wild-type p53 can suppress growth of lung cancer cells, and whether mutations of 
single amino acids changes the biological effects of the wild-type p53 gene. They 
worked with two cell lines, NCI-H358, which is p53 null and NCI-H23, which 
expresses mutant p53, and transfected each with a wild-type p53 expression vector, 
and a mutant p53 expression vector. They found that expression of exogenous wild- 
type p53 was incompatible with cell growth in the p53 null cell line. Other groups 
have reported expression of truncated or rearranged p53 in p53 null cell lines 
transfected with wild-type p53 (Cajot etal., 1992; Baker et al., 1990).
The p53 null cell line included in our study was H1299. Similar difficulties were 
observed in isolating a p53-transfected clone of this cell line that expressed functional 
protein. P53 was detected in the mixed population of transfected HI 299, yet only one 
clone was determined to express p53. However, the p53 protein expressed in this 
clone did not appear to be functional. This was determined by inducing DNA damage 
and observing that no accumulation of the protein occurred. All of the clones isolated 
from the H1299-p53 transfection were tested for changes in sensitivity to adriamycin, 
taxol and carboplatin. Although some significant changes were detected in the 
sensitivity of the clones to the drugs tested, these have to be attributed to the 
transfection since no p53 protein was detected in most of these clones.
H1299-p53 is the only clone of the H1299-p53 transfectants that expresses the p53 
protein. The parent cell line is p53 null. Results show that this p53-expressing clone is 
less invasive and superinvasive than the parent cell line. Very little is known about the 
involvement of p53 in invasion and metastasis, however p53 has transcriptional control 
over a number of genes involved in invasion, such as PAI-1, KAI-1, maspin and 
Nm23-Hl (Harms et al., 2004). The results also show that some of the other 
transfected cell lines, including control transfected cells also show changes in invasion 
potential, so these effects are most likely due to transfection rather than expression of 
p53.
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The p53 protein expressed in H1299-p53 does not seem to function as normal wild- 
type p53. The assay used to test for functional wild-type p53 involves stressing the 
cells with a DNA-damaging agent and allowing the protein to stabilise and accumulate 
in the cell. Wild-type p53 is characterised by low levels of the protein in untreated 
cells and higher levels of protein after treatment. Mutant p53 will be present at high 
levels in the cells regardless of DNA damaging treatment. In H1299-p53, p53 is 
present at quite a low level untreated and does not accumulate after treatment. It is 
unlikely that the protein is mutant p53 (since wild-type p53 cDNA was transfected), so 
the probable reason is that the cell has switched to other mechanisms for dealing with 
DNA damage, since there is no endogenous p53 protein in H1299.
The parent and transfected cells express Mdm2, which is a regulator of p53 and p73, a 
p53 family member, which acts in a similar manner to p53. A recent study by 
Yamauchi et al., (2005) found that p53 introduced into H1299 was remarkably stable 
and had a much longer half-life than in normal cells. They hypothesise that a mediator 
between ubiquitinated p53 and the proteasome exists and that it is downregulated in 
H1299. Therefore, there is a possibility that something similar is occurring in the 
present system, that rather than p53 not accumulating after DNA damage, it is merely 
more stable before DNA damage.
H1299-p53 clone 8, which was found to express p53 protein after transfection, was 
compared to control transfected and parent cells by microarray analysis. The negative 
control for the experiment was H I299 transfected with the empty vector 
pcDNA3.1Zeo (H1299-EV). To ensure that this control was appropriate to the 
experiment, clones of H1299-EV were used. The triplicate for this sample was three 
separate clones isolated from the mixed population of H1299-EV. Section 3.1.11.1 
shows the hierarchical cluster for this experiment. The triplicate samples for H1299- 
EV did not cluster together, and this is probably explained by the fact that three 
separate clones were used, rather than biological replicates of the same cell line, as for 
the other samples included.
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Taking this into consideration, the experiment was continued, despite the quality 
control issues. The genes differentially expressed between H I299 parent and HI 299- 
p53, not differentially expressed in H1299-EV were investigated. The microarray 
analysis results show that the p53-transfected cell line had close to equivalent levels of 
the p53 transcript compared to the parent, which is in contrast to RT-PCR and western 
blotting results. This might be explained by an observation from an earlier microarray 
experiment conducted in our laboratory. In the earlier experiment, a cell line was 
transfected with a plasmid containing EIF-4E, a translation factor. RT-PCR and 
western blots confirmed the success of the transfection, but the Affymetrix results 
showed no appreciable increase in the measured levels of the transcript. This anomaly 
was investigated and it was discovered that the Affymetrix probe sets 
had been designed to the 3' UnTranslated Region (UTR) of the gene sequence. In 
contrast, the plasmid only contained the coding sequence for the gene and 
as a result, the probe sets were not picking up the increased levels of the 
transcript that we had observed by RT-PCR.
An outcome of this was that it was realised that sequences transfected by plasmid may 
not always produce mRNA transcripts that are detectable using the Affymetrix system. 
Two of the reasons that Affymetrix have designed many of their probes to the 3' UTR 
is firstly to improve the efficiency of the IVT process and secondly to ensure that full 
length transcripts are detected (as opposed to 5' fragments).
Since the western blotting and RT-PCR results represent repeated experiments with the 
inclusion of controls, this result should be a true reflection of the p53 status of the 
transfected cells
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In summary, the results presented in this thesis indicate that p53 status alone does not 
determine a cell lines response to chemotherapeutic agents. This finding does not 
agree with the findings in the literature that tumours with inactivated p53 are more 
likely to be drug resistant since functional p53 is necessary to induce apoptosis (Lowe 
et a l, 1993; Ferreira et al., 2000). Also mutant p53 has been associated with 
upregulation of Mdrl, (Sampath et a l, 2001), so this would be consistent with 
increased resistance. It has also been shown here that introduction of wild-type p53 
into mutant and p53 null cell lines was not sufficient to restore sensitivity to the cell 
lines. Several groups have successfully shown chemosensitivity upon introaduction of 
wild-type p53 into cancer cells (Fujiwara et al., 1994; Osaki et al., 2000). As 
discussed earlier there are several publications indicating that inactivation of p53 is 
associated with an increase in sensitivity, rather than the other way around (Hawkins 
et al., 1996; Das et al., 2001). The results presented in this thesis strongly suggest that 
wild-type p53 alone is not sufficient to significantly alter resistance to 
chemotherapeutic agents.
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4.2 Establishment of drug resistant variants
The most commonly used drugs for the treatment of NSCLC are taxanes and platinum 
compounds, however, development of resistance to these drugs is frequent and has 
been described. To study the molecular events giving rise to resistance we repeatedly 
exposed four lung cell lines to taxol and carboplatin giving rise to eight drug resistant 
cell lines, which act as models for the in vitro investigations. The four parent cell lines 
derived from two adenocarcinomas (A549, SKLU-1) and two large cell carcinomas 
(NCI-H1299, NCI-H460) allowing the comparison of two common subclasses of lung 
cancer.
In the clinical setting patients receive chemotherapy treatment once every 1-3 weeks 
allowing for recovery in between. To match the clinical setting as close as possible a 
pulse treatment with drug once per week for four hours was chosen, which also 
allowed for recovery of the cells in between. The newly established cell lines showed 
only modest changes in resistance to taxol and carboplatin together with some cross- 
resistance to other drugs. It is important to note that previous attempts to study drug 
resistance in vitro were based on continuous exposure to clinically non relevant high 
drug concentrations, which resulted in 100-1000 fold increases in resistance, however, 
resistant tumour cells in situ are usually no more than 5-10 fold resistant (Simon and 
Schindler, 1994).
The mechanisms involved in the development of low-level resistance may be more 
relevant for in vivo studies and clinical practice than using models with very high 
resistance levels. Belvedere et al. (1996) compared resistance levels and mechanisms 
of resistance in two cell lines obtained from the ovarian murine reticulosarcoma 
M5076. One of these cell lines was obtained through continuous selection and the 
other by pulse selection with the anticancer agent cisplatin. Both cell lines were found 
to have a stable low-level resistance of 3-fold to cisplatin and showed similar cross- 
resistance to other alkylating agents. These cell lines were implanted in mice and the 
tumours were found to be resistant in vivo to cisplatin, but not to some other agents to 
which they were resistant in vitro.
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4.2.1 Analysis of taxol resistance
Mechanisms of resistance to taxol include increased drug efflux, usually associated 
with increased P-gp expression, changes in microtubules affecting taxol binding, 
differential expression of various tubulin isotypes and changes in expression of 
apoptosis-related proteins e.g. caspases and the bcl-2 family (Wang et al, 2000).
Low concentrations of taxol (lO-lOOnM) lead to suppression of microtubule dynamics 
by inhibiting the formation of mitotic spindles and resulting in cell cycle arrest at the 
G2/M phase. This eventually leads to apoptosis. Higher concentrations of taxol lead to 
massive microtubule damage (Wang et al, 2000). Mechetner et al. (1998) studied the 
expression of P-gp and resistance to taxol and adriamycin in resistant breast cancer cell 
lines and tumour samples and found that P-gp expression significantly contributed to 
levels of clinical resistance to MDR drugs and that treatment with chemotherapeutic 
drugs may induce P-gp expression. This would link taxol resistance to an increase in 
P-gp expression rather than microtubule damage.
Other groups have demonstrated that resistance to taxol can be due to a P-gp unrelated 
mechanism. Parekh et al. (1997) established a series of taxol-resistant human ovarian 
carcinoma clones with increasing degrees of resistance. These were used to study the 
mechanisms by which cancer cells develop resistance to taxol. The cell lines displayed 
resistance to taxol in the range of 250 to > 1500-fold. They found that taxol resistance 
can develop via P-gp-mediated and non-P-gp-mediated mechanisms. Non-P-gp- 
mediated resistance to taxol may be due to alterations in the taxol-binding affinity of 
the microtubules and alterations in tubulins. This was focus of a study by Han et al. 
(2000). The group developed a taxol-resistant NCI-H460 cell line (H460/T800), which 
is 1000 fold more resistant to taxol than the parent cells and even showed cross­
resistance to colchicine, vinblastine and doxorubicin. Beside an increased expression 
of P-gp the resistant cells had an overexpression of a-and |3-tubulin. The down- 
regulation of the a-tubulin expression by antisense resulted in an increased drug 
sensitivity of the cell line.
Giannakakou et al. (1997) isolated taxol-resistant sublines from a human ovarian 
carcinoma cell line in the presence of the P-gp antagonist verapamil resulting in
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resistant variants, which did not express P-gp. These cell lines were found to be 24- 
fold resistant to taxol. The study concluded that the taxol resistance was due, at least in 
part to mutations in P-tubulin.
Martello et al. (2003) studied two taxol resistant variants of A549 called A549-T12 
and A549-T24. A549-T12 is 9-fold resistant to taxol and does not express P-gp. 
A549-T24 is 17-fold resistant to taxol and expresses low levels of P-gp. As well as 
being resistant to taxol these cell lines are dependent on taxol for normal growth. 
These cell lines display normal taxol-dependent polymerisation of tubulin. However, 
they have a mutation in the major a-tubulin iso-type K al. This report highlights the 
complexity of taxol resistance in mammalian cells.
The taxol-selected cell lines developed in this project showed resistance in the range 
from two to over five fold, which was stable even after weeks in culture. The 
concentrations of taxol used for these pulse-selections ranged from 10-150ng/ml 
reflecting a pharmacologically achievable concentration.
A recent study by Scripture et al. (2005) showed that the achievable levels of taxol in 
the plasma of a patient ranges from 1.2 - 5.3(xg/ml, depending on the dose.
Interestingly A549-tax and NCI-H1299-tax expressed double the fold resistance to 
taxol compared to taxotere, although the mechanism of action of these two drugs is 
very similar. Previous studies on another lung cell line, DLKP, in our laboratories have 
shown similar results; pulse-selection with taxotere resulted in a 420-fold resistance to 
the pulsing drug and only 210-fold cross-resistance to taxol (Rasha Linehan, PhD 
thesis, 2003).
A typical MDR phenotype is characterised by a specific cross-resistance pattern, which 
includes resistance to VP-16, taxanes, anthracyclines and vinca alkaloids and is based 
on an increased P-gp expression. None of the selected variants represented the 
classical MDR phenotype and P-gp could not be detected in any of them except in 
NCI-H1299 and NCI-H1299-tax. microarray analysis of the drug resistant variants 
revealed a significant upregulation of Mdrl gene in the taxol-resistant cell lines
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compared to the parent. It is possible that a change in mRNA levels of Mdrl are not 
translated into an increase in protein levels.
Since P-gp expression was not evident, we tested all cell lines with a combination of 
GF120918, a P-gp inhibitor, and taxol. GF120918 has been shown to reverse P-gp 
mediated resistance, but not MRP-mediated resistance (de Bruin et ah, 1999). As 
discussed above, P-gp protein was only detected in two of the cell lines H I299 and 
H1299-tax and therefore, the most potent effect of the combination was observed in 
these cell lines. Some effect could be found in A549-tax and SKLU-1 tax suggesting a 
small level of P-gp protein in these cell lines, which might be enough to contribute to 
taxol resistance. Studies have shown that even a small increase in P-gp protein can 
result in an MDR phenotype explaining the cross-resistance pattern of the SKLU-1-tax 
cell line. Since only small effects can be seen in the taxol selected variants when P-gp 
is inhibited with GF120918, it is reasonable to assume these cell lines possess 
alternative mechanisms of taxol resistance.
If P-gp is present in the H460-tax its expression level seem to be even lower and 
therefore does not show an effect in the combination assays. From microarray intensity 
values it was evident that Mdrl is expressed at very low levels compared to the 
expression levels of other genes studied, which will be discussed in a later chapter.
4.2.2 Analysis of carboplatin resistance
The mechanisms of resistance to carboplatin are not as well characterised as those of 
taxol. Cisplatin, another platinum-containing anticancer agent has a similar mechanism 
of action to carboplatin. Resistance to cisplatin and carboplatin has also associated 
with decreased uptake of the drug into the cells; inactivation of the drug by cellular 
thiol compounds; enhanced repair of platinum-related DNA damage and absence of 
mismatch repair. The formation of conjugates between the thiol glutathione (GSH) 
and platinum drugs results in a complex, which is a substrate for ABC transporter 
proteins. A study by Ikuta et al. (2005) examined the expression of MDR1, MRP1 and 
LRP in NSCLC cells and compared this with the cells’ sensitivity to cisplatin. They 
found no correlation between expression of these markers and sensitivity to cisplatin in 
the NSCLC cells.
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The range of carboplatin used for pulse-selection of the cell lines used in this thesis 
was from 10 - 100(j.g/ml. Achievable plasma concentrations in patients for carboplatin 
range from 9 - 55|ig/ml, depending on the dose (Oguri et a l, 1988). The 
concentrations used for pulse selection were very high and are not as clinically 
achievable as the taxol pulse selections. Nevertheless, these carboplatin-resistant cell 
lines are valuable models for the study of carboplatin resistance. The cell lines pulse- 
selected with carboplatin were found to range in fold resistance to carboplatin from 1.3 
to 2.7 fold. This is considerably less than the resistance obtained in the taxol-selected 
cells. There was no common cross-resistance pattern observed in the carboplatin- 
resistant cell lines. In general, the cell lines display cross-resistance to cisplatin, which 
was expected since these drugs share such a common mechanism of action. SKLU1- 
cpt displays the most cross resistance. This cell line showed upregulation of MRP 1 
and this is consistent with the cross-resistance to adriamycin and VP-16. The 
resistance observed in the carboplatin cells were unstable compared to the resistance of 
the taxol-selected cells. This phenomenon of unstable resistance has been seen in 
previous studies in our laboratories. The cell RPMI 2650 was pulse-selected with a 
range of chemotherapeutic agents. This selection led to an initial resistant phenotype, 
which was quickly reversed with increasing passage number (Rasha Linehan, PhD,
2003).
There is an increase in the expression of MRP 1 in some of the carboplatin-selected 
variants in this study. Sulindac has been shown to circumvent MRP 1-mediated 
resistance in vitro (Duffy et al., 1998). In agreement with this, in the present study, the 
effect of sulindac combined with the chemotherapeutic agent adriamycin appeared 
more potent in cells expressing MRP1. A549 and H460 parent cell lines express the 
most MRP1 prior to selection and it is in these cell lines that the greatest synergy can 
be seen. There is also an increase in MRP1 protein in the carboplatin-selected 
variants, which leads to greater synergy in the combination of sulindac and 
adriamycin. These results suggest that carboplatin may lead to an increase in MRP- 
mediated drug resistance, and that sulindac may be an effective drug for combination 
in such situations.
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4.2.3 The effect of pulse selection on in vitro invasion
Pulse-selection with a chemotherapeutic agent has been known to affect other 
functions of the cell, such as proliferation and invasion. Previous studies in our 
laboratories have shown that selection with some chemotherapeutic agents can lead to 
increased in vitro invasiveness (Liang et al., 2001). Another study on the invasive 
breast cancer cell line MDA-MB-435S-F found that selection with the agents taxol and 
adriamycin led to a more aggressive invasive phenotype termed “superinvasive” 
(Glynn etal, 2004).
The invasive capabilities of the selected cell lines were tested for this reason. In the 
cell lines A549-tax and H1299-tax, taxol selection was not found to drastically change 
the invasiveness of the cell lines, with both cell lines displaying a slight increase in 
invasiveness compared to their respective parent cell line. In the cell lines H460-tax 
and SKLUl-tax, there was a considerable decrease in the invasiveness compared to the 
parent cells. It was also found that pulse-selection with taxol did not affect the ability 
to super-invade to the cells.
Taxol treatment has been linked to decreased invasion. A study by Westerlund et al.
(1997) examined the effect of taxol on ovarian cancer cell invasion. Taxol was found 
to suppress invasion, motility and cell attachment of ovarian cell lines. This inhibition 
of invasion was found to be accompanied by an increase of TIMP-2 protein release. 
This is in agreement with the results obtained for H460-tax and SKLUl-tax, which 
were less invasive after pulse-selection with taxol.
Interestingly, all of the carboplatin-selected cell lines were less invasive than the parent 
cell line. As discussed earlier, some chemotherapeutic agents have been associated 
with changes in invasion in vitro. Previous studied in our laboratories indicated that 
pulse-selection with cisplatin led to increased in vitro invasiveness in the human lung 
cancer cell line DLKP (Liang et al., 2004). This increased invasiveness was associated 
with increased expression of the matrix metalloproteases MMP-2 and MMP-13.
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In summary, the results presented in this section of the thesis indicate that the pulse- 
selected variants displayed low-level resistance to the pulsing drug (>10-fold). Since 
these cell lines were established with the clinical setting in mind, and considering that 
resistant tumour cells in situ are usually no more than 5-10 fold resistant (Simon and 
Schindler, 1994), these resistant cell lines provide excellent models for the study of 
taxol and carboplatin resistance. The results indicate that the taxol resistance obtained 
may be in part associated with upregulation of P-gp, but it is likely that other 
mechansims are also in play. The carboplatin-resistance observed might be due in part 
to increased MRP-1 expression, however in some of the variants this was not observed 
so other mechanisms must be involved. The most interesting result presented for the 
carboplatin-resistant cell lines was the consistent decrease in invasion observed in 
these cell lines compared to the parent cells. These cell lines provide a model for the 
future study of invasion.
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4.3 Microarray analysis of taxol-selected variants
The four lung cancer cell lines A549, H I299, H460 and SKLU1, and their taxol- 
resistant variants were analysed using microarray. The aim of this analysis was to 
identify genes involved in the development of taxol resistance in lung cancer cell lines. 
These taxol-resistant cell lines did not display classical MDR, and offered a unique 
opportunity to study the less-well characterised mechanisms of taxol resistance. 
Another strong point of this analysis was the straightforward nature of the comparison. 
The microarray data was used to analyse differences between parental (sensitive) and 
resistant cell lines, and the only differences were due to taxol treatment. Therefore, 
any differentially expressed genes identified by the microarray analysis should relate to 
taxol resistance.
Several groups have used microarrays to identify genes involved in resistance to 
chemotherapeutic agents. Wittig et al. (2002) compared the gene expression patterns 
of the drug sensitive melanoma cell line MeWo and three sublines with resistance to 
etoposide, cisplatin and fotemustine in order to identify common genes involved in 
resistance to these DNA-damaging agents. This study indicates the involvement of two 
genes in particular, MPP1 and CRYAB, in resistance to DNA-damaging agents. A 
more general study on genes involved in chemoresistance in gastric cancers was 
conducted by Suganuma et al. (2003). This group compared gene expression and drug 
resistance patterns in gastric cancer surgical specimen and, although they identified 
several resistance related candidate genes, they concluded that the mechanisms of 
resistance to chemotherapeutic agent are very complex.
Similarly to the present study, Lamendola et al. (2003) investigated taxol resistance in 
vitro using microarray analysis. This group established taxol-resistant cell lines from 
the ovarian carcinoma cell line SKOV-3 through continuous selection with increasing 
concentrations of taxol in order to identify novel candidate gene families involved in 
taxol resistance. This study used array technology in the area of pattern recognition 
and similarity clustering to identify many associated changes in gene expression rather 
than single gene changes. This might provide more insight into the development of a 
taxol-resistant phenotype. An earlier study by this group discovered a novel gene that 
was overexpressed in the taxol resistant cell line called taxol resistance associated
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gene-3 (TRAG-3). This gene was also found to be overexpressed in other cell lines 
displaying resistance to taxol. TRAG-3 is not expressed in normal tissue but is 
expressed in 43% of cancer cell lines (Duan et al., 1999).
4.3.1 Quality control in microarray experiments
The quality control measures used in the microarray experiments in this thesis adds to 
the strength of the data. Hierarchical clustering of the parent and taxol-resistant lung 
cancer cell lines was carried out to ensure that the triplicate samples were 
representative and as a quality control measure. This allows confidence that the 
differntially expressed genes are indeed involved in taxol resistance. Hierarchical 
clustering grouped samples together based on similar expression levels of the genes 
analysed by the microarrays. The first important point about the clustering results is 
that the biological replicate samples used in the microarray experiment did group 
together. The taxol-selected variants from each cell line grouped next to the parent 
samples in each case, showing that these taxol resistant variants remain very similar in 
overall gene expression to the cell lines from which they were established. This result 
is verifies that the specific gene changes determined from analysis of the data is solely 
due to selection for taxol resistance.
Another point that was highlighted by the clustering was that, interestingly, the 
different lung cancer cell types did not cluster together. A549 and SKLU1 are both 
lung adenocarcinoma cell lines and H460 and HI299 are both large cell lung 
carcinomas, however, the clustering shows that A549 and H460 were most similar in 
gene expression. SKLU1 was then similar to both of these, with H I299 having the 
least similar gene expression to all the other cell lines.
A study by Bhattacharjee et al. (2001) used clustering methods to analyse 186 lung 
tumour samples, mostly adenocarcinomas. They demonstrated that using different 
clustering methods, there are distinct subclasses of adenocarcinoma based on specific 
gene expression. In a sililar study, a 7685-element microarray was employed to create 
expression profiles for lung tumours and cell lines (Virtanen et al., 2002). Hierarchical 
clustering resulted in tumour samples and cell lines forming two distinct groups. 
Within the tumour group, SCLC and NSCLC grouped separately. Most SCLC cell
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lines grouped with the SCLC tumour samples. Similarly, most of the squamous cell 
carcinomas clustered together. None of the adenocarcinoma cell lines tested grouped 
with adenocarcinoma tumour tissue. This study might explain in part why the different 
lung cancer cell types in this microarray study did not group together in the 
hierarchical cluster. Microarray analysis compares the samples at a more detailed level 
and picks up differences in samples that are not possible to detect at the cellular level. 
In this way, microarrays have the potential to completely change lung cancer 
classification and staging to improve diagnosis and hence treatment options for 
patients.
4.3.2 Differentially expressed genes in taxol-resistant cell lines
Genes that were differentially expressed in the taxol-selected cell lines compared to the 
parent cell lines were uncovered using parameters of fold change of 1 .2 , a difference of 
intensity of 100 and a p value of <0.05 (see section 2.12.4). Fold change is the most 
common parameter utilised to generate gene lists from microarray experiments. The 
shortcoming of this parameter is that there is a bias towards genes that are expressed at 
very low levels in the parent samples, and “turned on” in the experimental samples. 
For example, when comparing A549 to A549-tax, for the gene ABCB1 there is a 9- 
fold increase in A549-tax, and an intensity difference of 109. However, for the gene 
CRYZ there is a 1.6-fold decrease in A549-tax, but an intensity difference of 1,024. 
For this reason, a low fold change and also a difference of intensity criteria was used to 
filter the genelists. These criteria will detect genes that are expressed at low and high 
levels.
As discussed earlier, the comparison between parent and taxol-resistant cell line is 
straightforward. However, the limitation is that there are thousands of genes 
differentially expressed by the taxol-resistant cell lines. It is only feasible to work with 
a small number of genes at a given time. The stringent filtering criteria used to narrow 
down genelists to a manageable study inevitably means discarding of potentially 
interesting genes.
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As described in Section 3.3.3, nineteen genes were found to be differentially expressed 
in all taxol variants compared to the parent cell lines. The nineteen genes were not, 
however, similarly expressed in all cell lines, for example vascular endothelial growth 
factor is upregulated in two of the cell lines, but down regulated in the other two cell 
lines. Two genes were identified as upregulated in all the taxol-resistant cell lines 
compared to the parent cell lines, Mdrl and phosphoglucomutase-2. There is no 
correlation in the literature between these two genes. Mdrl, which codes for the P-gp 
protein is well characterised as involved with resistance to taxol. However, there have 
been no reports of phosphoglucomutase-2 (PGM-2) being involved in taxol or 
resistance to any cytotoxic agent. PGM-2 was not followed up in subsequent 
experiments, considering the very low fold changes (1 .2 -fold) and low expression 
values observed in this gene, it would be difficult to discern any changes in expression 
and to see effects in functional assays. It is another interesting point that no genes 
were downregulated in all the taxol selections. PGM-2 is upregulated to the same 
degree in all of the selections, whereas Mdrl upregulation ranges from two to nine 
fold. It was expected that Mdrl upregulation may correlate with fold taxol resistance, 
but this was not the case. In fact, the least resistant cell line, A549 displayed the 
greatest fold increase in Mdrl (Section 3.3.3).
Ten target genes were chosen for further analysis (Section 3.3.4). Five of these genes 
were upregulated in taxol resistant cells and five were downregulated. The five 
upregulated genes were as follows: Mdrl (ABCB1); inhibitor of DNA-binding 3 (Id3); 
quinone reductase (CRYZ); engulfment adapter protein (GULP1) and stromal cell 
protein (SCP). The downregulated target genes were as follows: follistatin-like 1 
(FSTL1); epithelial membrane protein 1 (EMP1); connective tissue growth factor 
(CTGF); cysteine-rich intestinal protein 1 (CRIP1) and insulin-like growth facto 
receptor binding protein 6 (IGFBP6). Some of the functions of the target genes are not 
well characterised in the literature. The following paragraphs give a brief description 
on what is known about these genes.
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Mdrl, as discussed earlier is the gene that codes for P-gp. P-gp is drug efflux pump, 
known to be involved in resistance to a variety of chemotherapeutic agents. Mdrl was 
upregulated in all of the taxol variants compared to the parent cell lines.
Inhibitor of DNA binding 3 (ID3) belongs to a subfamily of helix-loop-helix (HLH) 
proteins, which are a family of transcription factors. The ID proteins for a distinct 
group within this family, due to their lack of a basic DNA binding domain. They act 
as dominant-negative regulators of basic HLH proteins through formation of inactive 
heterodimers with intact basic HLH (bHLH) transcription factors (Sikder et al., 2003). 
These heterodimers are then unable to bind to DNA. Most bHLH regulate genes 
involved in cell fate determination and cell differentiation and ID proteins are also 
known as inhibitors of differentiation (Norton, 2000). ID proteins can also act as 
positive regulators of cell growth and their function is important for cell cycle 
progression. These proteins are involved in cellular differentiation and development, 
but have also been implicated in cell cycle and apoptosis. ID3 has been shown to be 
phosphorylated in late G1 phase of the cell cycle by cyclin-dependent kinase 2 (cdk2). 
ID3 has also been found to be a strong inducer of apoptosis in serum-deprived 
conditions (Norton & Atherton, 1998). The role of ID3 in taxol resistance is discussed 
later.
CRYZ encodes a crystallin protein which has NADPH-dependent quinone reductase 
activity. Quinone reductase is a phase II detoxification enzyme. CRYZ lacks alcohol 
dehydrogenase activity although by similarity it is considered a member of the zinc- 
containing alcohol dehydrogenase family (Rao et al., 1992). It is expressed at 
extremely high levels in the lenses of some mammals (Gonzalez et a l, 1995). CRYZ 
was expressed at a relatively high level in A549-tax and H1299-tax, however, the fold 
changes were quite low (>2 -fold).
GULP1 is an evolutionarily conserved adaptor protein required for efficient 
engulfment of apoptotic cells by phagocytes. Removal of apoptotic cells is an 
essential part of the apoptotic pathway, since dying cells release toxins that could lead 
to inflammation (Su et al., 2002). This gene was upregulated in taxol-resistant cells.
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SCP stromal cell protein is a poorly annotated gene. Its function is not fully 
understood. However, this gene was upregulated in taxol-resistant cells. Follistatin- 
like 1 (FSTL1) encodes a protein with similarity to follistatin.
Follistatin is a monomeric glycoprotein that binds activin A with high affinity. It has 
been associated with rheumatoid arthritis (Ehara et al., 2004). This gene was down- 
regulated in taxol-resistant cells.
Epithelial membrane protein 1 (EMP1), also known as tumour membrane protein 
(TMP) is a member of the PMP22 family of proteins. EMP1 has been found to be 
downregulated in esophageal cancer (Wang et al., 2003). A recent study by Jain et ah 
(2005) identified EMP-1 as a potential biomarker of gefitinib resistance, both de novo 
and acquired, in NSCLC patient samples. EMP-1 was found to be downregulated in 
association with taxol resistance to taxol, in agreement with this study.
Connective tissue growth factor (CTGF) is a secreted protein that binds to integrins. It 
is known that CTGF can modulate the invasive behaviour of cell lines in vitro, and this 
may be moduulated by MMP-2 expression (Fan & Kamovsky, 2002). CTGF gene 
expression has been shown to be regulated by transforming growth factor-^ (TGF-P). 
As well as its role in invasion, CTGF has been demonstrated to induce apoptosis in 
certain cell lines (Hishikawa et al., 1999). Connective tissue growth factor was found 
to be downregulated in taxol-resistant cells. Downregulation gene could possibly 
explain the decrease in invasiveness observed in H460-tax and SKLUl-tax, although 
this phenomenon was not observed in A439-tax and HI 299-tax.
Cysteine-rich intestinal protein 1 (CRIP1) is a member of the LIM protein family. It is 
a small protein that is abundant in the intestine and in the immune system (Cousins & 
Lanningham-Foster, 2000). LIM proteins are characterised by a repeat of a double 
zinc finger cysteine-rich sequence. There is a shortage of literature on this gene and 
little is known about its function. CRIP 1 is believed to be involved in zinc transport, 
since it has metal-binding abilities (Hempe & Cousins, 1991). Overexpression of 
CRIP1 in transgenic mice has been found to alter cytokine expression, suggesting a 
roel for CRJP1 in the immune response (Lanningham-Foster et al., 2002). A recent
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microarray study by Mackay et al. (2003) identifies a CRIP1 as a differentially 
expressed gene in ERBB2 expressing breast cancer cells.
Insulin-like growth factor binding proteins act as carrier proteins for IGFs in the 
bloodstream, modulate the half-lives and cellular bioavailability of the IGFs (Grellier 
et al., 2002). IGFBP6 is one of these binding proteins and was downregulated in 
taxol-resistant cells.
4.3.3 Relationships between differentially expressed genes
Pathway analysis was carried out using Pathway Assist in order to determine if a 
relationship exists between the target genes. A common pathway was built (Section 
3.3.5). This pathway contains genes involved in signalling (JAK2, CCL4, TNF and 
EL6), transcription factors (TCF4) and growth factors (TGFf3). Only two of the target 
genes shared a direct link, SCP and CRYZ, both of which were upregulated in the 
taxol resistant cell lines. It was also of interest that GULP1 was found to be related to 
the major vault protein, also known as lung resistance related protein, though this gene 
was not found to be differentially expressed in the taxol-resistant cell lines. Pathway 
analysis is usually carried out on large genelists. Building a pathway based on ten 
targets is limiting and more could be extracted from this experiment by carrying out 
pathway analysis on a larger genelist. Nevertheless, the built pathway indicated that 
transforming growth factor-P is important in this system as it regulates four of the ten 
genes: CTGF; IGFBP-6 ; CRYZ and SCP.
4.3.4 Expression of ID3 in pulse-selected variants
ID3 was found to be upregulated in the taxol resistant cell lines A549-tax, H1299-tax 
and H460-tax. Expression of ID3 protein in the selected cell lines is shown in Section 
3.5.2. The protein expression does not parallel with the microarray results, since in 
A549-tax and H1299-tax there appears to be downregulation of the protein. It is a 
possibility that post-transcriptional mechanisms may be involved. SKLUl-tax shows 
an increase in ID3 protein compared to SKLU1, though this was not detected by 
microarray analysis. ID3 has been implicated in resistance to cisplatin in a recent
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study by Koyama et al (2004). Inactivation of a family member of ID3, ID1 was 
found to lead to increased sensitivity to taxol in prostate cancer cells (Zhang et al, 
2005). In addition, this group found that the JNK pathway was activated in ID1- 
transfected cells and they conclude that inhibition of ID1 is a possible target for 
increasing taxol-induced apoptosis. It is possible that ID3 is capable of activating 
similar apoptosis pathways, and this recent study could indicate a possible mechanism 
for the role of ID3 in taxol resistance. Another study by Cheung et al. (2004) found 
that the expression of EDI was able to protect nasopharyngeal carcinoma cells from 
taxol-induced cell death. This study strengthens the possibility that ID family 
members are involved in taxol resistance. ID1 and ID3 were also recently found to be 
involved in the activation of angiogenic processes (Sakurai et a l, 2004).
4.3.5 Expression of CRIP1 in pulse-selected variants
CRIP1 was found to be downregulated in the taxol resistant cell lines A549-tax, 
HI 299-tax and H460-tax. In fact, in HI 299-tax, expression of CRIP1 was virtually 
“turned off “ with an intensity value of less than 20. Section 3.5.3 shows the 
expression of CRIP1 protein in the cell lines. The protein is downregulated not only in 
the taxol-selected cells, but also in the carboplatin-selected cells. SKLUl-tax also 
shows downregulation of the protein, though this was not detected by microarray 
analysis.
In summary, the microarray analysis revealed ten genes with a possible role in taxol 
resistance. The roles of some of the genes in taxol resistance, for example Mdrl, are 
clear and well documented (Section 4.2.1). Many of the genes identified are not well- 
characterised. These genes are potential markers for taxol resistance in lung cancer. 
Further study into the function of these genes will provide an insight into their 
function, and identify possible pathways involved in taxol resistance.
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4.4 RNA Interference
RNA interference is a powerful technique to study the functions of genes using 
siRNAs to specifically silence them (see sections 1.8 and 2.13). The ten target genes 
mentioned above were silenced using two distinct siRNAs in order to determine their 
role in taxol resistance. RNA interference is a relatively new technique so the 
literature on its uses in the investigation of chemotherapy resistance is limited. Celius 
et al. (2003) established a modified colon carcinoma cell line Caco-2 with stable 
suppression of MDR1 gene expression and associated downregulation of P-gp protein. 
A more recent study by Stierle et al. (2005) downregulated MDR1 and P-gp levels in 
multidrug-resistant MCF7 cells using an siRNA against MDR1. They found that 
transfected cells displayed sensitivity to the P-gp substrate daunorubicin and increased 
cellular accumulation of this agent.
4.4.1 Effects of transfection of target genes siRNA on taxol sensitivity
SiRNAs directed at the ten target genes were transfected into A549, A549-tax, H1299 
and H1299-tax and the effect on taxol sensitivity was examined. A summary of the 
results obtained can be seen in Table 4.1.
Table 4.1 Summary of results from transfection of target genes siRNA
Gene A549 A549-tax H1299 HI 299-tax
ABCB1 - + + +
ID3 + - + -
CRYZ - - - +
GULP1 - - - +
SCP - - - -
CTGF - - - -
CRIP1 + + - -
IGFBP6 - - - -
EMP1 + + - -
FSTL1 + + - -
+ Indicates that an effect was observed 
- Indicates that no effect was observed
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The genes ABCB1, ID3, GULP1, SCP and CRYZ were upregulated in the taxol- 
resistant cell lines. Transfection of the cell lines with siRNAs towards these 
upregulated genes should lead to increased sensitivity to taxol. Transfection of 
ABCB1 siRNA into H1299 and especially H1299-tax gave the largest increase in 
sensitivity observed. Transfection of ID3 siRNA was found to have an effect on 
proliferation of all the cell lines tested. However, a specific effect of increased 
sensitivity to taxol was observed in A549, and slightly in H1299. Although H1299-tax 
had a higher fold change in expression of ID3, the overall protein levels show that ID3 
is more highly expressed in A549, which may explain why this effect was only seen in 
this cell line. Transfection of GULP1 siRNA was found to have no specific effects on 
A549, A549-tax and H1299-tas, and a slight increase in sensitivity to taxol in H1299- 
tax. The change in expression of GULP1 was found to be highest in HI 299-tax, so 
this result was expected. Despite increases in its expression in the taxol-resistant cell 
lines, transfection of SCP siRNA gave no effect on taxol sensitivity in any of the cell 
lines. Transfection of GULP1 siRNA increased the sensitivity to taxol in H I299, but 
not in any of the other cell lines. This gene appeared to be expressed quite highly in 
both A549 and H1299 and the taxol variants, so it is surprising that no effect was 
observed.
The genes EMP1, CRIP1, FSTL1, CTGF and IGFBP6 were downregulated in the 
taxol-resistant cell lines. Transfection of the cell lines with siRNAs towards these 
downregulated genes should lead to increased resistance to taxol. Transfection of 
EMP1 siRNA had no effect on taxol sensitivity in H1299 or H1299-tax. However, 
transfection of EMP1 siRNA led to a slight increase in sensitivity to taxol in A549 and 
A549-tax, which is the opposite effect than expected from the microarray results. This 
may indicate that EMP1 has involvement in taxol resistance as part of a pathway, 
rather than on its own.
CRIP1 was almost 3-fold downregulated in A549-tax compared to parent cells in the 
microarray analyses. In both parent and taxol-selected cells siRNA transfection of 
CRIP1 led to a dramatic increase in resistance. H1299-tax cells displayed a very large 
(30-fold) decrease in CRIP1 compared to the parent cells. Unlike A549 cells, siRNA 
transfection of CRIP1 did not lead to an increase in resistance. This is surprising 
considering the large fold change compared to the much lower fold change in A549.
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Transfection of FSTL1 siRNA into H1299 and H1299-tax had no effect on the 
sensitivity of these cells to taxol. In A549 and A549-tax, however, there was an 
unexpected increase in sensitivity to taxol. Transfection of CTGF or IGFBP6 siRNA 
had no effect on taxol sensitivity in any of the cell lines tested.
In a number of cases, the transfection of siRNA led to the opposite effect on taxol than 
expected from the microarray results. It is possible that these genes are involved in 
pathways in taxol resistance and that their function depends on expression of other 
genes.
4.4.2 Effect of transfection of ABCB1 siRNA on resistance to chemotherapeutic 
agents
It is evident from the microarray analysis of the taxol-selected cell lines that P-gp plays 
a role in the development of the resistance observed in these cell lines. In order to 
determine if the effect of P-gp is taxol-specific, ABCB1 siRNA was transfect cells 
were tested for sensitivity to taxotere, adriamycin and carboplatin. Taxotere is in the 
same family of agents as taxol, and these drugs have similar mechanisms of action and 
resistance. Adriamycin is an anthracycline. It is a substrate for P-gp, but has 
completely different mechanisms of action from the taxanes, such as DNA 
intercalation and topoisomerase II inhibition. Carboplatin also has a different 
mechanism of action, however, it is not a substrate for P-gp.
In a similar manner to taxol, transfection of ABCB1 siRNA led to increases in 
resistance in A549-tax, H460-tax and especially H1299-tax. H1299 and H1299-tax 
have been shown to express P-gp. The other taxol-resistant cell lines show an increase 
in mRNA levels from the microarray experiments, but have no detectable P-gp protein. 
The increase in sensitivity to taxol and taxotere observed in these variants suggests that 
P-gp is present in these cell lines. It also indicates that P-gp only needs to be 
expressed at very low levels to have a substantial effect on the sensitivity of the cells to 
chemotherapeutic agents. Interestingly, it was only in H1299-tax that an increase in 
sensitivity to adriamycin was observed after transfection of ABCB1 siRNA. This 
suggests that the P-gp mechanism active in A549-tax and H460-tax may be taxol 
specific, which would not be expected from the literature. It is also noteworthy that in
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H1299 and H1299-tax a small sensitisation of the cells to carboplatin was observed 
after transfection of ABCB1 siRNA. This is unusual since carboplatin is not a 
substrate for P-gp. Overall the results obtained on taxol and taxotere sensitivity from 
transfection of ABCB1 siRNA are not surprising. P-gp is well characterised as a 
mechanism of resistance for the taxanes. The lack of an effect in adriamycin 
sensitivity is surprising. H1299-tax expresses the most P-gp, and was the only cell line 
to show detectable levels of the protein. However, the taxol and taxotere results, along 
with results from microarray analysis indicate that there is expression of P-gp in all of 
the taxol-resistant cell lines. The results from the siRNA experiments with ABCB1 
seem to suggest a taxane-specific effect of P-gp, which has not been reported. This 
may be due to the extremely low levels of protein expressed, and further analysis of 
the P-gp in the taxol-resistant cell lines would elucidate this mechanism.
4.4.3 Effect of transfection of ID3 siRNA on resistance to chemotherapeutic 
agents
ID3 showed a slight sensitising effect on taxol in A549, so it was decided to 
investigate the effect of transfecting ID3 siRNA on the sensitivity of taxotere, 
adriamycin and carboplatin, as with ABCB1. The effects seen with transfection of ID3 
siRNA may not be specific for taxol sensitivity. In A549 transfection with ID3 siRNA 
led to an increase in sensitivity to taxol. However, the same effect was not observed 
with taxotere, which is unusual since these drugs share very similar mechanisms of 
action. No effect was observed on adriamycin sensitivity in any of the cell lines after 
transfection of ID3 siRNA. Interestingly, a small increase in resistance to carboplatin 
was observed in both H I299 and H I299 tax after transfection with ID3 siRNA. 
Conversely, an increase in sensitivity to carboplatin was observed in A549, but not in 
A549-tax after transfection with ID3 siRNA.
As discussed in Section 4.3.4, a family member of ID3, ID1 has recently been 
implicated in the response of cancer cells to taxol (Zhang et al., 2005;Cheung et al.,
2004). The results demonstrated in this thesis are inconclusive for the role of ID3 in 
taxol specific resistance, but point to some involvement in drug sensitivity.
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4.4.4 Effect of transfection of CRIP1 siRNA on resistance to chemotherapeutic 
agents
The transfection of CRIP1 siRNA showed a dramatic increase in resistance to taxol in 
A549 and A549-tax, so the effect on sensitivity to taxotere, adriamycin and carboplatin 
was examined. These experiments led to some unexpected and interesting results. 
Transfection of CRIP1 siRNA had the opposite effect on taxotere sensitivity in A549 
and A54-tax than taxol, leading to a small increase in sensitivity. This increase in 
sensitivity was also observed in H1299 and H1299-tax, but not in H460 or H460-tax. 
Transfection of CRIP1 siRNA also led to an increase in resistance to adriamycin in 
H I299, H460 and H460-tax. The most interesting results emerged from the 
carboplatin experiments. Transfection of CRIP1 siRNA led to an increase in resistance 
to carboplatin in H1299, H1299-tax and A549-tax, but an increase in sensitivity to 
carboplatin in A549. Despite these interesting effects in A549 and H I299, there was 
no change in sensitivity to carboplatin in H460 or H460-tax after transfection of 
CR1P1 siRNA.
Little is known about the functions of CRIP1 in mammalian cells. There is nothing in 
the literature to suggest the involvement of this gene in the development of 
chemotherapy resistance. Nonetheless, the results presented here indicate that this 
gene is involved in determining the sensitivity of lung cancer cells to chemotherapeutic 
agents. The effects observed on carboplatin sensitivity suggest that this gene is not 
specifically involved in taxol resistance.
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Overall, the results from RNA interference experiments show that the three genes 
studied in detail have a possible role in taxol resistance, but that it may not be taxol- 
specific. Although P-gp was well characterised as involved in taxol resistance, two 
interesting points emerge from the transfection of ABCB1 siRNA. Firstly, the known 
involvement aided the optimisation of siRNA experiments, since it was expected that 
silencing of P-gp would lead to increased sensitivity to taxol. In this way, inclusion of 
ABCB1 in these experiments validates the results obtained in the other siRNA 
transfections. Secondly, the effects observed after transfection of ABCB1 suggest a 
taxane-specific effect of P-gp in these cell lines. The results observed after 
transfection of CRIP1 siRNA demonstrate that this gene has a possible role in 
resistance not only to taxol, but also to carboplatin. This gene has not been implicated 
in pathways of resistance before.
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Section 5.0: Conclusions & Future work
5.1 Conclusions
1. Wild-type p53 was transfected into three lung cancer cell lines in order to 
determine the role of p53 in the development of drug resistance. Wild-type p53 
transfection into a cell line expressing endogenous wild-type p53 (A549) resulted 
in populations of this cell line which over-expressed the protein but displyed no 
considerable changes in sensitivity to adriamycin, taxol or carboplatin. In general, 
wild-type p53 is associated with decreased resistance to DNA-damaging drugs. 
However, it is possible that after sensing the DNA damage, p53 is causing the cell 
cycle to arrest, allowing time for cells, bearing drug-induced mutations, to repair 
the damage and continue growing. This would result in an observed increase in 
resistance of the cells. The results presented in this thesis strongly suggest that 
wild-type p53 alone is not sufficient to significantly alter resistance to 
chemotherapeutic agents.
2. Of the cell lines transfected, H1299 was chosen to study further since the parental 
cell line does not express p53. A transfected clone which expresses p53 protein 
was further analysed H1299-p53 was compared to control transfected clones by 
microarray analysis. This clone was shown by western blotting to express p53 
protein; however, the protein did not seem to be functional since it did not stabilise 
and accumulate in response to DNA damage. It is probable that the p53 pathway in 
H1299 has adapted to be controlled by other mechanisms, such as the family 
member p73, so that introduced p53 no longer interacts with these pathways.
3. Pulse selections were carried out on four lung cancer cell lines, two lung 
adenocarcinoma cell lines A549 and SKLU1 and two large cell lung carcinoma cell 
lines H1299 and H460, with either taxol or carboplatin, resulting in eight novel cell 
lines with relatively low resistance. Selected cell lines show no obvious cross 
resistance pattern to other drugs except within families of drugs, e.g., taxol and 
taxotere; carboplatin and cisplatin. The low-level resistance (2-5 fold) observed in 
these selected cell lines may be more clinically relevant to study than higher levels
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of resistance obtained by other methods of selection. Cells pulsed with taxol 
resulted in more stably resistant cells than those pulsed with carboplatin. It is also 
worth noting that in the cell line panel pulse selected in the course of this thesis, 
p53 status did not correlate with development of resistance. A549 and H460 
express wild-type p53, H1299 is p53 null and SKLU1 expresses mutant p53.
4. Taxol-resistant cell lines show no consistent alterations in invasion, whereas 
carboplatin-resistance seems to correlate with a decrease in invasion. In all four 
cell lines, the carboplatin-selected variants are less invasive than the parent cells. 
Of the taxol-selected variants, however, two of the variants had decreased invasive 
potential compared to the parent cell lines and two showed slight increases in 
ability to invade.
5. Taxol-resistant cell lines were chosen for further analysis using microarrays. 
Microarray experiments were carried out on four parent cell lines and their taxol- 
selected variants. Microarray analysis identified nineteen genes which were 
significantly differentially expressed in all taxol variants compared to parent cell 
lines. Only two of these genes were up-regulated in all four taxol variants, Mdrl 
and phosphoglucomutase 2. Interestingly, no genes downregulated in all four taxol 
variants.
6 . Ten targets were chosen for further analysis based on up-regulation or down- 
regulation in three out of the four taxol variants compared to parent. These were 
ATP-binding casette sub-family B member 1 (ABCB1), Quinone reductase 
(CRYZ), Epithelial membrane protein 1 (EMP1), Inhibitor of DNA binding 3 
(ID3), Cysteine-rich intestinal protein (CRIP1), Stromal cell protein (SCP), 
Insulin-like growth factor binding protein 6 (IGFBP6), Engulfment adaptor PTB 
domain containing 1 (GULP), Follistatin-like 1 (FSTL1) and Connective tissue 
growth factor (CTGF). Three of these targets, ABCB1, ID3 and CRIP1 showed an 
interesting functional effect on taxol sensitivity in the cell lines tested. Based on 
the results, these genes have definite involvement in the determination of resistance
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to taxol in the cell lines studied. Changes in expression of these genes alone is not 
enough to completely change the sensitivity of the cell lines to taxol and most 
likely many genes are involved.
7. ABCB1 (P-gp) has a well documented role in modulating resistance to 
chemotherapeutic agents. The results presented in this thesis indicate a possible 
taxane specific effect of low levels of P-gp, since transfection of ABCB1 siRNA 
did not affect sensitivity of adriamycin, a known P-gp substrate, in cells which 
should express low levels of P-gp.
8. The gene CRIP1 has not been implicated in resistance to chemotherapy resistance 
before. The results presented in this thesis suggest that, although it is probably not 
taxol-specific, this gene may have a possible role in the determination of resistance 
to chemotherapeutic agents.
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5.2 Future work
1. The taxol and carboplatin selected cell lines in this thesis represent valuable 
models for the study of mechanisms of resistance to these drugs. Most of the 
analysis in this thesis focussed on the taxol-resistant cell lines, however, similar 
analysis would be interesting in the carboplatin-resistant cell lines. The 
carboplatin-resistance cell lines could be examined by microarray analysis and 
candidate genes for development of carboplatin resistance could be identified. 
Moreover, the genes identified as involved in taxol resistance could be analysed in 
the carboplatin-resistant cell lines, since most of these genes are probably not 
taxol-specific.
2. The microarray analyses carried out in this thesis generated vast amounts of data. 
Only a fraction of this could be analysed further, and consequently, much of the 
data containing interesting information on the models used still remains to be 
examined. An alternative method of analysis, other than that used in this thesis 
involves examining large gene lists generated by dChip in the pathway analysis 
packages discussed. Pathway analysis of genelists can indicate interesting groups 
of genes to study based on common pathways they are involved in. Two 
microarray experiments were included in this thesis, one on taxol resistant lung 
cancer cell lines and the other on a p53-expressing cell line. Both of these 
experiments could be further analysed using pathway analysis.
3. Three genes that were candidates for involvement in the development of taxol 
resistance were identified -  ABCB1, ID3 and CRIP1. The involvement of ABCB1 
in resistance is well documented, however this is not the case for ID3 and CRIP1. 
Although the experiments carried out using siRNA transfection suggest a role for 
these genes in resistance to chemotherapeutic agents, further elucidation of the 
mechanisms involved is necessary. Firstly, silencing of the genes by siRNA 
transfection should be verified by western blotting, to show silencing at the protein
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levels. The next step would be to include a wider range of chemotherapeutic agents 
and also more cell lines with varying resistance.
4. During pulse-selection of the cell lines A549, H1299, H460 and SKLU1, cell 
stocks were established after 2, 4, 6 and 8 pulses before the cells received the full 
ten pulse of either taxol or carboplatin. These intermediate cell lines have not been 
charaterised for drug resistance, invasion or expression of any markers. Using 
these cell lines, it may be possible to track the development of resistance to taxol 
and carboplatin. In the taxol-resistant variants specifically, it may be possible to 
identify when the expression of the genes ABCB1, ID3 and CRIP1 began to 
change, and also if there is a correlation between the level of expression of these 
genes and the development of taxol resistance,
5. Proteomic analysis of the taxol-resistant lung cancer cell lines, along with the 
parent cell lines would be an interesting addition to the microarray analysis already 
carried out. This will involve 2-dimensional gel electrophoretic separation of the 
proteins in a cell extract in order to determine proteins that are differentially 
expressed. Differentially expressed proteins will be identified using MALDI.
6 . The genes identified in this thesis as potentially involved in taxol resistance should 
be further analysed. Taxol resistance remains a serious problem in the treatment of 
cancer, and the genes identified here could help increase our knowledge of the 
complex mechanisms involved.
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